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ABSTRACT 
ZHE ZHANG: The Use of Microarray Data Integration to Improve Cancer Prognosis 
(Under the direction of David Fenstermacher) 
 
Microarray is a high-throughput technology used to simultaneously measuring the 
expression of thousands of genes in each sample. Therefore, it has the potential to benefit the 
treatment of complicated diseases like cancer. This study made efforts to improve the 
application of microarray technologies to clinical medicine with two separate, but related 
phases. The first phase dealt with the generation of clinically valuable expression profiles 
from microarray data. By re-analyzing several published cancer datasets, we first confirmed 
that microarray data presented extra information about prognosis of cancer patients beyond 
currently used indexes such as tumor size. At the same time, it was noticed that those indexes 
generally confounded the correlation between gene expression and cancer outcome, so the 
contents of expression profiles were highly dependent on the clinical background of sample 
patients. Consequently, integrating multiple datasets was revealed by this study to obtain 
more general and reproducible cancer expression profiles. A novel data analysis procedure 
incorporating bootstrap re-sampling and training/testing validation was performed to 
impartially compare strategies of expression profiling. The results illustrated that after two 
independent datasets were integrated, the resultant expression profiles more correctly 
differentiated cancer patients in terms of disease outcome. 
 ii
The second phase of this study was to develop MAMA (Meta-Analysis of MicroArray), a 
data mining platform for conveniently collecting, managing, and analyzing multiple 
microarray datasets altogether.  The complete MAMA system included three components: a 
relational database storing microarray cancer datasets; a web server providing the access to 
the database; and a client-side application implementing data manipulation and analysis 
methods. MAMA had an open-source framework allowing other developers to plug in their 
own data analysis methods. Moreover, it made cross-dataset analysis possible by 
standardizing annotation of samples and sequences in microarray datasets.  
 
 iii
ACKNOWLEDGEMENTS 
 
To my family (father Guozhong Zhang, mother Ming Zhu, sister Wei Zhang, and wife 
Yanye Maggie Li in particular), without who I could not finish this work. 
My special gratitude goes to Dr. David Fenstermacher, who has always been there to 
advice and inspire me all these years. I also thank Dr. Lauren Gollahon for giving precious 
supporting during my first two years in US.   
 
 iv
TABLE OF CONTENTS 
Page 
LIST OF TABLES.....................................................................................................................x 
 
LIST OF FIGURES..................................................................................................................xi 
 
Chapter 
I INTRODUCTION...................................................................................................1 
II BACKGROUND.....................................................................................................7 
2.1 Gene Expression Profiling of Cancer Tissues...................................................7 
   2.2 Microarray Standards, Databases, and Software.............................................18 
III METHODS............................................................................................................24 
   3.1 Data Analysis...................................................................................................24 
    3.1.1 Datasets and Data Pre-processing........................................................24 
    3.1.2 SEP: Score for Expression Profile.......................................................26 
    3.1.3 Correlation Analysis............................................................................26 
    3.1.4 Partial Correlation Analysis.................................................................27 
 v
3.1.5 Rank Sum Test.....................................................................................28 
    3.1.6 Logistic Regression Model..................................................................29 
    3.1.7 ROC Curve...........................................................................................29 
    3.1.8 Bootstrap Re-sampling.........................................................................30 
    3.1.9 Gene Categorization According to Gene Ontology.............................31 
   3.2 MAMA Project................................................................................................32 
    3.2.1 Developmental Stages..........................................................................32 
    3.2.2 Data Models.........................................................................................32 
    3.2.3 Relational Database.............................................................................33 
    3.2.4 Server Program....................................................................................33 
    3.2.5 Client Program.....................................................................................34 
    3.2.6 File Formats.........................................................................................35 
    3.2.7 Open Source Framework.....................................................................36 
    3.2.8 Meta-analysis Methods........................................................................36 
IV Results and Discussions.........................................................................................38 
   4.1 Data Analysis...................................................................................................38 
    4.1.1 Pilot Studies.........................................................................................38 
     4.1.1.1 Confounding Effect of Clinical Indexes........................................38 
     4.1.1.2 Partial Correlation Analysis...........................................................43 
     4.1.1.3 Case Study: a Gene Regulatory Pathway.......................................45 
 vi
    4.1.2 Expression Profiling Using Multiple Datasets.....................................50 
     4.1.2.1 Analysis of Individual Datasets.....................................................50 
     4.1.2.2 Cross-validation of Two Datasets..................................................56 
     4.1.2.3 Combination of Individual Datasets..............................................59 
     4.1.2.4 Results from Lung Cancer Datasets...............................................66 
    4.1.3 Sensitivity vs. Specificity of Reporter Gene Selection........................71 
   4.2 MAMA Project................................................................................................75 
    4.2.1 Project Requirements and Use Cases...................................................75 
    4.2.2 Design of MAMA System...................................................................80 
     4.2.2.1 Software Development Environment.............................................80 
     4.2.2.2 System Architecture.......................................................................82 
     4.2.2.3 Database Schema...........................................................................84 
     4.2.2.4 Data Flow.......................................................................................87 
     4.2.2.5 Software Architecture....................................................................89 
     4.2.2.6 Graphical User Interface................................................................94 
    4.2.3 Data Annotation...................................................................................96 
    4.2.4 Working with Data Objects.................................................................98 
     4.2.4.1 Workspace......................................................................................99 
     4.2.4.2 Query............................................................................................100 
     4.2.4.3 Experiment...................................................................................101 
 vii
     4.2.4.4 Analysis........................................................................................105 
    4.2.5 Implementation of Analysis Methods................................................105 
V Conclusion...........................................................................................................109 
   5.1 Data Analysis.................................................................................................110 
   5.2 MAMA Project..............................................................................................116 
 
APPENDICES  
Appendix A Demo of Data Analysis Steps Using a Pseudo-dataset......................109 
Appendix B Sample Class Diagrams of MAGE-OM............................................117 
Appendix C Architecture of Tomcat/Servlet Server..............................................119 
Appendix D Architecture of MVC Design Pattern................................................121 
Appendix E Meta-analysis Methods......................................................................123 
Appendix F Complete Lists of Reporter genes......................................................126 
Appendix G Requirements of MAMA Project.......................................................139 
Appendix H User Cases of the MAMA Client Program........................................148 
Appendix I Client-server Communication Protocol of the MAMA System........160 
Appendix J Database Schema of MAMA project.................................................163 
Appendix K Specification for Pre-processing of Expression Data........................164 
 viii
Appendix L Mapping between XML Elements and Java Data Objects................170 
Appendix M Glossary.............................................................................................171 
 
REFERENCES......................................................................................................................177 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix
LIST OF TABLES 
Page 
Table 
1. Microarray Datasets Used in This Study...........................................................................25 
2. Chi-square Tests on SEP Scores and Clinical Indexes......................................................41 
3. Comparison of SEP and Clinical Indexes Using Logistic Regression Models.................44 
4. Correlation of Genes in a Cell Cycle Pathway to Breast Cancer Recurrence...................49 
5. Bootstrapping Test Statistics Collected from 10,000 Re-samplings.................................53 
6. Cross-validation of Expression Profiles Derived from Breast Cancer Datasets................57 
7. Comparison of Prognostic Indexes using Logistic Regression Models.............................58 
8. Examples: Reporter Genes of 3-year Breast Cancer Recurrence......................................63 
9. Example: ‘Create Workspace’ Use Case...........................................................................77 
10. Data Annotation Resources................................................................................................97 
 
 
 
 
 x
LIST OF FIGURES 
Page 
Figure 
1. Density Distribution of SEP Scores...................................................................................40 
2. Confounding Effect of Clinical Index on Gene-Outcome Correlation..............................42 
3. Clustering of 127 Reporter Genes and 78 Breast Cancer Patients.....................................46 
4. A Cell Cycle-related Pathway Revealed by Partial Correlation Analysis.........................48 
5. Bootstrapping Statistics Separately Obtained from Breast Cancer Datasets.....................55 
6. Comparison of Expression Profiling Strategies.................................................................61 
7. Comparison of Reporter Selection Consistence................................................................61 
8. Mapping of Reporter Genes to Gene Ontology.................................................................65 
9. Bootstrapping ROC Curve Statistics Obtained from Lung Cancer Datasets.....................68 
10. Comparison of Expression Profiling Strategies Using Survival Curves...........................70 
11. Changing of Expression Profile Quality with Sensitivity and Specificity.........................72 
12. Examples: Use Cases. .......................................................................................................78 
13. System Architecture...........................................................................................................83 
14. A Fraction of Database Schema.........................................................................................86 
15. The Data Flow within MAMA System..............................................................................88 
 xi
16. Software Architecture........................................................................................................93 
17. Graphic User Interface of the Client Program...................................................................95 
18. Demo: Database Query....................................................................................................102 
19. Demo: Microarray Experiment Customization................................................................104 
20. Demo: Data Analysis Operation......................................................................................106 
 xii
CHAPTER I 
INTRODUCTION 
 
While many biomedical researchers agree that we are now at the dawn of a ‘Genomic 
Age’, there are still short of clear visions about how to fit high-throughput technologies, such 
as microarray, into the diagnosis, prognosis and treatment of diseases. A large number of 
experiments using these technologies have been carried out to generate information-rich 
datasets. Analysis of these datasets, however, barely brought us results applicable in medical 
practice. A quick response to this problem is probably that the technologies are still immature. 
However, before the technologies become ideal, researchers can still work on fundamental 
questions such as: 
• Does high-throughput data really include helpful information for clinical decisions? If 
so, how valuable are they and what are their advantages and limitations?  
• Have we dug out as much as possible meaningful information from experimental data 
having been generated? If we have not, what data analysis techniques can we use to 
fully take advantage of these data?  
• What kind of evidences will we need to justify that information presented by high-
throughput technologies is clinically informative, and what data analysis methods and 
protocols should be applied to collect these evidences?  
• How much will these technologies change our current way of evaluating and treating 
disease? 
The current study gave its answer to above questions by investigating the relationship 
between microarray data and cancer. As a complex disease, cancer is an ideal subject of 
genomic research because its initiation, progression, and metastasis have been related to a 
series of genomic disorders. A large number of studies have been carried out in recent years 
to find out gene expression patterns in tumors or tumor subtypes. This study applied its own 
strategies to re-analyze published microarray datasets about cancer with the purposes 
different from those of the original studies. The process of identifying the expression patterns 
of samples is known as ‘gene expression profiling’. Identified patterns can be used to classify 
tumor tissues. For example, expression patterns obtained in this study were used to 
distinguish breast cancer patients having good or poor prognosis. A strategy of gene 
expression profiling can be evaluated by the quality of expression patterns identified. An 
expression pattern of good quality should classify samples precisely and consistently. The 
theme of this study is how to achieve more accurate, reproducible and efficient expression 
profiling of tumor tissues. Two independent but related phases were carried out, both taking 
about the same efforts to accomplish.  
In the first phase, published cancer microarray datasets were analyzed to verify two 
hypotheses: 
1. Microarray data present extra clinical information that is not available via currently 
used methods. 
2. It is feasible to perform gene expression profiling across multiple datasets to increase 
the overall sample size and quality of acquired profiles. 
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The first hypothesis was verified by proving that microarray data classified patients better 
than currently used clinical indexes. The confirmation of this hypothesis was the basis of all 
following steps, because if it is wrong, applying microarray technology to medical practice is 
not necessary. Although all similar studies should assume the correctness of this hypothesis 
too, few have verified it in their reports. 
It was observed in early stage of this study that the contents of gene expression patterns 
were highly dependent on the clinical scenario of sample patients. The expression patterns of 
the same features, such as the recurrence outcome of cancer, varied substantially when they 
were obtained from different subpopulations of patients. Consequently, the usefulness of 
these patterns to general population is limited. The major cause of this observation, ironically, 
was that the size of most microarray datasets was too small to give reproducible results of 
expression profiling. This suggestion led to the hypothesis about multi-dataset microarray 
analysis. The confirmation of this hypothesis will allow researchers to comfortably reuse and 
combine existing datasets, so information unable to be obtained from individual datasets can 
be discovered. Furthermore, multi-dataset analysis is a potential solution to the issue about 
medical application of high-throughput technologies since it can provide stronger statistical 
evidences by covering various patient subpopulations.  
The second phase of this study is the development of a software system called MAMA 
(Meta-Analysis of MicroArray). This project was motivated by the experience of the data 
analysis phase, which demonstrated that multi-dataset expression profiling was not 
technically straightforward. Systematic variation caused by experimental protocol to data 
annotation exists everywhere in independent microarray studies and datasets. Datasets 
collected from individual studies can be integrated together only after they have been 
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consistently annotated, processed and formatted. For biologists and statisticians whose 
primary interest is high-level data analysis, dealing with these issues is distracting and time-
consuming. The MAMA system was developed to provide users a software environment 
within which they could simultaneously and conveniently investigate multiple microarray 
datasets. Collected cancer microarray datasets were stored in a relational database after they 
were re-processed and re-annotated according to pre-defined guidelines. This database was 
made accessible on the web by a server program that can handle concurrent requests of 
multiple clients. The MAMA client program was a software application for users to 
manipulate and analyze microarray datasets. It has a graphical user interface. Using this 
program, users can selectively download data from the server or directly import their own 
data, and work with these data on their local disk. High flexibility was a priority of 
developing MAMA. For example, users were provided with programming interfaces to plug 
in their own data analysis methods. On the other hand, data objects were formally and 
consistently annotated. Popular sequence databases, such as GenBank and Unigene, were 
used to annotate nucleotide sequences; and controlled vocabularies, such as MGED ontology 
and NCI thesaurus, were used to describe biological samples. Implemented data analysis 
methods were focused on the correlation between genes and features of cancer samples, or 
other genes. Meta-analysis methods, such as combined tests and measures of effect size, were 
made available too.  
This dissertation is organized into following chapters, which usually illustrate the data 
analysis and MAMA projects separately: 
• Chapter 1. Introduction. 
• Chapter 2. Background: 
 4
o high-throughput technologies; 
o literature review about gene expression profiling in cancer research;  
o summary of standards, databases, and software used in microarray research.  
• Chapter 3: Methods:  
o description of analyzed datasets;  
o statistical methods and procedures used for data analysis;  
o software and standards used to develop MAMA. 
• Chapter 4: Results and Discussions:  
o pilot studies and the implications of their results;  
o verification of hypothesis about clinical value of microarray technology; 
o verification of the advantages of multi-dataset gene expression profiling; 
o a novel strategy of performing and evaluating gene expression profiling; 
o sensitivity vs. specificity of reporter gene selection; 
o vision, design and data model of MAMA system; 
o data analysis functions implemented in MAMA. 
• Chapter 5: Conclusion. 
• Chapter 6: References. 
• Chapter 7: Glossary. 
• Chapter 8: Appendices: 
o step-by-step data analysis procedure; 
o reviews of software development tools and standards; 
o review of meta-analysis methods; 
o supplementary results of data analyses; 
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o design documents of MAMA project, such as use cases and database schema; 
o user guides of MAMA, such as software installation and method plug-in; 
o source codes and deliverables of MAMA.  
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CHAPTER II 
BACKGROUND 
 
2.1 Gene Expression Profiling of Cancer Tissues 
Cancer threatens human life by destroying normal tissues with uncontrollable 
proliferation of malignant cells. While the disease is usually curable by surgery as long as the 
primary tumors are locally restrained, most cancer-related deceases are caused by metastasis: 
malignant cells escape from the primary tumor, enter lymphatic or vascular circulation, and 
establish inoperable secondary tumors at distant locations. Clinical decision about cancer 
treatment is mostly based on pathological observations of tumor status. The most referred to 
cancer clinical index is TNM classification, which categorizes cancer patients jointly 
according to tumor size (T), local lymph node metastasis (N), and distant metastasis (M) [1]. 
Other common indexes, such as histological grade and angioinvasion, have been used as 
supplements of TNM system [2, 3]. 
The search for a general cure of cancer has become the biggest dilemma of biomedical 
research. On one side, the knowledge about the molecular basis of cancer has been 
substantially improved after decades of enormous research effort. It is already known that 
cancer is caused by a series of genetic disorders, from point mutations to insertion/deletion to 
chromosome rearrangement [4-7]. Genetic defects destroy the balance between cell growth 
and cell death, and transform normal cells into malignant. Therefore, the investigation of 
cancer-related genes, such as tumor-suppressor genes and oncogenes, has been the focus of 
cancer research for more than 10 years [8, 9]. Some of these genes have been used as 
molecular markers in cancer clinics, such as p53 [10] and HER-2/neu [11]. On the other hand, 
discoveries in molecular biology have hardly benefited more cancer patients. Pathological 
indexes still dominate the diagnosis of cancer in clinics. Although the list of cancer-related 
genes is continuously growing, the addition of most new members was unable to improve the 
comprehensive image of malignancy transformation, advocating high genetic variability of 
cancer [12]. Regular laboratory approaches, which laboriously investigate a single gene or 
several closely linked genes at a time, have been proven ineffective to this complex and 
genomic-level disease. To improve cancer treatment, cancer patients should be classified 
based on genomic information produced by more efficient technologies. 
Development of high-throughput technologies in recent years is about to bring 
biomedicine into a genomic age. These technologies have promising potentials in cancer 
research by allowing investigators examine cancer from a systematic perspective. CGH 
(Comparative Genomic Hybridization) is able to detect chromosomal gains and losses 
through the entire genome [13]. Chromosomal DNA obtained from both cancer and normal 
tissues is labeled with two fluorescent colors, and the difference in signal intensity indicates 
sequence deletion or amplification. Although array-based CGH has been developed to 
improve the resolution of this technology [14], CGH is not suitable for detecting mutations of 
short sequences. Since point mutations are the most common chromosomal alteration, 
genomic sequencing is a thorough solution for identifying genes mutated in cancer. However, 
the effort and cost of whole-genome screening are still impractical for most research facilities. 
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Technologies such as heteroduplex analysis and CSGE (Conformation Sensitive Gel 
Electrophoresis) have been used as alternatives of sequencing for mutation detection [15-17]. 
While sequence information is mostly static, expression profiling technologies can describe 
the dynamic status of cancer cells at gene transcription level. SAGE (Serial Analysis of Gene 
Expression) and microarray have been used to generate source data of expression profiling. 
By assuming that 10-12 bp nucleotide sequences will uniquely represent most human 
transcripts, SAGE concatenates short cDNA fragments into sequencing vectors to constitute 
a SAGE library [18, 19]. The library will be sequenced to comprehensively quantify gene 
expression. SAGE constitutes an open system, so it can measure the expression of unknown 
or rarely-expressed genes in cells under investigation. Microarray is the most applied high-
throughput technology in recent years. By fixing probes (synthesized oligonucleotides or 
sequences extracted from cDNA libraries) of transcripts onto a solid surface as tiny spots, 
microarray technology is able to simultaneously and efficiently measure the expression of 
thousands of genes [20-22]. Microarray is not as sensitive as SAGE because background 
noise on arrays makes the measurement of low abundance mRNA inaccurate, but it is less 
laborious and expensive. Individual microarray studies are usually able to measure 
expression of genes in 20 to 200 samples. Therefore, in cancer research, microarray datasets 
are often used for classifying samples into categories such as cancer subtypes [23-26]. The 
protein-level genomic technology is proteomics, which relies on high-throughput platforms, 
such as array slides or 2-D electrophoresis gels, to simultaneously analyze a large number of 
proteins [27-29]. Proteomics has been used to classify biological samples as microarray, and 
to discover, identify, and quantify cancer biomarkers [30, 31]. Since proteins are the 
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functional units in cells, proteomics could be considered as the bridge connecting genomics 
and clinical medicine.  
As a relatively mature high-throughput technology, microarray has been used to produce 
gene expression datasets about a variety of types of cancer. A common application of 
microarray datasets is to identify gene expression patterns corresponding to the sample 
features under investigation, such as the recurrence of cancer. The process of identifying 
gene expression patterns is often referred to as ‘gene expression profiling’, which is 
characterized by the major trends in biomedical research: large datasets, computer-assisted 
data analysis, and integration of scientific domains including biomedicine, statistics, and 
information sciences. Because of its clinical prospects, expression profiling of cancer tissues 
has been extensively explored [32-35]. 
Statistical analysis plays a critical role in gene expression profiling. Clustering and 
reporter gene selection are two extensively applied techniques [36-38]. Clustering is 
relatively more visual and straightforward, while reporter selection is usually more complex 
and has more variations. Methods having been used to reporter selection include simple 
hypothesis testing methods, such as Student or permutation t test [39, 40], ANOVA [41], and 
advanced models, such as Bayesian Networks [42] and Principal Component Analysis [43]. 
Selection of expression profiling methods should be determined according to the purposes of 
research and the characteristics of dataset. Complicated methods are not necessarily better 
than simple ones, and powerful methods usually make stricter assumptions on data than 
methods that are less powerful but more robust.  
Analysis of microarray data also presents a challenge to traditional statistics because the 
number of variables (genes) in a microarray dataset is usually much larger than sample size. 
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Repeating a hypothesis test on a large number of variables will falsely reject the null 
hypothesis for some variables, an issue usually referred to as ‘multiple hypothesis testing’ 
[44]. For example, when a test is performed on each of 10,000 genes, averagely 100 genes 
will get a significant p-value less than 0.01 just because of the random distribution of data. 
Therefore, reporter gene lists derived from microarray datasets often include false positives. 
Decreasing the sample size or increasing the genes of a dataset will generally augment the 
rate of false positives in a reporter list. Reducing the size of the list will lift the specificity of 
reporter selection, but lessen the sensitivity at the same time. The ‘q-value’ index has been 
suggested to control the false positive rate of reporter selection by adjusting the test p-values 
by the number of tests performed [45, 46].  
The following gives a quick literature review about cancer microarray studies using 
breast cancer as an example. Breast cancer is aroused by an accumulation of genetic 
mutations, and its initiation, invasion, progression, and metastasis are related, but distinct 
diseases. The complexity of breast cancer makes it an ideal subject of genomic-level research 
[47]. Gene expression profiling about breast cancer has drawn many research interests in 
recent years and a large number of studies have been reported. The focuses of microarray 
studies about breast cancer ranged from biological differentiation of different cell lines [48] 
or normal/tumor tissues [49], to clinical classification of tumors into subtypes using 
expression profiles [49-52], to discovery of molecular markers and drug targets [53-56]. 
Since most breast cancer-related deaths are caused by recurrence and/or metastasis of disease, 
profiling of disease endpoints is clinically more valuable. It is a challenging topic at the same 
time because of the difficulty of predicting cancer outcome.  
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Practitioners usually measure and integrate a number of prognostic indexes to predict the 
outcome of breast cancer. The prediction guides the making of disease treatment decision, 
which is crucial for the quality of patients’ post-diagnosis life. Besides TNM classification, 
common prognostic indexes of breast cancer include age, ethnicity, grade, vascular invasion, 
and so on [57]. Moreover, molecular markers, such as HER2/neu and ER (Estrogen Receptor) 
status, have a growing utilization in the prognosis of breast cancer [57, 58]. For example, an 
extensive study (n>37,000) concluded that ER-negative patients were 7-times more likely to 
develop recurrent diseases than ER-positive patients after 5 years or more of adjuvant 
tamoxifen treatment [59]. However, currently used indexes often misclassify patients in 
terms of disease outcome because they are unable to describe the integral status of tumors 
with enough details. Microarray data, on the other hand, has the potential to characterize 
subtypes of cancer more specifically by making a census about gene expression in tumors. 
Microarray studies have reported expression profiles related to outcome of breast cancer. 
Sørlie et al  collected 85 tissue samples from breast cancer patients (78 cancers, three benign 
tumors, and four normal tissues), and categorized them with hierarchical clustering of their 
microarray data [49]. The categorization was supervised by post-diagnosis survival of 
patients. All samples were classified into 6 sub-groups and Kaplan-Meier survival curves of 
these sub-groups were significantly separated (p<0.01). Van‘t Veer et al  applied different 
approaches to identify gene expression profiles associated to recurrence of breast cancer, 
during which the correlation between expression of each gene and 5-year prognosis was 
evaluated with statistical tests across 78 breast cancer patients [60]. Genes having the most 
significant correlation were selected as reporters of recurrence outcome. ‘Leave-one-out’ 
cross-validation was then applied to optimize the length of reporter gene list. The 70-gene 
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profile achieved optimal validation results. When the expression profile including these 
genes was used to classify patients, observed recurrence outcome of 65 out of 78 patients 
(83%) was correctly matched by the classification. Furthermore, when this profile was 
applied to a testing group of 19 patients, 17 patients (89%) was correctly classified. Although 
previous study acquired inspiring results, its weakness should also be noticed. The self-
validation result might be an overfitting and the size of the testing group was too small to 
give enough statistical power. Furthermore, all sample patients were selected from a specific 
sub-population of breast cancer (lymph node negative, tumor size less than 5 cm, and age 
under 55 at diagnosis), so the expression profile obtained from these patients might not be 
generally applicable. 
The dependence of gene expression profiles on clinical background of sample patients 
has been observed in microarray datasets. Gruvberger et al noticed that 165 out of 231 top-
ranked genes in the study of van ‘t Veer had significant correlation with ER status of patients 
[61], and suggested that expression profiling should be performed separately on ER-positive 
and -negative patients. It has been reported that some clinical indexes, such as ER status and 
tumor size, ubiquitously influence the expression of genes in tumor cells [62, 63]. Therefore, 
these indexes are confounders of gene expression profiling. Since microarray data are 
expected to provide extra clinical value beyond currently used indexes, expression profiles 
will be more valuable if the intervening effect of clinical scenarios is controlled. The 
suggestion of Gruvberger, though, is not an ultimate solution to this issue because there are 
other confounders of expression profiling besides ER status and it is not feasible to further 
split sample patients into subgroups corresponding to all confounders. 
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Both of the sample size and confounder issues discussed above put doubts on the general 
usability of expression profiles identified from individual datasets about cancer. 
Consequently, recent microarray studies have been trying to give a solution by integrating 
multiple datasets. The advantages of data integration are apparent because it increases the 
overall sample size of data analysis. Furthermore, since research questions often need to be 
re-defined for data integration analysis, information not discovered by individual studies can 
be uncovered from integrated data. One of the most common techniques of data integration is 
meta-analysis [64, 65]. Meta-analysis is often referred to as ‘analysis of analyses’. It takes 
the results of individual studies as its inputs to carry out secondary analysis, and how those 
studies got their results is irrelevant to the process of meta-analysis.  
Meta-analysis and other data integration strategies have been used in cancer microarray 
studies [66-69]. Ghosh et al investigated the consistence of four prostate cancer microarray 
datasets using a meta-analysis process [68]. They concluded that the profiles derived from 
these independent datasets shared significant similarity and proposed candidate gene 
pathways with the results. Microarray datasets of various cancer types were meta-analyzed 
by Rhodes et al [69]. They applied a comparative meta-profiling method to 40 published 
datasets with an overall sample size greater than 3,700. Gene expression profiles identified 
from these data were mapped to several characteristics of cancer tissues. For example, 
comparison of gene expression in cancer and normal tissues across 21 independent datasets 
and 12 cancer types recognized 67 genes that had significantly high possibility to be selected 
as reporters from individual datasets. The expression profile including these genes was 
proposed as a general gene expression signature of neoplastic transformation. Altogether, 
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previous results shed light on the possibility to combine multiple microarray datasets for 
more precise profiling.  
Rhodes’ study implied that samples of disparate subpopulations might still share 
considerable commonness in terms of expression profiling results, which advocated the 
feasibility of integrated profiling of cancer outcomes. If a gene is highly correlated to a 
disease outcome in one patient subpopulation but not the others, its role in the integrated data 
will fade out as disparate patient cohorts are involved. On the other hand, genes whose 
correlation to an outcome is independent of clinical background of samples will have a 
bigger chance to be identified in integration analysis. Nevertheless, for multi-dataset 
expression profiling, it should be assumed that a common expression profile corresponding 
to the investigated output variable does exist regardless of the experimental design of 
individual studies and the substantial systematic variations between microarray datasets. 
Therefore, it is often necessary to re-define the output variables to make them proper for 
integration analysis. As a result, sample patients of the original studies may need to be 
filtered and re-categorized accordingly.  
Categorizing cancer patients into prognosis groups is not as straightforward as it looks. In 
ideal situation, sample patients will be followed up until their disease endpoint is reached, so 
they can be unquestionably categorized. In the case of breast cancer, patients are considered 
as being cured if they keep recurrence-free long enough (usually 15 to 20 years) until their 
hazard to the disease is not greater than that of the general population. In clinics, however, 
outcome of cancer patients is often censored by short follow-up or incomplete medical record. 
Survival analysis is the most common method dealing with censored data [70]. It builds a 
Kaplan-Meier curve with follow-up data of each patient group and calculates test statistics 
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about the separation of curves. Survival analysis is statistically powerful since it takes all 
available follow-up information into account. However, its assumption about the constant 
effect of predictive index on output variable is not the fact in the case of cancer outcomes 
because survival and recurrence rates of cancer patients usually change from time to time. 
Alternatively, classifying patients into pre-defined prognosis groups would simplify the 
subsequent statistical analyses. The clinical convention is to categorize patients according to 
their 5-year follow-up. Patients who survive and keep disease-free for at least five years will 
be thought as having good prognosis and who die or recur within five years after diagnosis 
will be thought as having poor prognosis. Such a classification will exclude some sample 
patients from the following data analyses if they have not been followed up long enough to 
be categorized. Meanwhile, it will make the generating and validating of expression profiles 
more convenient, and if the cutoff value for classification is properly chosen, the 
corresponding expression profiling could also be powerful. Nevertheless, it should be pointed 
out that the 5-year convention was established by usage rather than by any biological basis. 
Classifying sample patients arbitrarily regardless of their intrinsic difference in genetic 
background will considerably reduce the statistical power of gene expression profiling.  
Retsky et al. investigated the follow-up data of 1,173 breast cancer patients and 
discovered that their recurrence rate had two peaks [71, 72]. The summits of these peaks 
were located at about 18 and 60 months after mastectomy, separated by a nadir around 50 
months. It was also concluded that the appearance of this double-peaked distribution was 
independent of tumor size, number of positive nodes, and menopause status of patients. 
Computer simulation of tumor progression implied that this distribution might be caused by 
disparate dynamics of secondary tumor growth. It was proposed that early recurrence was 
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caused by mastectomy-initiated accelerated growth of secondary tumor, while the second 
peak was the result of steady stochastic transitions of tumor progression phases. It was 
further suggested that different treatment strategies should be applied to patients located in 
different peaks. 
Since Retsky’s recurrence model is independent of clinical indexes, it could be 
considered as applicable to general population of breast cancer. If the computer simulation 
model about growth of secondary tumors is true, patients respectively recurred during those 
two peaks have a good chance to be distinguished by their gene expression profiles. 
Therefore, as an output variable for expression profiling, 3-year prognosis of breast cancer 
has better grounds than 5-year prognosis.   
The medical application of microarray technology is at its very early stage. Researchers 
are actively bringing up new topics and methods in this field. The current study tried to 
verify that integration of microarray data from independent sources will improve expression 
profiling of cancer prognosis. A novel strategy of generating and validating gene expression 
profiles was developed and applied to two published microarray datasets about breast cancer. 
The two-peak recurrence model discovered by Retsky was adopted to make results more 
biologically meaningful and clinically beneficial. It was revealed after two datasets were 
integrated, not only selection of reporter genes had higher specificity, but also the expression 
profiles acquired were more predictive. Furthermore, when the same strategy was applied to 
four public microarray datasets about lung cancer, similar results were observed. It was also 
demonstrated that microarray data provide extra prognostic value besides commonly used 
indexes. 
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2.2 Microarray Standards, Databases and Software 
Handling of microarray data is challenging for most biomedical researchers since it 
involves many aspects of information technologies. First, the structure of microarray datasets 
is complicated and has many variations. To describe a reproducible microarray dataset, 
metadata from experiment design to data processing strategy should be completely and 
unambiguously given. Consequently, standards of formally describing microarray datasets 
are necessary. Secondly, microarray datasets include slide images, raw measurements, 
processed data and other related data types, which make their structure complicate and their 
size big. Storage of microarray datasets in centralized repositories, such as databases, will 
give researchers quick and convenient data access. Finally, methods for presenting, 
processing and analyzing microarray data are various and often sophisticated. Packing these 
methods into computer software will save researchers from the trouble of implementing these 
methods by themselves. 
MGED (Microarray Gene Expression Data) Society is the most active organization that 
creates microarray standards [73]. A series of standards established by MGED for annotating 
and exchanging microarray data are being widely used in microarray community. The 
following is a brief introduction to these standards.  
MIAME (Minimum Information About a Microarray Experiment) is the first standard 
proposed by MGED [74]. It is recommended to authors and editors of microarray 
publications as a set of information necessary to reproduce microarray datasets. Particularly, 
MIAME requires for description of array and experiment design, samples, experiment 
protocols, and measured data. These requirements are summarized in MIAME checklist. 
MIAME is mostly conceptual. It neither structuralizes the contents of microarray datasets nor 
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specifies the standard vocabularies to describe them, which are respectively the goals of 
MGED MAGE (MicroArray and Gene Expression) and Ontology working groups.  
MAGE has established two standards for structure of microarray data: MAGE-OM 
(Object Model) and MAGE-ML (Markup Language) [75]. MAGE-OM is a complex data 
model that defines over than 150 data types related to microarray experiments and the inter-
relationship of these types. Its development follows the principles of UML (Unified 
Modeling Language, Object Management Group, Inc.). MAGE-ML defines a set of XML 
(eXtensible Markup Language, World Wide Web Consortium) elements, which are 
automatically derived from MAGE-OM. Hence, XML documents tagged with these elements 
can be exchanged between MAGE-compliant data systems. Although MAGE standards have 
covered most aspects about microarray datasets, they are mostly focused on the generation of 
microarray data and do not strongly support high-level data analysis. Furthermore, the 
complexity of these standards makes them difficult to be implemented and may cause low 
performance of data processing programs.  
The aim of MGED Ontology is to provide a set of defined and tree-structured terms for 
description of microarray-related concepts [76]. It has two major branches: core and 
extended. The core ontology is limited to the description of data objects covered in MAGE-
OM while the extended one has a wider scope. Although a major part of MGEG Ontology 
has been put on the features of biological samples used in microarray experiments, the 
supplement of other controlled vocabularies is necessary to make unambiguous description 
of samples because the high diversity of biological entities. For example, NCBI (National 
Center for Biotechnology Information) Taxonomy database provides the official names of 
species and their categorization [77], and NCI  (National Cancer Institute) Metathesaurus is a 
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resource summarizing cancer-related vocabularies. The probes or nucleotide sequences 
included in array designs also need to be systematically annotated. Major sequence databases, 
such as GenBank [78] and Ensemble [79], have been used to annotate sequences in 
microarray datasets. However, these databases often store multiple sequence records 
belonging to the same genes and assign them different identifiers. Redundant appearance of a 
gene in an expression profile will reduce its sensitivity and artificially increase the weight of 
the gene, so it is better practice to condense data of redundant genes together for high-level 
analysis. Consequently, many researchers prefer annotating nucleotide sequences with 
systems developed for naming genes or gene products. NCBI Unigene database, which 
clusters GenBank sequences into a non-redundant set of genes, is such a system having been 
commonly used [80, 81]. Since individual studies use a variety of sequence annotation 
systems, mapping annotations between systems has became an ordinary data processing step 
in microarray studies. 
Databases play a crucial role in the storage, distribution, and standardization of 
microarray datasets. Public microarray databases are usually accessible via the web, so they 
have web-based interface for users to query for sequences, samples, experiments, and other 
data types. Some microarray databases also provide tools for data processing and analysis. 
Microarray data models such as MAGE-OM and RAD [82] have been taken as basis of 
database schemas.  
SMD (Stanford Microarray Database) is the first major microarray database whose 
source codes were released [83-85]. Although it was initially developed to serve human and 
yeast researches at Stanford University, its application was extended to a much larger scope 
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and has been adopted by other institutes. SMD was not MAGE-compliant originally, but its 
later version supported the exchange of data formatted with MAGE-ML.  
As more and more microarray studies are reported and their source data are available, the 
demand for centralized repository of published microarray datasets is increasing in research 
community. Two major bioinformatics organizations, NCBI and EBI (European 
Bioinformatics Institute), discretely provided their solution to this requirement. GEO (the 
Gene Expression Omnibus) is a database established by NCBI [86]. It currently stores about 
half a billion gene expression measurements generated by microarray or SAGE. The 
microarray database established by EBI is called ArrayExpress [87, 88]. The schema of 
ArrayExpress is consistent with MAGE-OM and other MGED standards including MIAME 
and MGED Ontology are also adopted by this database for data submission and description.  
Data-mining functions are provided by some microarray databases as their supplement. 
For example, ONCOMINE is a system combining a microarray database with a data-mining 
platform for discovering gene expression patterns in cancer [89]. Establishment of this 
system dramatically accelerated subsequent data analyses. Studies based upon ONCOMINE 
database have been carried out successfully and reported [69, 90-92].  
Computer software is a requisite part of microarray studies. To support their products, 
microarray hardware vendors such as Affymetrix, Inc. usually provide software tools for 
upstream handling of experimental results, such as image acquisition and in-chip 
normalization [93-95]. On the other hand, a large number of computer programs are available 
for high-level microarray analysis. These programs have been developed as simple desktop 
tools to powerful enterprise systems. Popular statistical programming language including R 
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(www.r-project.org), MatLab (MathWorks, Inc.), and SAS (SAS Institute, Inc.) are also 
extensively applied in microarray researches.  
GeneSpring GX (Aligent technologies, Inc.) is one of the most popular commercial 
microarray software. Like most of other business products, it has an attractive user interface 
and is relatively user-friendly. Besides rendering data with graphics, it implements various 
types of statistical methods, such as ANOVA and clustering, for identifying reporter genes or 
expression patterns. Furthermore, it provides programming interface that allows users to 
incorporate third party applications for data visualization or analysis. Although GeneSpring 
GX is gaining its popularity, sophisticated users may still feel that its functionality cannot 
fulfill their demand because of the rapid updating of data analysis techniques, which is 
probably the reason why most commercial microarray software did not succeed. 
Allowing users to modify or extend the source codes to meet their special requirements, 
open-source software has become a major driving force of microarray research [96-100]. 
BioConductor is an R-based open source project for the analysis of microarray and other 
genomic data [100-103]. Its newest version includes over 100 software packages 
implementing annotation, documentation, statistical analysis, and many other functions about 
genomic data. It should be pointed out that the quality of open source software varies. 
Unsophisticated programs may mistakenly implement statistical methods or inaccurately 
interpret results. Therefore, open source programs should only be recommended to 
experienced users.  
In spite of various options of microarray software, researchers often find it necessary to 
write programs by themselves, especially when they are developing new data analysis 
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methods or procedures. For example, the current study coded most programs used in its data 
analysis phase. 
The MAMA (Meta-Analysis of MicroArray) system presented in this dissertation is an 
open-source platform supporting data-mining in cancer microarray datasets. It has three 
major components: a relational database, a server program, and a data analysis package. The 
MAMA database provides a centralized storage of microarray datasets about cancer and the 
server program made this database web-accessible. Unlike ONCOMINE, the focus of the 
MAMA project is its data analysis package that could be run as a desktop application. This 
application supported basic operations about microarray dataset such as data import/export 
and re-processing. Furthermore, it provided an open-source framework to satisfy diverse user 
requirements on its functionality. Similar to GeneSpring GX, MAMA allows users to plug in 
their own methods by implementing specified programming interface. A highlight of MAMA 
project was the availability of meta-analysis functions, which was realized by using MGED 
Ontology and other controlled vocabularies to describe data from independent sources. The 
MAMA system was expected to provide microarray researchers an easy-to-use and 
extensible data mining platform with functions not fulfilled by other microarray software.  
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CHAPTER III 
METHODS 
 
3.1 Data Analysis 
3.1.1 Datasets and Data Pre-processing 
This study analyzed published microarray datasets, including two from breast cancer 
patients [49, 60] and four from lung cancer patients [104-107]. All datasets provided clinical 
data about patients, such as disease follow-up and tumor size, in addition to microarray data. 
Cancer patients in each dataset were re-sampled and classified into two prognostic groups. 
Breast cancer patients who developed secondary tumors within three years after mastectomy 
were put into the poor prognosis group while patients who were followed up for at least three 
years and had no observed recurrence were classified as having good prognosis. Patients 
inappropriate to either group were excluded from this study. (See Appendix A.1 for demo of 
patient classification.) In the case of lung cancer, patients were classified according to their 
two-year survival outcome, and only adenocarcinoma patients were selected. Disease 
outcome of patients in all datasets was denoted as a dichotomous variable for all statistical 
analyses (0: good prognosis and 1: poor prognosis).  The resulting sample sizes of all breast 
and lung datasets are summarized separately in Table 1A and 1B. Before analyzing these 
datasets, several data pre-processing steps were carried out. Sequences of all datasets were 
mapped to Unigene clusters and expression levels of redundant entries were averaged to
generate a set of genes without redundancy. In the case of breast cancer, there were 5,569 
non-redundant Unigene clusters presented in both datasets. (See Appendix A.2 for demo of 
mapping sequences to Unigene.) Expression measurements having low quality and sequences 
unable to be mapped to Unigene were filtered out of the datasets. Ratio expression data of 
cDNA datasets were log10-transformed. Furthermore, expression measurements in each 
dataset were normalized for each patient and then for each gene, making the median 
expression level of each patient or gene equal to 0.0 and the standard deviation equal to 1.0. 
(See Appendix A.3 for demo of expression data pre-processing.) 
 
Table 1: 
Microarray Datasets Used in This Study 
 
Table 1A: Two Breast Cancer Datasets 
Poor prognosis: patients recurred within three years after diagnosis; good prognosis: patients had 
no observed recurrence and were followed up for at least three years. Patients who were in the 
original datasets, but could not be categorized into either group were removed from this study.  
 
Dataset [reference] / Platform Poor Prognosis Good Prognosis Total 
Rosetta Breast [60] / cDNA 31 51 82 
Stanford Breast [49] / cDNA 37 25 62 
Total 68 76 144 
 
Table 1B: Four Lung Cancer (Adenocarcinoma) Datasets 
Poor prognosis: patients died within two years after diagnosis; good prognosis: patients survived 
after at least two years of follow-up. Only adenocarcinoma patients were selected. Patients who 
were in the original datasets, but could not be categorized into either group were removed from 
this study.  
 
Dataset [reference] / Platform Poor Prognosis Good Prognosis Total 
Harvard Lung [106] / Oligo 30 33 63 
Michigan Lung [105] / Oligo 17 43 60 
Stanford Lung [104] / cDNA 10 9 19 
Ontario Lung [103] / cDNA 3 8 11 
Total 60 93 153 
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3.1.2 SEP: Score for Expression Profile 
A designed variable, Score for Expression Profile or SEP, was defined as a qualifier of 
gene expression profiles. Given a profile with N reporter genes, the SEP of each patient was 
calculated as: 
(1).     SEP = ΣN [wi ∗ (Xi – Ei)] 
In Formula (1), wi was the weight of ith gene in the profile. The sign of wi corresponded 
to a positive or negative correlation between ith gene and the output variable under 
investigation while the magnitude of wi indicated its relative importance in a profile. Xi was 
the expression measurement of ith gene in the patient while Ei was its expected expression 
level. Since the output variable was dichotomous, Ei was the expression level that had equal 
probability to be found in either sample group and could be denoted as E (Xi | p+=p-=0.5). 
The Ei of each gene was empirically estimated from the training data. By using Formula (1), 
the difference between Xi and Ei of each gene in the profile was weighted and then be 
linearly summarized to obtain a SEP score. According to this process of calculating SEP, 
patients with poor prognosis were expected to have lower SEP scores than patients with good 
prognosis in general. SEP demonstrated its advantage in the current study as a numeric 
variable appropriate for common quantitative methods, such as chi-square test and 2-group 
comparison. Consequently, it was treated as a potential prognostic index, representing the 
information provided by microarray data. (See Appendix A.8 for calculation of SEP score.) 
 
3.1.3 Correlation Analysis 
Genes whose expression is highly correlated to an investigated sample feature can be 
considered as the reporters of that feature. Identifying reporter genes from a genome involves 
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procedure called ‘feature selection’, during which one or more statistical tests are applied to 
evaluate gene-feature correlation. Among all the methods used to evaluate correlation 
between two variables, Pearson’s correlation is most common and straightforward [70]. It has 
the best performance when data follows linear distribution. Pearson’s correlation reports an r 
statistic as its result. After this r statistic is further transformed into a normally distributed t 
statistic, a p-value corresponding to a hypothesis testing about correlation can be acquired. In 
this study, reporters of an output variable were defined as those genes having the most 
significant p-values. (See Appendix A.5 for more details about correlation analysis.) 
 
3.1.4 Partial Correlation Analysis 
Partial correlation is a statistical technique used to control the effect of confounders out 
of the correlation between two variables [108]. In the case of cancer microarray analysis, it 
was observed that the correlation between gene expression and disease outcome varied with 
some clinical indexes (see Fig. 2), such as Estrogen Receptor (ER) status of breast tumors. 
This confounding effect causes the dependence of cancer expression profiles on the clinical 
scenarios of sample patients, and then reduces the reproducibility of profiles. A partial 
correlation analysis was proposed by this study, during which the gene-outcome correlation 
is re-evaluated after a confounding variable is controlled. The first step of this analysis is to 
transform each gene expression measurement to a residual using: 
(2).     Xresidue = X − E (X | controlled variable) 
In Formula (2), X was the original expression measurement of a gene and E was the 
expected X given a known value of the controlled variable, such as positive or negative ER 
status. Patients were classified into groups according to the controlled variable and E values 
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of each gene were estimated by averaging X of all patients in each group. Subsequently, the 
partial correlation coefficient (r’) of each gene to the output variable was calculated using the 
residuals. Once each measurement in the original data matrix was transformed to a residual, 
the gene-outcome correlation will be re-calculated, with X replaced by Xresidual, to get a 
partial correlation coefficient (r’). The r’ statistic was considered the same as r through the 
subsequent analyses. Theoretically, Formula (2) could be reiterated until all the confounders 
were controlled.  (See Appendix A.6 for more details about partial correlation analysis.) 
 
3.1.5 Rank Sum Test 
Since samples had only two outcome categories in this study, two-group comparison 
methods were potentially appropriate for calculating gene-output correlation. Wilcoxon Rank 
Sum Test (RST) [70] was used as the main method to evaluate differential expression of 
genes between opposite patient groups. As a non-parametric method, RST does not assume 
the normality of data as parametric methods, such as commonly used Student’s t test. Large 
portions of the genes in analyzed microarray datasets do not satisfy this assumption of 
normality. Although non-parametric methods have less statistical power, such a disadvantage 
is insignificant if reporter genes are selected based on relative ranks of genes instead of their 
p-values. RST reports a Z statistic as its result. It first transforms all expression 
measurements of a gene into ranks, and then calculates the Z statistic with the ranks assigned 
to the compared groups. When both groups have no less than eight observations, Z statistic 
follows standard normal distribution, so a corresponding p-value can be obtained. With the 
procedure used in this study, the Z statistic of a gene would be positive if it is generally over-
expressed in good prognosis patients; otherwise, it would be negative. No matter which 
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statistical test was used, the resultant test statistics were used to rank genes. In this study, 
genes having the highest magnitude of Z statistics or the smallest p-values were selected as 
reporter genes. (See Appendix A.7 for guide of calculating RST Z statistic.) 
  
3.1.6 Logistic Regression Model 
Logistic regression is a statistical technique used to evaluate the predictive ability of 
independent variable(s) on a dependent variable having dichotomous outputs [108]. Building 
logistic regression models is process during which the best estimation of the parameters of a 
regression formula is achieved based on input data. The resultant model has a statistic called 
-2 Log Likelihood (-2LL), which is used to compare fitness of models to actual observation 
of an output variable. For a fixed sample size, a smaller -2LL represents better model fitness. 
A model is uni-variate if it has only one independent variable and is multi-variate if it 
includes more than one independent variable. Models generated by this study utilized 
available prognostic indexes including SEP as independent variables and disease outcome as 
the dependent variable. Multi-variate models were built using a forward stepwise procedure, 
during which independent variables were added into a model one by one in the sequence of 
their significance. The resultant −2LL of each step was recorded to trace the changing of 
model fitness. All models were generated using SAS System for Windows, Release 8.02 
(SAS Institute, Inc.). 
 
3.1.7 ROC Curve 
ROC (Receptor Operating Characteristic) curve is a type of plot used to evaluate the 
accuracy of a clinical test [70]. It shows the tradeoff of sensitivity (true positive rate) and 
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specificity (true negative rate) when the test result is at each of its cutoff points. From a ROC 
curve, one can determine the false positive rate that needs to be tolerated to guarantee a 
certain sensitivity of a test. The curve is usually drawn from the lower left corner to the upper 
right corner in a 1.0Χ1.0 scale, so its AUC (Area Under the Curve) ranges from 0.0 to 1.0; 
the larger the AUC, the higher accuracy of a corresponding clinical test. A test will be ideal if 
its ROC curve has AUC equal to 1.0. In this study, the SEP scores of patients were 
considered as the results of a clinical test based on microarray experiment, and ROC curves 
built with these scores were used to evaluate the clinical value of expression profiles.  
 
3.1.8 Bootstrap Re-sampling Strategy 
Some reporter genes selected into expression profiles could be false positives because of 
the issue of multiple hypothesis testing. Consequently, validating a profile with the same data 
used to generate it will cause overfitting in results. To avoid self-adaptive overfitting, 
patients of each dataset were randomly re-sampled into training and testing subgroups. 
Thereafter, the expression profiles were generated from training data and validated with 
testing data. Although this strategy eliminated overfitting, it still had a major drawback. The 
random re-sampling process introduced bias into the profiling and validating results, 
especially when the sample size of a dataset was small. A bootstrap strategy was applied to 
remove sampling bias by repeating the sampling-profiling-validating process a large number 
of times. Each bootstrapping repeat created an expression profile from the training data, 
which was used to calculate SEP scores of testing patients. SEP scores were used to classify 
patients and build an ROC curve, insulting in classification accuracy and AUC as test 
statistics to indicate the quality of the expression profile. These statistics obtained from all 
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bootstrapping repeats were summarized to get their median and 90% Confidence Interval (CI) 
values. Hence, this bootstrap re-sampling strategy allowed the objective and unbiased 
comparison of gene expression profiles and the approaches used to generate them. Every 
bootstrapping repeat also assigned a Z statistic and a rank to each gene. These results were 
summarized to make a final ranking of all genes for entire dataset. Genes consistently getting 
significant Z values or top-ranked were selected as reporters. (See Appendix A.4 for demo of 
patient re-sampling.) 
 
3.1.9 Gene Categorization According to Gene Ontology 
Gene Ontology (GO) is an infrastructure of controlled vocabularies supporting 
unambiguous description of genes and their products [109]. All vocabularies of GO are 
organized as a tree-like structure with three roots: ‘Biological Processes’, ‘Cellular 
Components’, and ‘Molecular Functions’. GO allows researchers consistently and 
conveniently query for attributes of a given gene, genes of a specific category, and even the 
associations between genes. In this study, reporter genes were categorized into the 
‘Biological Processes’ domain of GO, which includes sub-categories such as Cell Cycle and 
Signal Transduction. The route of mapping Unigene clusters into GO categories was: 
Unigene ID → Entrez Gene Symbol [110] → International Protein Index [111] → GO ID.  
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3.2 MAMA Project 
3.2.1 Developmental Stages 
The development of the MAMA (Meta-Analysis of MicroArray) project followed the 
common criteria of software engineering. It started with vision and requirement analyses, 
followed by use case analysis, system architecture design and data modeling. The database of 
MAMA was designed and implemented before developing a software application of data 
analysis. The sequential developmental stages of this application were software architecture 
design, package and class design, coding and testing. Other efforts involved in this project 
included loading data into database, User Interface (UI) design, and documentation. 
 
3.2.2 Data Models 
MAMA project used two data models to describe microarray data objects and their 
relationship. The data model adopted by the MAMA database is MAGE-OM (MicroArray 
Gene Expression – Object Model) [75]. MAGE-OM is a complex data model developed by 
MGED (Microarray Gene Expression Data) Society to facilitate the sharing of microarray 
data. It defines the concepts about most aspects of microarray-based experiments and their 
associations. (See Appendix B for more details about MAGE-OM classes.) Although the 
MAMA database is fully MAGE-compliant, only a minor portion of its tables have data 
loaded into them because the current project only dealt with the high-level analysis aspect of 
microarray data. Despite of the complexity of MAGE-OM, it is focused on the description of 
static data, but not the data analysis procedures. Therefore, the data analysis application 
needs its own data model. Since this application was coded with Java (J2SE, v1.4.2 Sun 
Microsystems Inc.), an object-oriented programming language, its data model has an object-
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oriented tree structure. Specifically, its root class is called ‘Workspace’, within which various 
data manipulation and analysis operations can be performed by end users. Each Workspace 
includes various types of data objects, such as ‘Query’, ‘Experiment’, and ‘Analysis’. Each 
of these objects has its own contents and associations to other types of data. For example, a 
‘Query’ object has attributes including its identifier, subtype, created date, and selection 
limits, and it can be related to a ‘Query Result’ object.  
 
3.2.3 Relational Database 
The database schema of MAMA included the schema of ArrayExpress [87, 88], a 
MAGE-OM-based public database. Denormalization tables were added to improve query 
performance. The MAMA database was implemented into an Oracle 9i (Release 9.0.1, 
Oracle Corporation) database system located on a Sun 280R server (Sun Microsystems Inc.). 
In the current version of MAMA, a server program interacts with this database using Java 
JDBC package to load or retrieve data. The open architecture of MAMA allows other 
developers to integrate other methods for these tasks. The MAMA database provides a 
centralized repository of public microarray datasets about cancer. End users have free, but 
limited, access to this database. They will be able to freely query about the stored microarray 
datasets or directly download complete datasets, but cannot modify existing data or load data 
into the database, which are the tasks of data curator and administrator.  
 
3.2.4 Server Program 
The MAMA server program is running as a Java servlet (J2EE Servlet Specification 2.3, 
Sun Microsystems Inc.) deployed in a Tomcat container (Apache Tomcat Version 4.1, 
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Apache Software Foundation). A servlet uses threads to handle concurrent requests sent by 
different clients and send back responses. (See Appendix C for more details about 
Servlet/Tomcat server.) The server program interacts with the MAMA database with Java 
JDBC package to query or load data, and the client program accesses data in the database 
through the server. The server and client programs communicate with each other through a 
pre-defined protocol. Beyond the client program provided by the current build, other 
developers can write their own as long as this protocol is implemented.  
 
3.2.5 Client Program 
The MAMA client program is a data analysis application executable on any computer 
system running JVM (Java Virtual Machine). Although it requires network connection to 
retrieve data from MAMA database through the server program, this program can be used as 
a stand-alone application. End users can load microarray datasets into the client program 
either by downloading them from the MAMA database or by directly importing them from 
text files. Afterward, they will be able to save or work with loaded datasets on their local 
machine. The client program has a Graphical User Interface (GUI) programmed with Java 
Swing to improve its user-friendliness. The software development followed the MVC 
(Model-View-Controller) design pattern. The ‘Model’ package defined the Java classes for 
data objects and maintained them in a hierarchical structure, the ‘View’ package included 
GUI components, such as List and Table, to render data objects, and the ‘Controller’ package 
implemented handlers of user events that might modify the data objects and/or the GUI 
components. These packages encapsulate the functions of the client program and interact 
with each other through software interface. (See Appendix D for more details about MVC 
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design.) The MAMA client also includes a data analysis package, which implements the 
statistical methods of microarray analysis, such as Pearson’s correlation analysis or Student’s 
t test. These methods are called by the ‘Controllers’ in response to the initiation of data 
analysis operations. The Eclipse Platform (version 3.0.1, Eclipse contributors and others, 
http://www.eclipse.org), an open-source product, was used for the creation, organization, and 
compilation of Java source codes.  
 
3.2.6 File Formats 
The MAMA client program accepts and processes two file formats. The first one is tab-
delimited text. It is the only data format accepted by the current build for data importing, and 
is also used for saving matrixes of expression measurements in ‘Workspaces’. The other 
format is XML (eXtensible Markup Language). XML documents organize data in 
hierarchical structure and label them with defined tags. They are machine-readable files and 
proper for data exchange between different computer programs. The MAMA client uses 
XML for the storage of all data objects in ‘Workspaces’ except matrixes of expression 
measurements, whose amount is usually too large to be processed as XML documents. The 
current project did not define any schema or DTD (Data Type Definition) for XML 
documents. Instead, it utilized the XML data-binding functions provided by Castor XML 
(version 0.9.6, Exolab Group, Intalio Inc., and Contributors), which could automatically map 
Java objects to XML documents or vice versa. The mapping rules were defined in an XML 
document, which can be downloaded together with the client program. (See Appendix L for 
Java-XML mapping with Castor.) 
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3.2.7 Open Source Framework 
MAMA is an open-source project. Its source code will be freely downloadable. 
Furthermore, the three components of MAMA project: database, server, and client, are 
independent of each other, which means other researchers can develop their own programs to 
interact with any of these components as long as those proper interfaces to existing 
components are implemented. The current version also provides a mechanism for users to 
plug in their own data analysis methods into the client program. The plug-in of a method 
includes two steps. The first step is to create a Java class that realizes the method. This class 
will be able to activate a procedure to run the method. It should also implement the API 
(Application Program Interface), which is designed for the method category belonged to by 
the method. Methods sharing the same API will have the same types of inputs and outputs. 
For example, all methods evaluating correlation between two genes will have two arrays of 
expression measurements that have the equal length as its inputs, and the value of a test 
statistic and its corresponding p-value as its outputs. The second step of method plug-in is to 
register the new method by providing information about its type, name, and path of Java 
class. A file including all registration information can also be downloaded together with the 
client program. (See Appendix O for more description of method plug-in.)  
 
3.2.8 Meta-Analysis Methods 
A key feature of MAMA data analysis software is the availability of meta-analysis 
methods. Meta-analysis is often referred to as ‘Analysis of Analyses’, a statistical technique 
that reviews the results from multiple individual studies to draw integrated conclusions. 
MAMA implemented two major types of meta-analysis methods: ‘combined tests’ and 
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‘measures of effect size’ [64]. Combined tests are applied to the results from individual 
studies, such as p-values, t and z test statistics, to obtain a combined test statistic. Examples 
of these tests are Fisher, Winer, and Stouffer combined tests, all of which were adopted by 
MAMA. Compared to combined tests, which provide only the statistical significance of 
hypothesis tests, measures of effect sizes are more informative because ‘effect size’ 
represents ‘the degree to which the null hypothesis is false’. Many meta-analysis methods 
have been developed to deal with two types of effect size: correlation coefficients (r) and 
standardized mean differences between two groups (d). These methods usually utilize r or d 
statistics obtained from individual studies to generate a summary statistic. (See Appendix E 
for more description of meta-analysis methods.) 
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CHAPTER IV 
RESULTS AND DISCUSSIONS 
 
4.1 Data Analysis 
4.1.1 Pilot Studies 
The pilot studies analyzed two published breast cancer datasets (Table 1A), mostly the 
Rosetta dataset. The purposes of these studies are to: 
• Evaluate the feasibility of using SEP as a prognostic index of cancer. 
• Verify the confounding effect of clinical indexes on expression profiling of cancer 
outcome. 
• Try partial correlation analysis to control the effect of confounders. 
• Confirm the prognostic value of microarray data on cancer outcome. 
 
4.1.1.1 Confounding Effect of Clinical Indexes 
The original study of Rosetta dataset selected 78 breast cancer patients from it to carry 
out expression profiling. 44 patients who did not develop recurrence and were followed up 
for at least five years were categorized into a good prognosis group, while the other 34 
patients who recurred within five years after diagnosis were considered as having poor 
prognosis. This study calculated the Pearson’s correlation between the expression of each 
gene and the recurrence outcome of patients, and 231 genes obtained significant correlation 
 
coefficient (|r| > 0.3, p < 0.01). The current study used these genes to calculate a SEP for the 
same 78 patients using Formula (1) within which the correlation coefficient r of each reporter 
genes was taken as its weight w.  
The density distribution of all 78 SEP scores was plotted in Fig. 1A and an unexpected 3-
peak mode was observed. Fig. 1B, on the other hand, separately plotted the density 
distributions of the scores of good and poor prognosis patients. Comparison of Fig. 1A and 
1B showed that the most of right and middle peaks were correspondingly composed of good 
and poor prognosis patients while the left peak was a mixture of patients from both prognosis 
groups. Shapiro-Wilk test [112] was used to test the normality of the two curves in Fig. 1B. It 
rejected the normality of good prognosis curve with p-value of 0.0022, but failed to reject it 
for the poor prognosis curve with p-value of 0.49. 
The existence of the left tails of both curves in Fig. 1B suggested that although all 
reporter genes were identified because of their observed significant correlation to recurrence 
outcome, some of them might more significantly correlated to other variable(s). This 
suggestion could be verified if the patients located in the left peak of Fig. 1A shared some 
common attributes that were not possessed by the patients in the middle and right peaks. This 
interpretation was consistent with the observations that most patients in the left tails were 
ER-negative and the majority of the reporter genes (165 of 231) were also significantly 
correlated to ER status of patients (p < 0.01).  
Chi-square tests were performed to evaluate the dependence of SEP scores on common 
clinical indexes. All 78 scores were artificially separated into two groups using -5 (left valley 
in Fig. 1A) as the cutoff. Clinical indexes were categorized according to the criteria used by 
the original study (e.g. ER: positive and negative; Grade: 1, 2, 3, and 4). Test result of all six  
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Figure 1A Density Distribution of SEP Scores 
of All 78 Breast Cancer Patients 
 
 
 
 
 
 
Figure 1B Density Distribution of SEP Scores 
of Both Prognosis Groups 
 
  
Figure 1C Density Distribution of SEP Scores 
of Both Prognosis Groups after Partial 
Correlation 
 
 
Figure 1 Density Distribution of SEP Scores 
Correlation or partial correlation analysis was 
based on microarray data of 78 breast cancer 
patients in Rosetta dataset. (1A) The 
distribution of all 78 scores were plotted 
together. SEP was calculated with 231 reporter 
genes identified by the original study. All 
reporters had significant correlation (p < 0.01) 
to 5-year recurrence outcome of breast cancer 
patients. Correlation coefficient r of each 
reporter was used as its weight to calculate SEP. 
(1B) The distributions of 44 scores from good 
prognosis patients and 34 scores from poor 
prognosis patients were separately plotted. SEP 
score were calculated with the same 231 genes 
and their weight. In general, good prognosis 
patients were expected to have higher SEP 
scores. (1C) The distributions of scores from 
good and poor prognosis patients were plotted 
again after partial correlation analysis. SEP was 
calculated with 127 reporters that had 
significant partial correlation (p < 0.01) to 5-
year recurrence after ER status of patients was 
controlled. Partial correlation coefficient r’ was 
used as weight of reporters. 
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available indexes were summarized in Table 2, which showed that the value of SEP was 
significantly dependent on tumor size, histological grade, ER and PR (Progesterone Receptor) 
status. Therefore, the confounding effect of these variables might have considerable 
influence on the expression profiling of breast cancer recurrence. 
 
Table 2:  
Chi-square Tests on SEP Scores and Clinical Indexes 
 
d.f.: degree of freedom, number of categories of each clinic index minus 1; χ2: chi-square test 
statistic, measurement of the association between two variables: SEP and a given clinical index; 
Grade: degree of morphological abnormality of cancer cells; Angioinvasion: invasion of cancer 
cells into blood or lymph vessels; ER: Estrogen Receptor; PR: Progesterone Receptor. 
 
Clinical Index d.f. χ2 p-value 
Age 2 0.51 0.776 
Tumor size 1 10.24 0.014 
Grade 3 13.10 0.014 
Angioinvasion 1 0.41 0.520 
ER status 1 42.55 <10-8
PR status 1 24.61 7X10-7
 
Fig. 2 presents a general causal model about the interrelationship of gene expression, 
disease outcome, and clinical indexes. In the model, both gene expression and clinical 
indexes are causal variables of cancer outcome while they are correlated to each other. Thus, 
when the gene-outcome correlation between gene and outcome is under investigation, 
clinical indexes are potential confounders. In Fig. 2, if both r23 and r13 are significant, r12 will 
not represent the ‘intrinsic’ correlation of a gene to disease outcome. When an expression 
profile includes many confounded genes, the value of this profile as an independent 
prognostic index will be reduced because its predictive ability varies with the clinical 
background of patient cohorts. To avoid acquiring expression profiles with inconsistent 
 41
performance, Gruvberger suggested that expression profiling should be carried out separately 
for ER-positive and -negative patients [61]. However, this suggestion did not give an 
ultimate solution to the problem. Since ER status is not the only confounding index 
according to previous chi-square tests, patients need to be further sub-grouped to control 
other indexes. Consequently, sample size of subgroups will be too small to produce 
statistically meaningful results. More sophisticated statistical techniques are required to 
generate more general and independent prognostic index of cancer from microarray data.  
This section demonstrated the advantage of using SEP to summarize expression profile 
into a numeric value. Common statistical analyses could be applied to this variable to provide 
powerful and straightforward results. Therefore, the rest part of this study would use SEP as 
a potential prognostic index of cancer outcome and compare it to other indexes in terms of 
their clinical value. 
 
Figure 2 Confounding Effect of Clinical Index on Gene-Outcome Correlation  
Observed correlation between gene expression and disease outcome (r12) is intervened by the clinical index 
because of the gene-index (r13) and index-outcome (r23) correlations. Direction of arrowheads indicates causal 
relationships.  
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4.1.1.2 Partial Correlation Analysis 
This analysis controlled the confounding effect of ER status, which has the highest 
correlation to SEP according to Table 2, from the calculation of gene-recurrence correlation. 
The conditional expected expression levels (E) of each gene in ER-positive and -negative 
patients were separately estimated by calculating the group averages (Appendix A.6). 
Thereafter, Formula (2) was used to subtract E from the original measurements to obtain 
residuals. These steps were repeated for all genes to generate a data matrix composed of the 
residuals. This matrix was used to replace the original data matrix in subsequent steps.  
A partial correlation coefficient (r’) of each gene to recurrence outcome was then 
obtained from the residuals. Among all 19,174 Unigene clusters, 127 had significant partial 
correlation (|r’| > 0.3, p < 0.01), including Cyclins (B2, E2, etc.), kinases (PK428, PGK1, 
etc.), transcription factors (FOXM1, GTF3C1, etc.), growth factors (TGFB3, FGF18, etc.), 
and genes related to cytokinesis (KIF3B, PRC1, etc.). This list of reporter genes had only 
about half the size of the previous 231-gene list, which was not unexpected because many 
genes in the first list were highly correlated to ER status, the controlled variable.  
SEP scores of all 78 patients were re-calculated with Formula (1) while r and L were 
replaced with r’ and Lresidue. The density distributions of the new scores corresponding to two 
prognosis groups are separately plotted in Fig. 1C. Both curves are bell-shaped and Shapiro-
Wilk tests failed to reject their normality (p = 0.50 and 0.79 respectively). Although 
Student’s t test rejected the equality of group means with p < 0.0001, these two curves shared 
noteworthy overlapping. Classification of patients had the best fit to actual observations 
when cutoff of SEP was -2.2. In particular, nine poor prognosis and four prognosis patients 
were incorrectly classified, giving an overall accuracy of 83.3%.  
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Logistic regression models were used to compare the expression profiles derived from 
regular and partial correlation analyses. Table 3 summarized the -2LL (-2 Log Likelihood) 
fitness and classification accuracy of various models. All models had SEP as independent 
variable and multi-variate models also included ER status and other clinical indexes (PR 
status, tumor size, grade, angioinvasion, and age of patients). Results in Table 3 suggested 
that: 
• When SEP was acquired from partial correlation analysis, models had improved 
fitness. 
• The model including all available indexes and SEP obtained from partial correlation 
had the best fitness (51.7) and accuracy (84.6%). Nevertheless, the difference of 
classification accuracy among models was not significant. 
• Multi-variate models combining the clinical indexes and SEP had better fitness than 
uni-variate models of SEP. 
 
Table 3: 
Comparison of SEP and Clinical Indexes Using Logistic Regression Models 
 
Regular Correlation: reporter genes and their weight were obtained by calculating the Pearson’s 
correlation between expression measurements and breast cancer recurrence; Partial Correlation: 
reporter genes and their weight were obtained by calculating the Pearson’s correlation between 
expression measurements and breast cancer recurrence after the effect of ER status was controlled; -
2LL: -2 log likelihood, indicating the fitness of models to actual observations; Accuracy: accuracy of 
patient classification using the model; Intercept: initial model having no independent variable and 
including the constant term only; ER: Estrogen Receptor; all indexes: Age, Angioinvasion, Grade, 
Tumor Size, and ER/PR statuses. 
 
Regular Correlation Partial Correlation 
Independent Variable(s) 
–2 LL Accuracy –2 LL Accuracy 
Intercept 106.8 56.4% 106.8 56.4% 
SEP only 71.6 83.3% 66.5 78.2% 
SEP + ER 66.7 79.5% 63.8 80.8% 
SEP + all indexes 54.1 80.8% 51.7 84.6% 
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Although the superiority of partial correlation analysis was supported by Table 3, these 
results were obtained from self-adaptive processes and might include overfitting. For 
example, when both expression profiles were cross-validated with the Stanford dataset, the 
127-gene profile did not perform better than the 231-gene profile. This observation revealed 
a critical drawback of partial correlation analysis. Since the conditional expected expression 
level (E) in Formula (2) was estimated from experimental data, extra variance and overfitting 
was introduced into the analyses and results. Furthermore, there existed more confounders 
other than ER status as showed in Table 2. Chi-square tests showed that the SEP calculated 
with the 127-gene profile was not dependent on ER status any more (p = 0.67), but still 
significantly correlated to PR status (p = 0.039), tumor size (p = 0.019), and histological 
grade (p = 0.0002). Although Formula (2) could be iteratively used to control all confounders, 
such a process would introduce even more variance and overfitting. Therefore, partial 
correlation analysis was not recommended by this study.  
 
4.1.1.3 Case Study: a Gene Regulatory Pathway 
In addition to expression profiling of sample features, an important application of 
microarray data is to discover or confirm gene regulatory pathways by revealing correlated 
expression of genes. Partial correlation analysis can be used for this purpose because gene-
gene correlation is also influenced by confounders. For example, if two genes are both highly 
correlated to ER status, they are very likely to have an observed correlation with each other 
too even they are functionally irrelevant. 
The residuals obtained from controlling ER status were used to perform a 2-way 
hierarchical clustering of 78 breast cancer patients and 127 reporter genes (Fig. 3). Patient  
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Figure 3 Clustering of 127 Reporter Genes and 78 Breast Cancer Patients 
Results were obtained from partial correlation analysis that controlled the ER status of patients from 
original expression measurements of Rosetta breast dataset. Identified 127 reporter genes were 
horizontally clustered into two major branches, corresponding to positive (right) and negative (left) 
correlation to disease outcome. Similarly, 78 breast cancer patients were vertically clustered into two 
major branches, corresponding to good (up) and poor (down) prognosis. Each of these branches also 
included two sub-branches. In the case of the branch of good prognosis patients, the bigger sub-branch 
included 33 patients, but only four of them had poor prognosis while seven of eight patients in the 
smaller sub-branch had poor prognosis. The branch of poor prognosis patients had the similar pattern.  
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clustering deviated in two first-level branches, corresponding to two prognosis groups. There 
was a large sub-branch of 29 patients including only two poor prognosis ones. Genes were 
clustered into two first-level branches too, corresponding to positive and negative correlation 
to recurrence outcome. A small sub-branch of eight reporter genes was further investigated 
because it demonstrated a very strong gene co-expression pattern. Literature searches 
indicated that six of these genes have functions directly or indirectly related to cell cycle 
regulation. Over-expression of CCNB2 (cyclin B2) will block the exit of mitosis [113]. 
MAD2L1 is located upstream of CCNB2 in a known gene pathway [114, 115]. BUB1 is a 
direct regulator of MAD2L1 [116] and HEC is required by kinetochore recruitment of 
MAD1-MAD2 complex [117]. Furthermore, FOXM1 gene is a transcription factor regulating 
several cyclins [118] while PRC1 is a substrate of several cyclin-dependent kinases [119]. 
Fig. 4 presented a diagram of regulatory relationship between these genes. The expression of 
all six genes was highly correlated to recurrence of 78 breast cancer patients in Rosetta 
dataset (Table 4), which implied that this pathway played an important role in breast cancer 
recurrence. 
The correlation between the genes described above and breast cancer recurrence was 
validated with testing data including 19 patients from Rosetta dataset and 48 patients from 
Stanford dataset. The resulting correlation coefficients (r) and corresponding p-values were 
listed in Table 4. As in training data, all genes had negative correlation to recurrence 
outcome. However, most of them did not get a significant correlation coefficient (Table 4), 
probably because of the relatively small sample size of testing data. Therefore, two meta-
analysis methods, Fisher and Stouffer combined tests, were applied to the results obtained 
from two testing datasets. The right side of Table 4 gave the p-values of each gene obtained 
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from both tests. All p-values were significant or marginally significant while Fisher 
combined test was more conservative than Stouffer in general. 
 
 
Figure 4 A Cell Cycle-related Pathway Revealed by Partial Correlation Analysis 
All Genes were related to a spindle checkpoint pathway according to literature search. Results were 
obtained from the microarray data of 78 breast cancer patients in Rosetta datasets. Direction of 
arrowheads indicated the regulatory relationship (solid line: direct regulation; dashed line: indirect 
regulation). Label numbers were the Pearson’s correlation coefficient (r) between each pair of genes. 
 
Although the focus of this study was not gene-gene relationship, this case study gave an 
interesting example about the application of microarray data to research of gene pathway. 
Moreover, cross-validation results suggested that independent datasets might share some 
common information. Meta-analysis demonstrated its value in microarray analysis by 
successfully combining such information from two testing datasets. 
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Table 4: 
Correlation of Genes in a Cell Cycle Pathway to Breast Cancer Recurrence 
 
Combined test: a type of meta-analysis test combining the test statistics of individual tests; n: number of 
patients having non-missing measurements of the gene; r: Pearson’s correlation coefficient, negative r 
indicated that gene was over-expressed in poor prognosis patients; Fisher: Fisher’s combined tests, using 
p-values of individual tests as its inputs; Stouffer: Stouffer’s combined test, using z test statistics of 
individual tests as its input.  
 
Training Data Testing Data Combined test
78 patients 
(Rosetta) 
19 patients 
(Rosetta) 
48 patients 
(Stanford) Fisher Stouffer
Gene 
Symbol 
Unigene 
ID 
n r p-value n r p-value n r p-value p-value p-value
BUB1 Hs.98658 77 -0.41 0.0002 19 -0.36 0.130 47 -0.21 0.157 0.064 0.038 
CCNB2 Hs.194698 78 -0.37 0.0009 19 -0.44 0.059 N/A N/A N/A 0.059 0.059 
FOXM1 Hs.239 77 -0.37 0.0009 19 -0.30 0.212 48 -0.29 0.046 0.034 0.022 
HEC Hs.58169 78 -0.39 0.0004 19 -0.14 0.568 7 -0.66 0.107 0.158 0.123 
MAD2L1 Hs.79078 78 -0.35 0.0017 19 -0.41 0.080 47 -0.13 0.384 0.090 0.064 
PRC1 Hs.344037 78 -0.37 0.0009 19 -0.45 0.053 N/A N/A N/A 0.053 0.053 
 
 
The pathway in Fig. 4 functioned as a block of mitosis exit, and the over-expression of 
CCNB2 and other genes was expected to slow down cell division and tumor growth, which 
would lead to good prognosis of patients. However, according to Table 4, the observed 
correlation coefficients between good prognosis and genes were all negative. This conflict 
might be explained by the fact that actively growing tumors had a larger portion of cycling 
cells than latent ones. Therefore, since above genes were known as being over-expressed 
during mitosis, quickly growing (poor prognosis) tumors would contain more mRNA of 
those genes. This observation occurred when the influence of cell cycle-dependent gene 
expression overwhelmed the functions of genes. This interpretation indicated the importance 
of biomaterial components on expression profiling.  
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4.1.2 Expression Profiling using Multiple Datasets 
Although the pilot studies confirmed the confounding effect of clinical indexes on 
expression profiling of cancer outcome, they did not propose practical approaches to generate 
more generally applicable profiles. Therefore, the following studies were carried out on more 
than one microarray dataset to: 
• Derive expression profiles from multiple independent microarray studies. 
• Combine training/testing validation and bootstrap strategies to make unbiased 
estimation about the quality of expression profiles. 
• Objectively compare SEP to currently used prognostic indexes by cross-validating of 
datasets. 
• Verify the recurrence model of breast cancer proposed by Retsky [71], and generate 
an expression profile corresponding to this model. 
 
4.1.2.1 Analysis of Individual Datasets 
In this section, expression profiles were generated separately from two breast cancer 
datasets, Rosetta and Stanford. Identical steps were applied to both datasets during the 
process. Patients were classified using 3-year recurrence outcome as the cutoff, according to 
the recurrence model of Retsky (Appendix A.1). The size of the resultant prognosis groups 
was given in Table 1A. Source expression data were pre-processed and filtered as described 
in Chapter 3. 
The first step was to split patients into training/testing subgroups. About two-thirds 
patients of each dataset were randomly selected into a training subgroup, leaving the rest for 
testing the expression profile derived from the training data (Appendix A.4). The testing 
 50
results would be critically influenced by sampling bias since the sample size of the current 
datasets could not provide satisfying statistical power. Consequently, a ‘no replacement 
bootstrap’ approach was performed to eliminate the sampling bias from the results. This 
approach repeatedly re-sampled patients into training/testing subgroups and executed 
identical analyses on each combination. The results obtained from all re-samplings were 
collected and summarized to draw an unbiased final conclusion.  
The differential expression of each gene in patients having good and poor prognosis was 
assessed using the data of each re-sampled training subgroup. A hypothesis test about gene-
outcome correlation was performed on every gene. Since it was a two-group comparison 
problem, Wilcoxon Rank Sum Test (RST) was used for the hypothesis test. As a non-
parametric method, RST was less powerful than Student’s t test, but it did not assume the 
normality of expression measurements, which was violated by many genes in microarray 
data. RST calculated a Z test statistic for each gene. When there were at least eight 
measurements in each prognosis group, RST Z followed standard normal distribution N (0, 
1). A gene would have positive Z if it was over-expressed in patients having good prognosis 
(Appendix A.7). Given the results of RST tests, all genes were ranked according to the 
magnitude of their Z values. Genes having the highest magnitude of Z statistic were top-
ranked and selected into an expression profile as reporters. The number of reporters in a 
profile was denoted as N. Some reporters might be false positives because of the problem of 
multiple hypothesis tests. Increasing N would improve the sensitivity of reporter selection, 
but reduce the specificity at the same time. Instead of arbitrarily setting the value of N, the 
current study applied a stepwise procedure to find an N that would optimal balance the 
sensitivity and specificity. This procedure increased the value of N one by one from 1 to 100, 
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and at each step, the SEP scores of testing patients were calculated with the top-ranked N 
genes. The SEP scores were calculated using Formula (1), while the weight w of each gene 
was its RST Z statistic and the expected expression level E was estimated from the training 
data (Appendix A.8). The resultant SEP scores were used to classify testing patients with 
cutoff = 0. Patients with positive or negative scores would be classified into good or poor 
prognosis group respectively. The accuracy of classification was obtained by comparing 
SEP-classification to actual patient outcomes. SEP scores of a testing subgroup were also 
used to build an ROC curve. The area under the curve (AUC) was an index indicating the 
ability of SEP to differentiate good and poor prognosis patients. Since ROC curve took the 
relative quantity of each score into account, it was more informative and powerful than 
dichotomous classification. 
Both datasets had totally 10,000 bootstrap re-samplings, each of which identically went 
through the above steps. Consequently, unbiased bootstrapping estimation of test statistics 
was concluded from all re-samplings. The upper half of Table 5A shows the median and 90% 
Confidence Interval (CI) of SEP-classification accuracy when N was 100. Bootstrapping 
statistics of two datasets were close to each other, although Rosetta dataset generally had 
better results. The left column in this table was the size-weighted averages summarized from 
both datasets. To calculate these values, the test statistics of both datasets were weighted by 
the size of the corresponding testing subgroups and averaged at each re-sampling. The final 
bootstrapping statistics were concluded from the size-weighted averages of all re-samplings. 
As in Table 5A, the median size-weight average accuracy was just above 70% and a 
symmetric 90% CI ranged from 61% to 80%. Eight of the 10,000 re-samplings got size-
weighted average accuracy lower than 50%, giving a 0.0008 bootstrapping p-value in favor 
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of that SEP of testing patients suggested their recurrence outcome. Table 5B presented the 
median and 90% CI of AUC when N was 100. The median of size-weighted average AUC 
was 0.767. Rosetta dataset got better results than Stanford data again, probably because of its 
relatively larger sample size and/or less diverse clinical background of patients. 
 
Table 5:  
Bootstrapping Test Statistics Collected from 10,000 Re-samplings 
 
10,000 bootstrapping re-samplings were performed on both individual breast cancer datasets and their 
combination. At each re-sampling, patients of each dataset were split into training/testing subgroups. 
Each dataset ranked genes based on RST Z statistic applied to training data and selected 100 top-ranked 
genes as reporter. These reporters and their weight were used to calculate SEP of testing patients. 
Resultant scores were used to classify testing patients and build ROC curves. Both classification 
accuracy and AUC were adjusted by size of testing subgroups to get the size-weighted averages. 
Bootstrapping median and 90% CI of these statistics were listed in tables.  
 
Table 5A: Classification Accuracy of SEP Scores 
 
Testing Dataset Training 
Dataset 
Bootstrapping 
Statistic Rosetta Stanford Size-weighted Avg. 
 5% high 84.00% 83.33% 80.00% 
Individual Median 71.43% 70.00% 70.59% 
 5% low 58.06% 55.00% 60.98% 
 5% high 83.33% 85.00% 80.43% 
Combined Median 71.43% 71.43% 71.11% 
 5% low 58.33% 56.52% 61.54% 
 
Table 5B: Area of ROC Curves (AUC) Built with SEP Scores 
 
Testing Dataset Training 
Dataset 
Bootstrapping 
Statistic Rosetta Stanford Set Size-weighted Avg. 
 5% high 0.895 0.902 0.860 
Individual Median 0.775 0.764 0.767 
 5% low 0.640 0.604 0.668 
 5% high 0.903 0.933 0.877 
Combined Median 0.786 0.799 0.789 
 5% low 0.654 0.636 0.689 
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The changing of size-weighted average accuracy and AUC with N were separately 
plotted in Fig. 5A and 5B. The middle curve in each figure corresponded to the medians 
while the other two curves parenthesized the ranges of 90% CI. Although all curves generally 
ascended with the increasing of N, they were not linear. They went up dramatically at the 
beginning and reached a plateau when N was around 60, suggesting that the classification 
and differentiation ability of expression profiles were about to get to their maximum. 
Consequently, it was empirically decided that the sensitivity and specificity of reporter 
selection were optimally balanced at N = 60.  Furthermore, the width of 90% CI in both 
figures had no noticeable change in both figures since N was larger than 5, indicating that 
increasing N would improve the performance stability of SEP as a classifier. 
In the next step, each gene was assigned a final rank from each dataset by counting how 
many times it was ranked top-100 by the dataset through all 10,000 re-samplings. The 60 
genes having the most counts were selected to make an expression profile of breast cancer 3-
year recurrence. The weight of each reporter was its RST Z statistic calculated with the data 
of all patients in the dataset. Both datasets got a 60-gene profile. The complete lists are 
presented in Appendix F. Both 60-gene profiles were precise classifiers when they were self-
validated by the same datasets generating them. SEP scores had 79.3% classification 
accuracy and 0.89 AUC in Rosetta dataset, and 82.3% accuracy and 0.93 AUC in Stanford 
dataset. These results clearly had overfitting because of the existence of false positives in 
expression profiles. 
The microarray analysis procedure developed in this section was able to provide unbiased 
estimation about the quality of expression profiles. Therefore, this procedure could be used to 
compare different strategies of expression profiling. Bootstrapping test statistics obtained  
 54
 Figure 5A Classification Accuracy of SEP Scores 
 
 
Figure 5B Area of ROC Curves (AUC) Built with SEP Scores 
 
Figure 5 Bootstrapping Statistics Separately Obtained from Breast Cancer Datasets 
Changing of average test statistics was traced with number of reporter genes in expression profiles (N). 
At each of 10,000 re-samplings, SEP scores of testing patients were calculated with N reporters and their 
weight derived from the training patients, separately in Rosetta and Stanford breast cancer datasets. The 
averages were adjusted by the size of testing subgroups. Three bootstrapping statistics were reported in 
each figure. The blue line represents the bootstrapping median of size-weighted averages while the 
orange lines parenthesize the bootstrapping 90 CI of size-weighted averages. (5A) Testing patients were 
classified according to their SEP scores. The accuracy of classification was obtained by comparing SEP-
classification to actual events. (5B) SEP scores of testing patients were used to build ROC curves. The 
area under ROC curve represented the ability of SEP to differentiate patients.  
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from two datasets had no significant difference, suggesting that they had similar quality and 
were potentially suitable for multi-dataset analysis. Furthermore, stepwise procedure denied 
the necessity of high sensitivity of reporter selection. The influence of false positives on 
quality of expression profiles will be discussed in last section of this chapter. 
 
4.1.2.2 Cross-validation of Two Datasets 
In last section, two breast cancer datasets had similar results in terms of bootstrapping 
test statistics. However, the 60-gene profiles generated from these datasets barely overlapped 
with each other (Appendix F) although reporters of both profiles were selected from the same 
5,569 Unigene clusters. Only two genes, BUB1 and LRP8, appeared in both profiles. The 
following steps cross-validated the 60-gene profile of each dataset using the data of the other 
dataset.  
SEP of validating patients was calculated with Formula (1), using the 60 reporters and 
their weights obtained from the validated dataset. Expected expression level E of each gene 
was set as 0 by default, assuming that patients of both datasets were sampled from the same 
population. SEP scores of validating patients were used to classify patients with cutoff = 0. 
Consequently, 48 Stanford patients were correctly classified by Rosetta profile, giving an 
accuracy of 77.4% (p < 0.0001, 90% CI [69-86%]); and 58 Rosetta patients were correctly 
classified by Stanford profile, giving an accuracy of 70.3% (p = 0.0002, 90% CI [62-79%]). 
SEP scores were also used to build ROC curves. Classification accuracy and AUC results 
were listed in Table 6. The size-weighted averages were 73.6% and 0.795 respectively, 
which are impressive results considering the difficulty of cancer prognosis.  
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 Table 6:  
Cross-validation of Expression Profiles Derived from Breast Cancer Datasets 
 
60 reporters top-ranked by each validated dataset and their weight were used to calculate a SEP for each 
patient in the validating dataset. Resultant SEP scores were used to classify validating patients with 
cutoff equal to 0 and to build ROC curves. Subsequent classification accuracy and AUC were listed. 
Average of these statistics was adjusted by the sample size of validating datasets.  
 
Validated Dataset Validating Dataset Accuracy AUC 
Rosetta Stanford 77.42% 0.808 
Stanford Rosetta 70.73% 0.786 
Size-weighted Average 73.61% 0.795 
 
The SEP of validating patients was compared to known prognostic indexes of breast 
cancer using logistic regression models. Each uni-variate model was built with an individual 
index as the independent variable. The fitness of models to actual observations of recurrence 
outcome was listed in Table 7A, which showed that the models of both datasets had the 
smallest -2LL and the largest AUC when SEP was the independent variable. This result 
suggested that SEP was superior to all the other indexes. Histological grade had the best 
performance except for SEP and surprisingly, models using tumor size as the independent 
variable were among those having the worst fitness. Multi-variate models jointly including 
all available indexes were also built since it was better practice to synthesize multiple 
prognostic indexes to make clinical decisions. A forward stepwise procedure was applied to 
generate these models. At each step, one independent variable, which would improve model 
fitness better than all the remaining indexes, was added into the model. Table 7B listed the 
sequential addition of the indexes and the consequent statistics of the models. When SEP was 
used as an independent variable, it was always the one to be added first. The SEP-included 
multi-variate models of two datasets had AUC equal to 0.858 and 0.837, the best results in 
this study. When SEP was excluded from the models, other indexes were added into models 
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in similar sequence. The model fitness difference between models with and without SEP was 
marginally significant. In the case of Stanford dataset, the model without SEP reduced the 
final AUC by 0.04 and increased the -2LL by 3.3. This result supported the first hypothesis 
of the current study: microarray data provides extra information about cancer outcome 
beyond currently used clinical indexes. This conclusion was objective since overfitting in 
results was avoided by cross-validation process. 
 
Table 7:  
Comparison of Prognostic Indexes using Logistic Regression Models 
 
ER: Estrogen Receptor status; PR: Progesterone Receptor status; Size: tumor size; Node: lymph node 
metastasis; Grade: degree of morphological abnormality of cancer cells -2LL: -2 log likelihood, smaller 
-2LL indicated better model fitness. Each uni-variate model (Table 6A) had only one independent 
variable. Multi-variate models (Table 7B) were built with forward stepwise procedure, which added 
independent variables into a model one by one. Table 7B also shows the comparison of multi-variate 
models with or without SEP. 
 
Table 7A: Fitness (-2LL) of Uni-variate Models  
 
Dataset Null SEP ER PR Size Node Grade Age 
Rosetta 108.7 92.2 98.0 103.5 101.2 N/A* 94.5 95.5 
Stanford 83.6 66.5 79.1 N/A 80.9 79.7 70.1 83.5 
 
 
Table 7B: Fitness (-2LL) of Multi-variate Models  
 
Dataset   Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 
SEP Age Grade Size ER PR With SEP 
92.2 82.7 79.9 78.6 78.2 76.9 
Age Grade ER Size PR  
  
Rosetta 
  Without SEP 
95.5 84.8 81.5 79.8 79.2  
SEP ER Grade Node Size Age With SEP 
63.5 61.3 60.2 59.5 59.3 58.9 
Grade ER Size Node Age  
  
Stanford 
  Without SEP 
70.6 65.2 63.2 62.5 62.2  
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Cross-validation results suggested that Rosetta and Stanford datasets share common 
information about prognosis of breast cancer. Therefore, such common information would 
constitute more general expression profiles if it could be extracted from multiple datasets. It 
was further implied that high sensitivity of reporter selection was unnecessary. Both 60-gene 
profiles performed well on the validating patients although the little overlapping between 
them suggested that both lists missed many true positives.  
 
4.1.2.3 Combination of Individual Datasets 
A straightforward strategy was used in this study for multi-dataset expression profiling. It 
directly combined the training subgroups of two datasets after each bootstrapping re-
sampling. No extra data processing was necessary for this combination as long as both 
datasets had been normalized to consistent scales. This assumed that patients of independent 
datasets were sampled from the same general population, which was also required by other 
cross-dataset analyses including meta-analysis. 
Reporter genes were selected from the combined subgroups with the same procedure 
performed on the individual subgroups. Thereafter, reporters and their weight were 
separately verified by both testing subgroups. The upper half of Table 5A and 5B gave the 
median and 90% CI of SEP-classification accuracy and AUC of 10,000 re-samplings when N 
was 100. Bootstrapping test statistics of size-weighted averages were also listed in these 
tables, which were generally higher than those obtained from the individual datasets. The 
median size-weighted accuracy and AUC were raised by 0.52% and 0.022 respectively. 
However, the difference was not significant. After 10,000 re-samplings, the comparison of 
results obtained from these two strategies showed that the difference in AUC had a one-tailed 
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bootstrapping p-value equal to 0.26. SEP scores incorrectly classified more than half testing 
patients only in five re-samplings when the cutoff was 0 (bootstrapping p = 0.0005). 
Fig. 6A and 6B compared the median size-weighted average accuracy and AUC obtained 
from individual datasets (blue lines) and the combined dataset (red lines). Blue curves were 
higher than the corresponding red curves at the beginning, which indicated that individual 
datasets were good at consistently identifying a few ‘true’ positive reporters having the 
highest ranks. These reporters and their weights were dataset-specific, so they did not 
perform on the combined dataset as well as on the individual ones. However, red lines grew 
up faster in both figures and they were generally above the corresponding blues lines after N 
was about 10. 
Same as the individual datasets, the combined dataset gave each gene a final rank 
according to how many times it was ranked within top-100 across the 10,000 re-samplings. 
The counts of top-300 genes obtained from both individual datasets and the combined dataset 
were plotted in Fig. 7. It illustrated that the specificity of reporter selection was low with 
given data. For example, the 100th genes of all three datasets had less than one-third 
probability to be selected into top 100 by any re-sampling. This observation explained why 
two re-samplings could generate fairly different expression profiles. Nevertheless, the 
combined dataset selected reporters, especially those finally ranked between 30 and 150, 
more specifically than the individual ones. Theoretically, increased sample size accounted for 
this improvement.  
The 60 genes top-ranked by the combined dataset and their weight defined an expression 
profile associated to 3-year recurrence of breast cancer. This was an optimal profile 
achievable with the current data and methods. Table 8 listed some of these genes by giving  
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 Figure 6A Comparison of Classification Accuracy between Single-dataset and Multi-dataset Profiling  
 
 
Figure 6B Comparison of ROC Curve Area (AUC) between Single-dataset and Multi-dataset Profiling 
 
Figure 6 Comparison of Expression Profiling Strategies  
Changing of average test statistics was traced with number of reporter genes in expression profiles (N). At each 
of 10,000 re-samplings, SEP scores of testing patients were calculated with N reporters and their weight derived 
from the training patients of individual datasets or their combination. The averages were adjusted by the size of 
testing subgroups. Both blue lines in the figures were the same bootstrapping medians as in Figure 5A and 5B. 
The red lines were made of bootstrapping medians derived after the integration of two datasets. The two lines in 
each figure intercept when N was less than 10, indicating that the data integration strategy became superior 
afterwards. (6A)  Expression profiling using individual datasets or combined dataset was compared in terms of 
patient classification accuracy of SEP scores. The combined dataset increased bootstrapping median of 
classification accuracy by 0.52% when N was 100. (6B)  Expression profiling using individual datasets or 
combined dataset was compared in terms of area of ROC curves built with SEP scores. The combined dataset 
increased bootstrapping median of AUC by 0.022 when N was 100. 
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Figure 7 Comparison of Reporter Selection Consistence 
Two individual breast cancer datasets and their combination ranked genes based on how many times they were 
selected into the top-100 reporter lists across 10,000 bootstrapping re-samplings. The counts of the top-300 
genes of each dataset are plotted in this figure. (blue line: Stanford dataset, green line: Rosetta dataset, red line: 
the combined dataset)  
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the counts and ranks of each reporter obtained from three datasets. (See Appendix F.1 for 
complete lists of reporter genes.) Two genes, BUB1 and LRP8, were presented in all three 
60-gene profiles while 15 others (CDC20, BECN1, etc.) were only within the profile of the 
combined dataset. These 17 genes got higher ranks from the combined dataset because of 
their low inter-dataset variance. Two well-known molecular markers of breast cancer, BCL2 
[120] and ESR1 [121], were ranked 4th and 30th by the combined dataset.  
To explore the functions of identified reporters, all genes in the final top-60 lists were 
mapped to the ‘Biological Process’ domain of Gene Ontology. Fig. 8 illustrated the 
categorization of these genes using GO and the numbers of genes in each category. 
According to this figure, most reporters have been related to important cellular processes 
such as cell cycle and transcription. Some sample reporters identified from the combined 
dataset and their GO categories were: 
• GO:0007049 || Cell cycle || CCNA2, CDC20, KIFC1, etc. 
• GO:0007165 || Signal transduction || ESR1, LRP8, EXT1, etc. 
• GO:0006350 || Transcription || TFDP1, GATA3, TLE1, etc. 
• GO:0050896 || Response to stimulus || BECN1, ACTL6A, BCL2, etc. 
• GO:0044267 || Protein modification || UBQLN1, BUB1, CDC25B, etc. 
Analyses in this section verified the second hypothesis of the current study: expression 
profiling across multiple datasets improved the quality of expression profiles. According to 
Fig. 7, this improvement was probably the consequence of higher reporter selection 
specificity. In the last section of this chapter will give more discussion on this topic. The 60-
gene profile derived from the combined dataset was recommended by this study as a valuable 
prognostic index of breast cancer. However, no more published datasets were available to  
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verify or further improve this profile. Up till now, all microarray analyses have been 
performed on breast cancer datasets. To verify the methods and results of previous studies, 
microarray datasets about lung cancer were also investigated in the following section.  
 
4.1.2.4 Results from Lung Cancer Datasets 
The microarray analyses of this section involved four published datasets about lung 
cancer (Table 1B). Because of their small sample sizes, Stanford and Ontario datasets were 
only used to validate the expression profiles derived from the other two datasets. Harvard and 
Michigan datasets were both generated from oligonucleotide gene chips produced by 
Affymetrix Inc. All genes were mapped to unique Unigene clusters. 4,036 clusters presented 
in both Harvard and Michigan datasets were used for expression profiling. Only 
adenocarcinoma patients were analyzed due to the high diversity of lung cancer subtypes. All 
four datasets provided clinical data and survival outcome of patients, but the recurrence 
information was incomplete. Literature searches failed to find a temporal model about lung 
cancer outcome similar to the model proposed by Retsky about breast cancer. Alternatively, 
lung cancer patients were classified according to their 2-year survival outcome. This 
classification was based on the fact that about 60% of invasive lung cancer patients did not 
survive more than two years after diagnose [122].  
Similar to what was applied to the breast cancer datasets, each lung dataset was analyzed 
with the following steps: 
• About two-thirds patients were randomly selected into a training subgroup. 
• Genes were ranked according to Wilcoxon RST performed on data of individual 
training subgroups and their combination. 
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• Top-ranked N genes and their RST Z were used to calculate SEP of the testing 
patients. 
• Resultant SEP scores were used as a 2-year prognostic index of lung cancer survival.  
• Above steps were repeated for 1,000 times.  
• Both individual datasets and their combination assigned a final rank to each gene 
according to how many times it was ranked within top 100 by all re-samplings. 
Fig. 9 plots the size-weighted median and 90% CI of AUC summarized from 1,000 
bootstrapping re-samplings. The blue and read curves respectively correspond to individual 
and the combined datasets. All curves grew up in the same pattern as what was observed in 
Fig. 5B when N was increased from 1 to 100. The red lines were generally above 
corresponding blue lines, confirming that the combined dataset generated more 
discriminative profiles. The difference of median AUC was 0.022 at N = 100. However, 
comparing to Fig. 6B, the curves of median AUC were located at an obviously lower level. 
Specifically, the median AUC of the combined dataset dropped from 0.789 to 0.685 at N = 
100. The classification accuracy of SEP had similar results and it bootstrapping p-value was 
0.029, in favor of rejecting the null hypothesis of 50% accuracy.  
The availability of Ontario and Stanford lung datasets made it possible to validate the 
expression profile derived from the combination of Michigan and Harvard datasets. Because 
of inconsistent microarray design, many identified reporter genes were not presented in the 
validating datasets. N of expression profile was increased from 60 to 100. Respectively, 53 
and 78 of 100 reporters identified from the combined dataset were found in Ontario and 
Stanford datasets. These genes and their weight were used to calculate SEP of validating 
patients, and patients were classified into two prognosis groups with the cutoff equal to 0.  
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Figure 9 Bootstrapping ROC Curve Statistics Obtained from Lung Cancer Datasets 
Changing of test statistics was traced with the number of reporter genes in expression profiles (N). 1,000 
bootstrapping re-samplings were carried out. The blue lines represent the bootstrapping medians and 
90% CIs of size-weighted average AUC when expression profiles were separately derived from 
individual datasets. The red lines represent the corresponding test statistics derived from the 
combination of two datasets. The combined dataset increased median AUC by 0.022 when N was 100. 
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The 2-year survival of 14 Stanford and 9 Ontario patients were correctly classified, 
giving an overall 76.7% accuracy (p = 0.005, 90% CI [62-92%]). ROC curves were 
separately built with SEP scores of each validating dataset. The size-weighted average AUC 
of two curves was 0.82. When the same patients were used to validate the 100-gene profile 
derived from the Michigan dataset, the size-weighted average accuracy and AUC is 66.7% 
and 0.77. (See Appendix F.2 for complete lists of reporter genes.) 
Because of insufficient patient follow-up, some patients in the validating datasets could 
not be classified into either prognosis group, which reduced the statistical power of validation. 
Kaplan-Meier survival curve, a technique frequently used in clinical research to deal with 
incomplete medical record, was generated with all 40 patients in the original datasets. These 
patients were categorized into two prognosis groups according to their SEP scores and 
survival curves were built based on the classification and patient follow-up data. Fig. 10A 
and 9B respectively showed the survival curves created with the combined dataset and 
Michigan dataset as the training data. The two curves in Fig. 10A were separated with a p-
value equal to 0.029, while those in Fig. 10B were insignificantly separated (p = 0.12).   
The analyses of lung cancer datasets further verified the superiority of multi-dataset 
expression profiling. However, as a prognostic index of lung cancer, SEP was not as 
differential as it was for breast cancer. An obvious reason of this difference was the smaller 
sample sizes of the lung datasets. The profiling quality might also be influenced by how 
patients were classified. Supported by the existing recurrence model, classification of breast 
cancer in this study might more ‘intrinsically’ reflect the difference of patients at genomic 
level. Nevertheless, when the profile derived from the combined dataset was validated by 
two other datasets, the results were satisfying.  
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Figure 10A Expression Profile Identified from the Combination of Harvard and Michigan Datasets 
 
 
Figure 10B Expression Profile Identified from Michigan Lung Dataset Only 
 
Figure 10 Comparison of Expression Profiling Strategies Using Survival Curves 
Expression profiles based on 1,000 re-samplings of lung cancer datasets were used to calculate SEP 
scores of all 40 patients in Stanford and Ontario testing lung datasets. Lung cancer patients were 
classified into prognosis groups with cutoff of SEP equal to 0. A Kaplan-Meier curve was built with 
each groups according to actual patient follow-up. The separation of two curves indicates the quality of 
an expression profile. (10A) Curves were generated from the expression profile identified from the 
combined dataset of Harvard and Michigan datasets. The separation of two curves is significant with p-
value equal to 0.029. (10B) Curves were generated from the expression profile identified from Michigan 
lung cancer dataset only. The separation of the two curves is marginally significant with p-value equal to 
0.12. 
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4.1.3 Sensitivity vs. Specificity of Reporter Gene Selection 
Microarray data are featured by the large number of variables (genes) and much smaller 
number of observations (patients). When a hypothesis test is repeatedly applied to all the 
genes for their differential expression, some tests will get significant p-values just because of 
the random distribution of data. Consequently, identified reporter gene list will include false 
positives. Shortening the reporter list will reduce its sensitivity while shortening it will 
reduce its specificity. Therefore, the balance between specificity and sensitivity of reporter 
selection should be considered during expression profiling.  
The necessity of achieving high sensitivity of reporter selection was questioned by 
previous results. As showed in Fig. 5 and 6, adding more reporters to profiles had little 
influence on bootstrapping results once the curves reached a plateau. Furthermore, the low 
consistence between reporter gene lists of two breast cancer datasets suggested that two 
disparate sets of reporters could perform very similarly on outcome prediction. This 
suggestion was advocated by a biological interpretation. Because of the regulatory interaction 
between genes, the expression of some genes is highly correlated with each other. If two 
genes are ideally co-expressed, they can replace each other in an expression profile. 
Including both of them in a profile has no impact on the profile except introducing 
redundancy. Therefore, it is not necessary to incorporate every true positive reporter to make 
a reliable profile. Conversely, low specificity of reporter selection can have considerably 
negative influence. Not only false positives will introduce extra variance into expression 
profiles, but also they will provide misleading information about functions of genes and their 
relationship to prognosis. 
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 Figure 21A Consequence of Decreasing Selection Sensitivity via Reduction Procedure 
 
Figure 11B Consequence of Decreasing Selection Specificity via Replacement Procedure 
 
Figure 11 Changing of Expression Profile Quality with Sensitivity and Specificity 
Stepwise simulation procedures were carried out to trace how the decreasing of reporter selection 
sensitivity and specificity would change the quality of expression profiles. Results were collected from 
1,000 re-sampling analysis of the combined dataset of two breast cancer datasets. The top-ranked 60 
genes selected by each re-sampling were used for the following stepwise procedures. (11A) At each step, 
three reporter genes were randomly selected and removed, which artificially decreased the sensitivity of 
expression profile. The remaining reporters were used to calculate the SEP scores of testing patients, and 
the resultant scores were used to build ROC curves. The bootstrapping median and 90% CI of ROC 
curve area (AUC) are summarized in the figure.  (11B) After the reduction procedure at each step, three 
replacing genes were randomly selected from all genes and added into the reporter list, which kept the 
length of list unchanged but artificially decreased its sensitivity. The replacing genes inherited the weight 
(z statistic of RST test) of the replaced genes. The revised list was used to calculate the SEP scores of 
testing patients, and the resultant scores were used to build ROC curves. The bootstrapping median and 
90% CI of ROC curve area (AUC) are summarized in the figure. 
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Two simulation strategies were designed to evaluate how the change of reporter selection 
sensitivity and specificity would change the quality of expression profiles. Both strategies 
were applied to the combination of two breast cancer dataset and their first step was to run 
another 1,000 bootstrapping re-samplings on this dataset. RST was performed on each gene 
and genes were ranked according to their Z statistics. 60 top-ranked genes were selected from 
each re-sampling as reporters. 
The next step of reduction strategy gradually decreased the sensitivity of reporter list 
using a stepwise process. Three genes were randomly selected and removed from the list at 
each step, followed by re-calculating SEP of testing patients with the remaining genes. Fig. 
11A presents the relationship between AUC of SEP scores and the sensitivity of reporter list. 
Generally, the median and 90% CI of AUC decreased when more genes were removed. 
However, the descending was slow most of the time. They were almost unchanged until 
about one-third genes were removed; decreased slightly after the removal of another one-
third genes; and dropped down more obviously afterwards. The profiles of last three reporters 
had a median AUC equal to 0.716. These results suggested that the loss of sensitivity could 
be tolerated by expression profiles to an extensive level. 
The replacement strategy, on the other hand, simulated the consequence of decreasing 
reporter selection specificity by substituting reporter genes with false positives. It had the 
same procedure as the reduction strategy except that in replacement strategy, the removed 
reporter genes were replaced by genes randomly selected from the whole datasets, keeping 
the size of expression profiles unchanged. The replacing genes inherited the weight of the 
replaced genes, so they could be considered as artificially introduced noises. The stepwise 
process continued until all 60 genes were replaced. Fig. 11B presented the relationship 
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between AUC of SEP scores and the specificity of reporter lists. Similar to Fig. 11A, all 
curves were gradually decreasing when more false positives were added. The median AUC 
was steady at the beginning; dropped by about 0.02 when half reporters were replaced; and 
fell rapidly afterwards. Furthermore, the range of 90% CI tended to be wider when more 
reporters were replaced. The median AUC was about 0.5 when the profiles contained only 
false positives.   
Comparison of Fig. 11A and 10B indicated that at the same level of selection sensitivity, 
drop of specificity might have considerable negative impact. This conclusion advocated the 
superiority of multi-dataset expression profiling, because the combined dataset selected 
reporters more specifically than the individual ones (Fig. 7). In the current study, the 
sensitivity and specificity of reporter selection were arbitrarily balanced according to Fig. 5A 
and other results.  
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4.2 MAMA Project 
4.2.1 Project Requirements and Use Cases 
The general purpose of the MAMA project was to provide researchers with a data-mining 
platform for discovering gene expression profiles about cancer. To serve this purpose, three 
core components of MAMA system were developed: the centralized storage of microarray 
data in a relational database, the access to the database via a server program, and the data 
manipulation/analysis functions packed in a client-side program. 
The requirement document of the MAMA project was given Appendix G. The schema 
design of the MAMA database had two considerations. On one side, the database was 
required to be MAGE-compliant, which accomplished the standardization of microarray data, 
but also increased the complexity of database schema. On the other side, the database was 
expected to enable quick access to its data by reducing the complexity of queries. The 
dilemma of these two requirements was solved by storing frequently requested data in 
denormalization tables. More details about MAMA database denormalization will be 
discussed in ‘Database Schema’ section. The requirements to the server program were 
straightforward. It should be able to connect to the database and handle concurrent requests 
from various clients. Requirements of the MAMA system related to data analysis were put on 
the client program. Besides regular data manipulation operations, this program was expected 
to maintain the data objects in a tree-like structure and provide the open-source APIs for 
developers to plug in data analysis methods. Unlike commercial microarray software, 
commonly available functions like clustering and graphics were not implemented. The client 
program was also required to have a Graphic User Interface (GUI), which should render data 
objects and system status in a consistent style.  
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Limited by the scale of the MAMA project, non-functional requirements was balanced to 
satisfy its essential utilities. The functionality and extensibility of the client program were 
given the priority. The targeted users of MAMA system are those researchers who are 
familiar with the basics of microarray analysis and want to apply more sophisticated or user-
specific statistical methods. As a result, the MAMA client was required to be functionally 
extensible. Ease of use was also a major concern. User guides and FAQ were needed to 
provide end users sufficient guidance. By reading the documentation, an experience 
microarray researcher was expected to grasp the basic operations of the MAMA system 
within an hour. On several occasions, however, user-friendliness was traded to give end users 
more control over their data and analysis results. For example, end users have to make more 
effort to maintain data on their local disk since all data analysis functions were assigned to 
the client program. Security, reusability, and portability of MAMA were not explicitly 
required, although the client program was coded with Java, which made it portable to all 
computers that installed the Java Virtual Machine (JVM). Finally, performance was 
considered as an unstable fact of MAMA system. The complexity and the amount of data 
involved would decide the performance of operations. Furthermore, the performance of plug-
in methods would be the responsibility of developers who added them into the application. A 
major bottleneck of performance was the operations performed on complete datasets, such as 
reading/writing them from/to files or retrieving them from database. The execution of these 
operations should be preserved as much as possible. Frequently used metadata about 
microarray experiments should be extracted and separately saved in advance, so it would not 
be necessary to dynamically summarize the metadata from all the source data when they 
were required. 
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Table 9:  
Example: ‘Create Workspace’ Use Case 
 
Use Case Name Create Workspace 
Author Zhe Zhang 
Date 2004/11/16 
Objective Create a new, empty workspace and open it. If there already is a workspace opened, close it 
Actor User, System 
Level Primary 
Trigger User decides to create a new workspace 
Included Use Case <<save workspace>> 
Extended Use Case  
Frequency Intermediate 
Pre-condition • Client program is running 
Post-condition • A new, empty workspace is created and opened in the client program 
Actor Action System Action 
1. User clicks ‘Workspace’ menu, then 
clicks ‘New’ menu item  
 2. System shows a dialog box asking for the name of the new workspace 
3. User specifies the directory of the 
workspace and names it, then clicks 
‘Create’ 
 
 4. System creates the new workspace object and opens it in the client program 
5. User Clicks ‘OK’  
Main Flow 
 6. System terminates process 
Steps Blanching Action 
4. There already is a currently opening 
workspace in the client program 
1. System prompts for what to do: 
• Save 
• Not save 
• Cancel 
2. User selects one 
3. System responds to user’s selection 
• Save it, open the new one 
• Not Save it, open the new one 
• Abort creating, keep the old one 
INCLUDE <<save workspace>> 
Sub flows 
3. User clicks ‘Cancel’ System aborts process 
Conditions Actions 
Exceptions 
4. Redundant workspace name 
System prompts for what to do: 
• Overwrite (will replace the old one) 
• Change name (will repeat step 3) 
• Cancel (will abort process) 
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Use cases of the MAMA client program were broken into multiple levels, from general 
categories to step-by-step description, following the design patterns of UML (Unified 
Modeling Language) [123, 124]. The major packages of use cases were diagramed in Fig. 
12A. It showed that most use cases were about management, presentation, or operation of 
data objects. Use cases of ‘Manage Workspace’ package and their relationship were 
summarized in Fig. 12B, and the flowchart of an example use case, ‘Create Workspace’, was 
given in Fig. 12C as an UML activity diagram. Furthermore, the details about ‘Create 
Workspace’ use case were described in Table 9. (See Appendix H for more use cases.)  
 
Figure 12A All Use Case Packages 
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Figure 12B All Use Cases of ‘Manage Workspace’ Package 
 
 
 
Figure 12C Event Flow Diagram of ‘Create Workspace’ Use Case 
 
Figure 12 Examples: Use Cases  
The functions of MAMA system were described as a number of use cases. All use cases were categorized into 
several packages (12A), and use cases might be related to each other (12B). The events happened during each 
use case could be represented in flow diagrams (12C). 
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4.2.2 Design of MAMA System 
Besides satisfying the requirements mentioned above, the basic objectives of designing 
MAMA include: 
• Minimize the requirement on hardware and maintenance resources. 
• Encapsulate software components. 
• Follow existing standards related to microarray as much as possible.  
• Control the scale of this project at a feasible level. 
 
4.2.2.1 Software Development Environment 
The following software and hardware were used for the development of MAMA system. 
This list can also be considered as the recommended system requirements of installing and 
running MAMA database or programs. 
Software: 
• Server computer 
o Operation system: Solaris 9 (Sun Microsystems Inc.). 
o Database management system: Oracle Release 9.0.1 (Oracle Corporation). 
o Database access API: Java JDBC Package (Sun Microsystems Inc.). 
o Web server and servlet engine: Apache Tomcat Version 4.1 (Apache Software 
Foundation). 
o Server program API: J2EE Servlet Specification 2.3 (Sun Microsystems Inc.). 
• Personal computer 
o Operation system: Microsoft Windows XP Professional Version 2002 
(Microsoft Corporation). 
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o Programming language: Java2 SDK, Standard Edition Version 1.4.2 (Sun 
Microsystems Inc.). 
o Source code and project management: Eclipse Platform Version 3.0.1 (Eclipse 
contributors and others). 
o Statistical functions: Common-Math Library Release 1.0, Jakarta Commons 
Project (The Apache Software Foundation). 
o Java/XML mapping: Castor XML Version 0.9.6 (Exolab Group, Intalio Inc., 
and Contributors). 
o UML diagrams: SmartDraw Version 7.01 (Hemera Technologies Inc.). 
o Local database management: Microsoft Access 2000 (Microsoft Corporation.) 
--- The local installation of the MAMA database was used just to simplify the 
coding/testing efforts during the developmental stages. To access this database, 
a local version of the server program and its Tomcat container were also 
installed. 
Hardware: 
• Server computer 
o Model: Sun Fire 280R (Sun Microsystems Inc.). 
o CPU: 2 Χ 1200 MHz UltraSparc-III+. 
o Memory: 2.0 GB of RAM. 
o Disk space: 10 GB assigned to the MAMA database. 
• Personal computer 
o Model: Inspiron 5100 Notebook (Dell Inc.). 
o CPU: Pentium(R) 4 CPU 2.66GHz. 
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o Memory: 1.0 GB of RAM. 
o Disk space: 15GB reserved for the development of MAMA project. 
 
4.2.2.2 System Architecture 
The system architecture of MAMA system was straightforward as shown in Fig. 13. The 
database maintained the permanent storage of microarray datasets collected and loaded by its 
administrators or curators. Any end users would be able to query this database. The server 
program is a Java Servlet managed by an Apache Tomcat container. This server can 
simultaneously handle multiple requests from different clients and interact with the database 
to query the data. The data retrieved from the MAMA database is wrapped into Java 
serializable objects by the server before they are sent to the clients. Therefore, all database 
operations are encapsulated in the server program and the client program does not need to 
directly interact with the database. The server and client programs communicate with each 
other using a pre-defined protocol, which codes the status of requests or responses. The 
complete protocol is listed in Appendix I. As long as the protocol is unchanged, the server or 
client program can be separately updated without notifying the other. Furthermore, other 
developers can add their own programs to communicate with the MAMA server or client via 
this protocol. The MAMA client program was also developed as a stand-alone application for 
microarray analysis. It can be run on the local computer without connecting to the server. 
Microarray datasets are imported into the client program directly from text files, annotated 
with standard vocabularies, and saved on local disk in pre-defined formats for users to load 
later. The client program saves all local files as XML documents except those containing 
expression data matrixes. Because of the large amount and simple structure of those matrixes, 
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they are saved as tab-delimited text files with sample identifiers as column names and gene 
identifiers as row names. XML documents and java objects are mapped to each other using 
functions provided by Castor XML API. The mapping rules are specified in file 
‘mapping.MAMA’, which is wrapped together with the client program.  
The system architecture of MAMA suggested a ‘light server’ and a ‘heavy client’. It 
simplified the development and maintenance of the server. Consequently, end users should 
rely on the computational power of their local computers for time-consuming operations. 
They also need to manage their data and analysis results on their local disk, which might be 
preferred by sophisticated users. Another critical feature of this architecture was the 
encapsulation of functions, which makes the MAMA system more modifiable and extensible.  
   
4.2.2.3 Database Schema 
The schema of the MAMA database had two levels. The first level copied the schema of 
ArrayExpress [87], a public microarray database developed by EBI (European 
Bioinformatics Institute). This schema was directly derived from MAGE-OM, which defines 
concepts related to most aspects of microarray experiments. MAGE-OM was designed as a 
complex data model using object-oriented mode. Consequently, the database schema of 
ArrayExpress would make the SQL queries intricate and inefficient. Many queries need to 
join a number of large tables and sometimes, the response time would be practically 
unacceptable.  For example, retrieving the identifiers of sequences in an array design 
involved the join of at least six database tables, most of which might contain millions of 
records. To improve the performance of the MAMA database, a second level of database 
schema was added, which included a group of denormalization tables. The purpose of these 
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tables was to redundantly store frequently requested data. Because of the introduction of 
redundancy, maintaining database integrity would be a heavy burden and error-prone when 
data were inserted, updated, or deleted. The MAMA database, however, would barely be 
harmed by this drawback of denormalization since it functions similar to a data warehouse. 
Insertions and deletions will be rare operations in this database, and updating will be even 
rarer because the existing data are the results of previous microarray experiments. Therefore, 
the two levels of the MAMA database serve different purposes. MAGE-OM tables 
permanently would store microarray datasets in a standard schema and allow other MAGE-
compliant systems to reuse them, while the denormalization tables benefits the data analysis 
applications by improving the accessibility of the database. To further reduce the response 
time of queries, most columns of denormalization tables are indexed.  
Database tables used by the current version of MAMA and their relationship are 
presented in Appendix J. Fig. 14 demonstrates a group of tables involved in the key entities 
of microarray analysis. The table located on up-left corner was a denormalization table 
storing the gene expression measurements. Each row of this table corresponds to a processed 
measurement, which is 2-dimensionally labeled with biomaterial (sample) and design 
element (sequence) identifiers. According to this diagram, each experiment can have only 
one array design, so the original experiment using multiple array designs should be split in 
advance. This diagram also contains a special table: ‘T_DATA_SUMMARY’. This table 
stores some common statistics about the expression level of a specific gene in a specific 
experiment. Since ‘experiment’ is the basic unit of data analysis in MAMA, these statistics 
are frequently queried metadata that should be conveniently acquired. 
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4.2.2.4 Data Flow 
The MAMA system provides two types of data storage: a remote database for publicly 
available long-term storage and a local file system for temporary, user-specific and analysis-
oriented storage. Fig. 15 demonstrates how data would be transferred between various 
locations of the MAMA system, which is directed by a group of software packages. The 
following sequentially described the data flow steps in a typical data analysis procedure: 
1. Source microarray dataset is imported in the format of tab-delimited text. The 
MAMA client program provides a GUI wizard to guide users through the process. 
The wizard prompts for the description and metadata of the dataset. The data 
submitter can choose to send the dataset to one of the two following locations: 
1A. The dataset is sent to the MAMA database for long-term storage through the 
server program. After receiving the submitted dataset, the server program pre-
processes its expression data before loading it into the database. The guidelines of 
data pre-processing are given in Appendix K. Loading datasets into database is a 
complicated and time-consuming operation and only the administrators or 
curators of the database have the authority to execute it. Ordinary users need to 
contact these people if they want their data to be stored in the database. 
1B. The dataset is parsed into an ‘Experiment’ object and added into the currently 
opened workspace of the client program. The new ‘Experiment’ object is saved as 
files in the local file system. This operation is simpler and faster comparing to 1A. 
It may be preferred by users who do not want to expose their data to the public.  
2. If a needed dataset already exists in the database, the client program fetches it from 
the database by sending a request to the MAMA server. Retrieved dataset are parsed 
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into an ‘Experiment’ object, added into the current workspace, and saved locally. 
Instead of fetching complete datasets, users can also query the database about the 
existing data, such as the sequences in an array design or the samples in a dataset.  
3. Before an analysis is performed on experiments in the current workspace, users might 
need to customize the contents or re-process the expression data of those experiments. 
For example, if users were only interested in analyzing genes whose expression 
varied radically in samples, a filtering operation would be carried out to remove genes 
having low-variance.  
4. The client program defined an ‘Analysis’ object and executed it using selected 
dataset(s). After the analysis was finished, its results are saved in local file system too.  
5. Saved data objects, such as analysis results, can be exported from the client program 
as text files. 
 
4.2.2.5 Software Architecture 
Source codes of both the client and server programs were written with Java2 SDK 
Standard Edition and managed within Eclipse platform. The fundamental software design 
principle in the MAMA project was to achieve the encapsulation of functions. Fig. 16A 
demonstrates the architecture of the client program, which mostly follows the MVC (Model-
View-Controller) software design pattern. The ‘Model’ package defines Java classes 
corresponding to various data objects, such as nucleotide sequences and biological samples. 
At runtime, the client program maintains all data objects in a tree-like structure within a 
‘Workspace’. The data objects kept by the client program are presented on the user interface 
through the ‘View’ package, which defines various graphic components, such as dialog 
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boxes and menus. Graphical components are used to render data objects (lists, tables, and so 
on), or listen to user actions (buttons, menu items, and so on) initiated by keyboard input or 
mouse click. User actions are passed to and handled accordingly by processes implemented 
in the ‘Controller’ package. The handling of actions might cause a change of system status. 
Consequently, the controllers notify the ‘Model’ and/or ‘View’ to update their contents. The 
controllers have the key position in this architecture. When necessary, they execute the 
methods implemented in the ‘Data Analysis’ package to carry out statistical analyses, or 
interact with the ‘Communication’ package to establish connection with the server program. 
The server program has a simpler structure with four layers: servlet, listener, handler and 
database facade. The whole server program is designed as a Java servlet, which is activated 
the first time it is requested by a client program and keeps running until it is explicitly shut 
down. The activated MAMA servlet creates a listener that listens to requests sent by clients at 
a network port. The listener responds to each request by generating a handler, so concurrent 
requests are handled simultaneously. Each handler interacts with a single client by 
exchanging data objects. Since the current version of MAMA server only handles database 
query requests, the incoming data objects are passed to the database facade layer. This layer 
parses the requests into database queries and sends the queries to the MAMA database. 
The details about client-server communication in MAMA system are illustrated in Fig. 
16B. The following gave the step-by-step description of this procedure: 
1. When a ‘Controller’ needs to access the MAMA database, it defines a Java ‘Query’ 
object and specifies the query attributes in this object. The controller sends this 
‘Query’ to a ‘Communication Facade’ and specifies the action, such as ‘insert’ or 
‘select’. 
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2. The ‘Communication Facade’ wraps the ‘Query’ and the action into a ‘Request’ 
object and assigns a key to the query. Each facade maintains a ‘Requester’, which 
might contain multiple ‘Request’ objects. Once all ‘Request’ objects are added into 
the ‘Requester’, the facade passes the ‘Requester’ to a ‘Communicator’, which 
handles the network communication with the server. 
3. The ‘Communicator’ contacts the ‘Servlet’ in order to set up a network connection. If 
the ‘Servlet’ has not been activated, it is loaded and creates a ‘Listener’ to listen for 
requests from the clients. 
4. The request for connection from the ‘Communicator’ is caught by the ‘Listener’. The 
‘Listener’ generates a thread as a ‘Handler’ to handle the incoming request. 
5. A network socket is established between the ‘Communicator’ and the ‘Handler’ for 
exchanging data. The ‘Requester’ is sent to the server through this socket. The 
‘Communicator’ waits for response from the server. 
6. The ‘Handler’ passes the received ‘Requester’ to a ‘Database Facade’ and waits for 
results. 
7. The incoming ‘Requester’ is unwrapped by the ‘Database Facade’ and the ‘Request’ 
objects inside it are collected. Each ‘Request’ is parsed into an SQL query based on 
its attributes. The query is sent to the database. 
8. The database returns query results to the ‘Database Facade’. 
9. The ‘Database Facade’ uses the returned results to generate a ‘Response’ object and 
assigns it a key equal to the key of the corresponding ‘Request’ object. A response 
code and a text message are also added to each ‘Response’ to indicate the 
consequence of executing the request. The interpretation of response codes are given 
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in Appendix I. After all ‘Response’ objects are collected, the ‘Database Facade’ 
wraps them into a ‘Responser’ and a status code is added to the ‘Responser’ to 
indicate the overall consequence of executing the requests. The interpretation of 
status codes are also given in Appendix I. Finally, the ‘Database Facade’ passes the 
‘Transfer’ to the ‘Handler’. 
10. The ‘Handler’ sends the ‘Responser’ including all the responses to the 
‘Communicator’, and terminates itself. 
11. The ‘Communicator’ reads data returned from the server, closed the network socket, 
and sends the ‘Responser’ object to the ‘Communication Facade’.  
12. The ‘Communication Facade’ retrieves the status code from the ‘Responser’ and 
reports it on the user interface if there is any error. The ‘Responser’ is then 
unwrapped to create a list including all the ‘Response’ objects. The response code and 
text message of ‘Response’ objects are reported on the user interface if there is any 
error. The ‘Communication Facade’ informs the ‘Controller’ that the query results are 
ready. Finally, the ‘Controller’ retrieves each ‘Response’ by providing its key and 
uses it to create a ‘Query Result’ object corresponding to the ‘Query’ object. 
The client-server communication architecture presented above gives an example of how 
various software modules were encapsulated in the MAMA system. The same principle was 
applied to other operations implemented in the client program.  
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Figure 16A Software Architecture of the MAMA Client Program 
 
 
Figure 16B Layered Software Structure of Client-server Communication in MAMA System 
 
Figure 16 Software Architecture 
The primary principal of software design in MAMA project was the encapsulation of functions. Therefore, a 
software package was designed for each basic function. (16A) The software architecture of the client program 
followed the MVC (Model-View-Controller) design pattern. The ‘Model’ package defined Java classes 
corresponding to various data objects, the ‘View’ package renders data objects on user interface, and the 
‘Controller’ package handles user actions. The ‘Controller’ was the key component in this architecture. It can 
interact with the ‘Data Analysis’ packages to execute data analysis methods or with the ‘Communication’ 
package to establish connection with the server program. (16B) The client-server communication had multiple 
layers. Each of these layers encapsulated certain functions. For example, the ‘Database Facade’ layer is in 
charge of translating user requests to database queries and wrapping query results into data objects. 
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4.2.2.6 Graphical User Interface 
The MAMA client program has a graphical user interface (GUI). The main window 
includes a split panel with two panes and a group of pull-down menus (Fig. 17A). The left 
pane renders the hierarchical structure of data objects in two trees. The upper tree is called 
‘Database Snapshot’, representing the status of MAMA database at the time when the 
snapshot was taken. The summary about the status of the database has three parts: existing 
array designs, experiments, and sample traits. The sample traits are a set of controlled 
vocabularies used to describe samples. The lower tree renders the contents of the currently 
opened workspace. Each workspace contains three types of objects: ‘Query’, ‘Experiment’, 
and ‘Analysis’, in any numbers. The details of a selected object are presented in the right 
pane, usually by table(s). For example, the right pane of Fig. 17A lists all samples of 
experiment ‘E-MICH-01’ with available clinical data of patients.  
Dialog boxes are extensively used for users to specify inputs or parameters of operations. 
Fig. 17B shows a dialog designed for inserting a new sample trait (ontology entry) into the 
database. In this dialog, an ontology entry called ‘Age’ is submitted by this dialog. 
According to the inputs, this entry is defined by MGED Ontology, which also assigned it an 
accession number and a URI link to it. Furthermore, ‘Age’ has ‘year’ as its unit. When an 
operation has too many inputs or parameters to be included in one dialog box, it is split into 
several steps sequentially organized by a wizard. Fig. 17C shows one of four steps of a 
wizard used to import a microarray dataset from text files. The name and location of the 
imported files are specified with this dialog. As shown in Fig. 17B and 16C, the design of 
GUI components has consistent style.  
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Figure 17A Main Window of the MAMA Client Program 
 
 
Figure 17B User Interface Example: Import New 
Entry of Biomaterial Ontology 
 
 
Figure 17C User Interface Example: Import 
Microarray Dataset from Text Files  
 
Figure 17 Graphic User Interface of the Client Program  
Graphic user interface was coded with Java Swing API. Dialog boxes were extensively used in a consistent 
style for users to specify the inputs of an operation. (17A) The main window of the client program has two 
panes. The left pane allows users to browser the data objects in the current workspace, and the right pane 
renders the details of a selected data objects, such as all samples in a virtual experiment. (17B) This dialog 
defines an entry of biomaterial ontology to be submitted into the database. (17C) This dialog is part of the 
wizard that imports a new experiment into MAMA system. Users can specify the imported files of samples, 
genes, and expression measurements within this box. 
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4.2.3 Data Annotation 
The results of microarray analysis are meaningful only when the sequences and samples 
in a dataset are properly annotated. Different microarray studies have been using various 
naming systems or terminologies to annotate their datasets. Since the MAMA system was 
design to allow for simultaneously analyzing multiple datasets, it is critical to consistently 
annotate different datasets with standard and/or common systems.  Consequently, the 
importing and the processing of microarray datasets often involve the mapping of annotation 
systems.  
The annotation of biological samples is more complicate. Researchers often use different 
terms to refer to the same concept, such as ‘tumor size’ and ‘tumor diameter’. Therefore, 
sample traits should be described with ontology or controlled vocabularies in the MAMA 
system to achieve cross-dataset analysis. The mapping between sample annotations was more 
difficult and error-prone. Data submitters should fully understand the definition of 
standardized terms before using them to describe samples. Currently, the controlled 
vocabularies used in MAMA have four sources as listed in Table 10A. MGED Ontology 
defines concepts and terms closely related to microarray experiments, such as ‘ArrayDesign’ 
and ‘SurfaceType’. Although MGED Ontology made a major effort on the description of 
biological samples (‘BioMaterial’), it only covered some general concepts, such as ‘Age’ and 
‘Sex’. While the terms provided by MGED Ontology had the priority, NCI Thesaurus and 
Metathesaurus were used as its supplements for cancer-specific traits and trait values, such as 
‘Angioinvasion’ and ‘Metastasis’. Comparatively, NCI Thesaurus was smaller and more 
stable and Metathesaurus was larger and more frequently updated. A number of ontology 
categories have been imported into the current version of MAMA. A list of these categories 
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and their definition can be obtained by taking a database snapshot and viewed by opening the 
‘Sample Traits’ folder in the left pane of Fig. 17A. Users are allowed to extend the pool of 
controlled vocabularies by submitting new ontology databases or entries to MAMA system. 
The sequences of microarray datasets are annotated with the identifiers assigned by 
various sequence databases. A large number of sequence databases about nucleotide acids 
(genes), gene products (proteins), and gene functions had been used to provide systematic 
annotations. Table 10B lists the sequences databases already registered in the MAMA 
database. Microarray sequences labeled with the identifiers of these databases is acceptable. 
The list can be further extended if necessary. In order to simplify the related operations, the 
client program recognizes and processes sequence annotations provided by four systems: 
GenBank, RefSeq, Unigene, and GO (Gene Ontology), which are highlighted in Fig. 11B. 
For example, to search a sequence in the database or the current workspace, only sequence 
identifiers provided by these systems can be used to specify the searched sequence. When a 
new ‘Experiment’ object was created in the client program by downloading from the 
database or directly importing from text files, other annotation types are not be accepted. 
Therefore, before a source dataset is loaded into the MAMA system, the annotation of its 
sequences should be mapped to identifiers of those four systems.  
 
Table 10: 
Data Annotation Resources 
 
Table 10A Biological Sample Annotation Resources 
 
Name Provider URI 
MGED Ontology MGED http://mged.sourceforge.net/ontologies/MGEDontology.php 
NCBI Taxonomy NCBI http://www.ncbi.nlm.nih.gov/Taxonomy/taxonomyhome.html 
NCI Metathesaurus NCI http://ncimeta.nci.nih.gov/indexMetaphrase.html 
NCI Thesaurus NCI http://nciterms.nci.nih.gov/NCIBrowser/Dictionary.do 
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Table 10B Nucleotide Sequence Annotation Resources 
 
Name Provider URI 
Affymetrix Probe Set Affymetrix http://www.affymetrix.com 
Blocks Database FHCRC http://blocks.fhcrc.org 
Enzyme Nomenclature IUBMB http://www.chem.qmw.ac.uk/iubmb/enzyme 
EMBL EBI http://www.ebi.ac.uk/embl 
Ensembl ENSEMBL http://www.ensembl.org 
Entrez Gene NCBI http://www.ncbi.nih.gov/entrez/query.fcgi?db=gene 
Entrez Protein NCBI http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Protein 
GenBank NCBI http://www.ncbi.nlm.nih.gov/Genbank/ 
GO GO Consortium http://www.geneontology.org/index.shtml 
GPCRDB GPCR http://www.gpcr.org/7tm 
InterPro EBI http://www.ebi.ac.uk/interpro 
KEGG Kanehisa Lab. http://www.genome.jp/kegg 
LocusLink NCBI http://www.ncbi.nlm.nih.gov/LocusLink 
MGD Jackson Lab. http://www.informatics.jax.org/ 
NetAffx Affymetrix http://www.affymetrix.com/ 
OMIM NCBI http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM 
Pfam SANGER http://www.sanger.ac.uk/Software/Pfam 
Protein Kinase 
Classification PKR 
http://pkr.sdsc.edu/html/pk_classification/pk_catalytic/pk_hanks_class.
html 
RefSeq NCBI http://www.ncbi.nlm.nih.gov/RefSeq 
SCOP UC, Berkeley http://scop.berkeley.edu 
SPTR Database MRC http://www.hgmp.mrc.ac.uk/Bioinformatics/Databases/sptr-help.html 
EGAD TIGR http://www.tigr.org/tdb/egad/egad.shtml 
Unigene NCBI http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene 
 
 
4.2.4 Working with Data Objects 
Since data objects are structured hierarchically by the client program, all user data can be 
saved on local disk as a single XML document for the ease of maintenance. However, 
reading, writing, and parsing such XML documents are very inefficient because of the large 
size of microarray datasets. A tradeoff was made to improve the performance of data 
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reading/writing at the cost of more software development and data maintenance efforts. It 
was decided that user data would be spilt into multiple files having proper size. The 
relationship between saved data objects is implied by the location and name of the files. Any 
file writing operation retains the consistency of data in related files. The client program uses 
Castor XML package to accomplish the mapping between Java data objects and XML 
elements. The mapping information is provided in an XML document named 
‘mapping.MAMA’, which was wrapped into the client program. (See Appendix L for details 
about XML mapping.) 
 
4.2.4.1 Workspace 
‘Workspace’ is the top-level data object and has a unique name (identifier). Users can 
create multiple Workspaces on local disk, but each running client program will open only 
one Workspace at any time. All data manipulation and analysis operations must be carried 
out within an opened Workspace. The ‘Default’ Workspace is opened automatically when 
the client program is activated. Contents of each Workspace are saved in an XML document 
and a directory of files, both named after its identifier. The XML document stores the 
metadata about a Workspace and the data objects inside it, while the contents of the data 
objects are stored in the directory as individual files. To simplify the maintenance of data, 
users are recommended to create a new Workspace for each data analysis project. 
The following illustrated an XML document of the metadata about ‘Default’ Workspace:
<?xml version="1.0" encoding="UTF-8" ?>  
<workspace name="Default" created="2005-09-30T19:19:28.603-04:00" last-
modified="2005-12-01T18:49:52.447-05:00"> 
<query identifier="BCL seq" subtype="Sequence" created="2005-10-
25T01:12:58.450-04:00" last-run="2005-10-25T01:13:00.132-04:00"> 
<inner-join-limit operator="LIKE" value="bcl" field="NAME" />  
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<outer-join-limit operator="=" value="E-MICH-01" field="Experiment 
Identifier" />  
<outer-join-limit operator="=" value="E-ROSE-01" field="Experiment 
Identifier" />  
       </query> 
<query identifier="My Query 1" subtype="Sample" created="2005-07-
21T16:56:28.877-04:00" last-run="2005-07-22T00:05:48.450-04:00"> 
<inner-join-limit operator=">=" value="50" field="Age" />  
<inner-join-limit operator="=" value="Cancer" field="DiseaseState" />  
<outer-join-limit operator="=" value="Breast" field="Organism Part" />  
<outer-join-limit operator="=" value="Lung" field="Organism Part" />  
       </query> 
       …… 
<experiment identifier="E-MICH-01" name="Michigan Lung Cancer - 
Adenocarcinoma" description="Complete dataset of Michgan Lung cancer 
study." created="2005-09-21T23:20:32.988-04:00" last-modified="2005-
09-21T23:20:32.988-04:00" num-samples="96" num-sequences="7129"> 
<source-experiments identifier="E-MICH-01" name="" description="" num-
samples="0" num-sequences="0" />  
      </experiment> 
<experiment identifier="E-ROSE-01" name="Profiling of breast cancer 
recurrence, Rosetta Inpharmatics" description="Complete dataset of 
Rosetta Breast cancer research" created="2005-09-21T23:03:08.255-
04:00" last-modified="2005-09-21T23:03:08.255-04:00" num-
samples="117" num-sequences="24481"> 
<source-experiments identifier="E-ROSE-01" name="" description="" num-        
samples="0" num-sequences="0" />  
       </experiment> 
       …… 
</workspace> 
 
4.2.4.2 Query 
‘Query’ is one of three data types contained by Workspaces. The client program creates a 
new Query by specifying its type and limits, such as ‘select all tissue samples collected from 
lung tumors’. The execution of Queries involves all three components of MAMA system. 
The client sends a Query to the server program, which parses it into an SQL query to the 
database. After results are returned from the database, the server wraps them into a ‘Query 
Result’ object and sends it to the client. Each pair of Query and Query Result objects is 
separately saved as two files within the directory of their Workspace. 
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The current version of MAMA supports the query of three data types: microarray 
experiments, biological samples, and nucleotide sequences. Fig. 18A shows a dialog box 
used to define a samples Query. Its upper half specifies the experiment, organism part, and 
material type of the required samples. The lower half, on the other hand, allows users to put 
up to three limits on any field of the samples. Therefore, the Query defined by Fig. 18A is 
interpreted as: ‘select all samples obtained from the breast or lung tissue of the donators who 
had been diagnosed with cancer before 60 years old’. The Query is named ‘Test Query’ and 
its results are given in Fig. 18B, which shows that totally 59 samples in two experiments 
were selected from the database.  
 
4.2.4.3 Experiment 
‘Experiment’ is the essential data object of the MAMA system. It contains the microarray 
dataset, and is the unit of query and data analysis results (Fig. 18B). It was arbitrarily decided 
that each Experiment included one and only one microarray dataset. The contents of this 
dataset is N sequences, M samples, and a 2-dimensional matrix of expression measurements 
whose size should be N x M. Therefore, each Experiment would be saved in Workspace as 
four files: metadata, sequences and their annotations, samples and their traits, and the 
expression data matrix.  
Each microarray dataset stored in the MAMA database usually corresponded to an actual 
microarray study. In the client program, however, Experiment objects are not always 
equivalent to studies carried out in laboratories. They were often generated for a specific 
analysis by filtering, splitting, or combining the data of existing datasets. Therefore, they are 
sometime ‘Virtual Experiments’. As shown in Fig. 17A, a new Virtual Experiment can be  
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Figure 18A Specification of a New Database Query 
 
 
Figure 18B Results of a Database Query 
 
Figure 18 Demo: Database Query 
The user defines a ‘Query’ object by specifying parameters in a dialog box and executed it to retrieve 
results. (18A) The inputs specify a query for biological samples. This query asks for all samples that were 
taken from lung or breast tissue of cancer patients older than 60 at diagnosis. (18B) The execution of 
query defined in Fig. 18A finds qualified samples in two experiments (2 in E-ROSE-01 and 57 in E-
MICH-01). The query results are saved and can be showed to users later in the right pane of the main 
window.  
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created by directly importing data from text files or querying the database. The former option 
allows users to use the client program without exposing their source data to the public, which 
would be required by those researchers who had not published their data.  
After an Experiment is created, it can be further customized to meet the requirements of 
subsequent data analysis. The current client program implements four types of data 
customization: sample filtering, sequence filtering, sample trait conversion, and 
normalization of expression measurements. Samples and sequences can be filtered with their 
annotations or values of summary statistics. For example, Fig. 19A specifies that all samples 
obtained from patients who were more than 40 years old will be removed from the 
Experiment, and Fig. 19B states that only sequences whose expression have a variance 
within the top 25% of all sequence will be kept. Conversion of trait values is used to change 
the scale or unit of a sample trait. Such modification is necessary when different studies 
measured a sample trait differently. For example, tumor size is represented as diameter 
(millimeter or centimeter) or TNM grading system (T1-T4) in different studies. Furthermore, 
discretizing continuous variables to categorical or interval variables was required by 
statistical methods like chi-square test. Fig. 19C shows a dialog box that changes the unit of 
patient follow-up data from ‘month’ to ‘year’ by dividing the original values by 12.0. Finally, 
the expression data of a Virtual Experiment is normalized by user specification. Since 
microarray data normalization had a large number of variations, the current version of 
MAMA was unable to implement enough normalization methods to meet the request of users. 
Instead, it allowed users to plug in their own methods using an API provided in the source 
codes. The process of method plug-in is discussed in the last section of this chapter.  
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Figure 19A Example of Experiment Customization: 
Filter Samples 
 
 
 
 
Figure 49B Example of Experiment 
Customization: Filter Sequences 
 
 
 
Figure 19C Example of Experiment Customization: 
Convert the Values of a Sample Trait  
 
Figure 19 Demo: Microarray Experiment 
Customization 
The client program is able to customize the contents 
of microarray experiment in various ways in order to 
perform certain data analysis procedure. (19A) 
Samples of an experiment can be filtered according 
to their values of a trait or a descriptive statistic. This 
dialog specifies that all samples taken from 
individuals older than 40 will be removed.  (19B) 
Sequences of an experiment can be filtered according 
to their availability of an annotation type or a 
descriptive statistic. This dialog specifies that only 
sequences whose variance of expression 
measurements are in the top-25% will be kept. (19C) 
Values of a sample trait can be converted to a 
different type of variable. Such conversion is 
necessary when the original variable cannot be used 
by a specific statistical method. Users can choose to 
cast the original variable automatically or manually, 
or change its unit. In this dialog, it is specified that 
the unit of patient follow-up will be changed to ‘year’ 
by dividing each original values by 12.0. 
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4.2.4.4 Analysis 
‘Analysis’ objects define the data analysis operations executed by the client program. The 
attributes of an Analysis include name of the statistical method, Experiments to be analyzed, 
and how to report the results. The execution of an Analysis generates an ‘Analysis Result’ 
object, which is saved in a separate file. If multiple Experiments were included in an 
Analysis, the results obtained from individual experiments can be used for meta-analysis. 
The results of meta-analysis are put into the Analysis Result object. 
The creation of an Analysis object had at least two steps. The first step is to specify the 
statistical method used for the analysis. As shown in Fig. 20A, the Rank Sum Test was 
selected to evaluate gene-trait correlation by measuring the differential expression of gene(s) 
between two sample groups. The second step was to specify the inputs of the Analysis with a 
dialog box (Fig. 20B). This dialog has three parts. The upper left box is used for specifying 
the variables to be analyzed. In Fig. 20B, the tested variable was the expression of all genes 
and the treatment variable was the survival outcome of patients. The upper right box is used 
for selecting the Experiments to be analyzed. All Experiments including the specified 
variables are listed. The bottom box specifies how to report the analysis results. If multiple 
Experiments are selected in this box, meta-analysis is possible. Results of data analysis are 
exported as text files if users want to process them using other programs such as Microsoft 
Excel.  
 
4.2.5 Implementation of Analysis Methods 
Because a large number of statistical methods have been applied to microarray analysis, 
the limited resources of developing MAMA system made it infeasible to satisfy users with  
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Figure 20A Selection of Data Analysis Method 
 
Figure 20B Specification of a New Data Analysis 
Operation 
 
Figure 20C Results of a Data Analysis Operation 
 
Figure 20 Demo: Data Analysis Operation 
Data analysis operations are initiated through a wizard: (20A) User selects the method category and the 
statistical method used for a new ‘Analysis’ object. (20B) User specifies the input variables of an analysis 
procedure and how to report the results. This dialog states that the correlation between cancer metastasis and all 
genes in experiment ‘E-ROSE-01_Unigene’ will be calculated with Rank Sum Test, and 100 genes having the 
highest magnitude of z statistic will be reported in the results. (20C) The results of an analysis are saved and can 
be showed to user later in the right pane of the main window. 
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enough methods. Consequently, a method plug-in mechanism is provided by MAMA to 
allow users to extend the client program by adding their own analysis methods. Therefore, 
the MAMA system is mostly considered as a platform of data-mining instead of a data 
analysis package. 
Statistical methods are classified into several categories, such as gene-trait correlation, 
and MAMA provides an API for each method category. The inputs and outputs of methods in 
the same category have the same data types, which were specified in a Java abstract class. 
For example, the API of gene-trait correlation methods stated that any method in this 
category should be a hypothesis test involving a sample trait and the expression of a gene. 
The inputs of this test were two equal-length arrays of double values and the outputs included 
a test statistic and corresponding p-value. Once the API of a method category was available, 
plug-in of a new method into this category had two steps. First, users implement the API by 
extending the abstract class. In the sub-class, users specify the name of the new method and 
the symbol of test statistic, and implement the algorithm of the method. The second step of 
method plug-in is to register the new method. All registration information should be written 
to an XML document called ‘plugins.MAMA’, which is wrapped into the client program. To 
register a method, users need to add an ‘analysis-method’ XML element under its category. 
This element itself should include two required elements: ‘name’, which is the method name 
readable to users, and ‘class’, which is the name of the Java class implementing this method. 
Before the creation of a new Analysis object, this registration file is loaded and parsed into a 
list of categories and methods for users to select (Fig. 20A).  
The following is a segment of the method registration file, which illustrates the 
registration information of two methods used to evaluate gene-trait correlation: 
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<analysis-type name="Gene-Trait Correlation">   
<analysis-method name="2 Group Comparison: Student's T" class="GeneToTraitStudentT"> 
</analysis-method>  
<analysis-method name="2 Group Comparison: Rank Sum Test (RST)" class="GeneToTraitRST"> 
</analysis-method>  
… 
       </analysis-type> 
 
Meta-analysis methods can be implemented and registered using a similar plug-in 
mechanism. The current version of MAMA provides two categories of meta-analysis method: 
combined test and measurement of effect size (Appendix E). 
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CHAPTER V 
CONCLUSION 
 
Complicated diseases, such as Alzheimer’s, cardiovascular diseases, and most types of 
cancer, are currently considered incurable because of the lack of systematic perspective about 
the molecular-level perturbations in individual patients. Development of high-throughput 
biological technologies presents a new opportunity to overcome these diseases. The 
enormous amount of data generated by these technologies is changing the face of biomedical 
studies, which involves statistical analysis and information process more and more. At the 
same time, researchers are being challenged by the requirement of translating technologies 
into clinical medicine. Properly designed data mining strategies are critical for recognizing 
causative information, which will help discovering new drug targets or making more reliable 
clinical decisions, from raw high-throughput data. 
Microarray is relatively more mature and less expensive compared to other high-
throughput technologies. Therefore, it has been commonly applied to the identification of 
gene expression patterns in specific types or subtypes of diseases. A variety of microarray 
datasets have been publicly available, which makes it possible to integrate multiple datasets 
for more powerful statistical analysis.  
The current study was performed to solve some issues involved in the practical 
application of microarray data to cancer. It included two related projects. The data analysis 
 
project justified the advantages of integrating microarray datasets and the necessity of 
developing a computer system like MAMA. The MAMA project, in return, will drastically 
accelerate the process of similar microarray analyses. 
 
5.1 Data Analysis 
The data analysis phase of this study was focused on the confirmation of two hypotheses. 
The first hypothesis was intended to validate the value of microarray technology in clinics by 
suggesting that microarray data provide extra clinical information besides commonly used 
indexes. The truthfulness of this hypothesis is the basis of all similar studies because its 
denial means that inclusion of microarray data in clinical decision will not make disease 
prognosis more accurate. Surprisingly, it has been overlooked by most microarray studies 
about cancer prognosis. Using two datasets about breast cancer and four datasets about lung 
cancer, this study attempted to validate this hypothesis by cross-validation of independent 
datasets and logistic regression models. The results implied that (1) when indexes were 
applied separately, gene expression profiles were superior classifiers of cancer patients than 
currently used prognostic indexes; (2) when all indexes were applied jointly, inclusion of 
expression profiles improved the overall accuracy of classification; and (3) to achieve 
optimal classification, expression profiles should be applied in corporation with other indexes. 
These implications altogether solidly confirmed the clinical value of microarray data. 
At the beginning of this study, it was proposed to perform expression profiling across 
multiple microarray datasets. The hypothetical advantage of this strategy is that larger overall 
sample size will increase the generality of resultant expression profiles. At the same time, it 
may be criticized of ignoring the extensive diversity of independently generated microarray 
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datasets. Our study demonstrated that as long as assumptions were properly made and source 
data were consistently annotated and processed, expression profiles derived from multiple 
datasets would have better quality than those obtained from individual datasets. In specific 
patient subpopulations, genes highly correlated to clinical indexes are more likely to have 
observed significant correlation to cancer outcome than other genes, but they will lose their 
status in other subpopulations having different clinical background. This is one of the reasons 
why expression profiles obtained from independent studies are mostly inconsistent. On the 
other hand, genes not influenced by the confounder would win over the long haul as long as 
they had certain level of consistent correlation to outcome in general population. CDC20 and 
BECN1 are the examples of such genes (Table 8).  
Expression profiles composed of those genes will be more reproducible, and more 
precisely differentiate patients into prognosis groups. The validation of this hypothesis is 
critical. Due to the high expense and complexity, microarray studies often do not have 
enough samples to obtain significant statistical results about cancer features. Therefore, 
reusing existing data by integration analysis will allow researchers to extract information or 
draw conclusions that can not be reached by analyzing individual datasets. The 60 reporter 
genes and their weight derived from the combined dataset made an optimal expression 
profile of breast cancer recurrence achievable using the given datasets. The value of this 
profile is worthy of some further investigation. 
The lung cancer datasets were also used to ensure the advantage of data integration. The 
source data were re-processed differently because of the disparity between breast and lung 
cancers. Since lung cancer subtypes are highly dissimilar in terms of tissue type, survival rate, 
and so on, only adenocarcinoma patients were used. Patients were categorized into two 
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prognosis groups according to their 2-year survival outcome because recurrence outcome of 
most patients was not available and about 60% invasive lung cancer patients did not survive 
more than two years after diagnosis. As shown in Fig. 9 and 10, results from lung datasets 
also strongly advocated integration analysis.  
In addition to the confirmation of those two hypotheses, the data analysis project of the 
current study also made the following conclusions: 
The artificial variable SEP (Score for Expression Profile) was designed and successfully 
fitted into data analysis procedures. The utilization of SEP was the key of statistical analyses 
in this study. As a numeric and continuous variable, SEP was suitable for many analytical 
methods. For example, the density distribution of SEP scores in Fig. 1A and subsequent chi-
square tests provided strong evidence about the general confounding effect of clinical 
indexes on gene-outcome correlation. Because of these confounders, the observed significant 
correlation of a gene to disease outcome could be the result of high correlation between the 
gene and a clinical index. Genes taking advantage of confounders will have higher chance to 
be selected as a reporter. This is why many reporter genes can be linked to one or more 
clinical indexes. Sampling criteria varies among studies. In the case of breast cancer datasets 
analyzed in this study, all patients in Rosetta dataset were lymph node-positive while 
Stanford dataset included both node-positive and -negative patients. Hence, controlling the 
confounding effect of clinical indexes will improve the generality of expression profiles.   
A partial correlation procedure was the first strategy used in this study to control the 
confounders of expression profiling. The procedure calculated a residual value for each gene 
expression measurement and replaces the original measurements with the residuals in the 
following steps.  Although theoretically all confounders could be controlled by recursively 
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calculating residuals, extra variance will be introduced into results since the residuals were 
estimated from the sample data. Consequently, the resultant expression profiles would have 
higher false positive rate and lower quality. For example, when the 127-gene profile obtained 
from the partial correlation analysis of Rosetta dataset was cross-validated with Stanford 
dataset, it did not perform better than the profile generated by regular correlation analysis. 
The major data analysis procedure of this study combined training/testing validation and 
bootstrap re-sampling. This procedure was used to avoid overfitting in results and make 
unbiased comparison of expression profiling strategies. However, it should be noted that this 
procedure did not take full advantage of the source data because all expression profiles were 
generated from the training data, which contained just about two-third of the complete 
datasets. For example, when the breast cancer 60-gene profile obtained from a complete 
dataset was cross-validated with the other dataset, the overall accuracy of patient 
classification using SEP was 73.61%, higher than the bootstrapping median (70.59%) 
obtained from within-dataset validation. 
Results of this study advocated a breast cancer recurrence model suggesting that the 
progression of secondary tumors had two growth patterns. Each of these patterns 
corresponded to a post-diagnosis recurrence peak. Instead of arbitrarily categorizing patients 
according to their 5-year prognosis as what most breast cancer studies prefer, this study 
adopted this 2-peak model and classified patients into two groups corresponding to the peaks. 
Considering breast cancer as a cell growth abnormality, this classification had more 
biological grounds. Comparison of Fig. 6B and 8 shows that at N=100, the median AUC 
obtained from the lung data was 0.1 lower than that from the breast data, a relatively 
significant dropping. This difference might be caused by smaller sample size of two training 
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lung datasets, but more possibly because of the lack of a well-defined biological model to 
support the 2-year survival classification of patients. In addition, recurrence is a better output 
variable of expression profiling than survival because the factors influencing survival are 
more diverse. 
The stepwise procedures were applied to trace the consequence of adjusting the 
sensitivity and specificity of reporter gene selection. The necessity of high reporter selection 
sensitivity was questioned by various results. First, as in Figure 5 and 6, medians of test 
statistics gradually reached a plateau with the raising of N. When N was greater than 60, 
increasing its value had very little influence on the quality of expression profiles. Secondly, 
cross-validation results demonstrated that two mostly different reporter gene list had similar 
performance on testing patients (Table 6). Thus, both lists must miss some true positive 
reporters since each of them was valid classifiers of testing patients and included some true 
positives. Finally, the result of the reduction process (Fig. 11A) showed that the loss of 
sensitivity could be tolerated to an extensive level without significantly reducing the quality 
of expression profiles. On the other hand, high selection specificity was proved to be critical. 
The relationship between higher reporter selection specificity and better expression profiles 
was suggested by results presented in Fig. 7. The combined dataset selected reporter genes 
more consistently, implying that the expression profiles obtained from it included less false 
positives. Furthermore, the replacement process (Fig. 11B) caused more dramatic 
subsequence than the reduction process. Comparison of Fig.10A and 10B concluded that 
with the same sensitivity, decreasing specificity of reporter selection would quickly decrease 
the quality of expression profiles. Therefore, an effective expression profile should include 
false positives as few as possible, but do not have to take in all or most of true positives. 
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Nevertheless, high sensitivity should still be preferred when no substantial tradeoff is 
required. The more true positives an expression profile includes, the more reliable and robust 
it will be. In this study, the optimal tradeoff was arbitrarily decided based on the observed 
trend as the value of N was increased. More investigation on this topic is expected in the 
future.  
The data integration strategy used in the current study was straightforward and easy to 
perform. It assumed that patients of independent studies were sampled from the same 
population and their expression data had similar distribution and range after proper data re-
processing. A major criticism of this strategy might be the information leaking due to the 
filtering of genes before combining two datasets having different array design. A large 
portion of genes in the source data were not included in the combined dataset because they 
were not in both datasets. However, both breast and lung combined datasets still included 
about 5,000 Unigene clusters. According to previous conclusion about reporter selection 
sensitivity, the quality of resultant expression profiles was merely influenced by the filtering 
process. If the data integration involves more than two microarray datasets, inconsistent array 
design will make the current strategy less feasible. For example, there were only about 1,000 
Unigene clusters included by all four lung datasets used in this study. An alternative strategy 
of integration analysis is meta-analysis, the analysis of results obtained from individual 
studies. With meta-analysis, each gene will get a summary statistic no matter its presence in 
multiple datasets. 
Microarray is an evolving technology. A pre-requisite of its clinical application is the 
standardization of platform, protocol, data analysis, and so on, which will make large-scale 
clinical tests doable and provide a common reference for sample categorization. Otherwise, 
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datasets generated by independent studies are not directly comparable. For example, when 
SEP was calculated with the same reporter genes and their weight in this study, scores of 
different patient cohorts usually did not have ranges analogous to each other. The 
standardization of microarray relies on the knowledge learned from the existing data. As 
more and more microarray datasets about cancer or other diseases are published, there is 
increasing interest on comparing and summarizing multiple datasets to discover general 
expression patterns, which help the design of standard array template. By successfully 
verifying and realizing the advantages of multi-dataset expression profiling, the current study 
will accelerate the standardization of microarray.  
 
5.2 MAMA Project 
Although its name highlighted meta-analysis, the MAMA system is more of a data-
mining platform than a meta-analysis toolbox. Particularly, it provided users with a 
centralized storage of microarray datasets, a data annotation and management tool, a data-
mining environment for simultaneously investigating multiple datasets. Therefore, any 
researcher interested in the expression profiling of tumor tissues may take advantage of it. 
MAMA is also an open-source project. Applications of MAMA include, but are not limited 
to: 
• Store and share microarray datasets about cancer. 
• Correlate the expression of genes to cancer features, such as recurrence or ER status 
of patients. 
• Identify or confirm co-expression of genes across multiple datasets to help the 
building of genetic pathways.  
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• Generate gene expression patterns from one or multiple datasets, and validate these 
patterns with data from independent sources. 
• Implement and test novel methods or procedures of microarray data analysis.  
• Help researchers to discover clinical indexes or molecular markers of cancer.  
A noticeable feature of the MAMA system is the simplicity of the server program. Due to 
the limited human and computer resources, a heavy duty server, which would handle data 
analysis operations for all users, was avoided to minimize the development and maintenance 
efforts. Therefore, MAMA does not provide a web-like interface for users to interact with the 
system through a web browser. Instead, all data manipulation and analysis functions were 
implemented in the client program, which need to be downloaded and installed by users 
themselves. Consequently, users have to take more responsibility on the execution of 
operations. For example, they need to ensure that their local computer meets the hardware 
requirements of complicate data analysis procedures. On the other side, this system 
architecture improved the extensibility of the MAMA system. Modification and addition of 
data analysis functions are limited at the client-side. Since all source codes are freely 
available, users are able to customize the functions of MAMA system without setting up their 
own database and server.  
MAMA was developed as a highly flexible system for both of data manipulation and 
analysis. It is assumed that independent datasets should have similar subjects and definition 
of variables when they are integrated by meta-analysis or other statistical techniques. For 
example, two studies respectively examining prognosis of breast and lung cancer usually 
cannot be integrated because their subjects are too dissimilar. In practice, since each study 
has its own purpose and experimental design, datasets used by meta-analysis usually need to 
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be re-processed first. The data manipulation functions provided by the MAMA client allow 
users to filter sample patients or sequence and convert variables before specific analyses. 
Consequently, user-defined ‘virtual’ studies, which have a different objective from the 
original studies, can be carried out to discover new information from existing data. 
Furthermore, by establishing a method plug-in mechanism, MAMA allows users to 
implement and apply their own methods of expression data normalization.  
Flexibility is critical for the usability of MAMA. Cancer is a complex disease involving 
many aspects. To identify an optimal gene expression pattern, researchers often want to 
conveniently try and compare different strategies (e.g. 5-year vs. 3-year prognosis) or 
methods (e.g. parametric vs. non-parametric test) of gene expression profiling. The MAMA 
system fulfilled this requirement by its high flexibility, which could be error-prone at the 
same time. If users do not thoroughly understand the data or methods of their analysis, 
variables could be incorrectly defined, methods could be misused or mistakenly implemented, 
and analysis results could be inaccurately interpreted. Therefore, the targeted users of 
MAMA are those already familiar with the characteristics and statistical methods of 
microarray analysis.  
An important lesson learned from this study is the complexity of realizing the medical 
application of microarray technology. Although most biomedical researchers would agree 
that high-throughput technologies will have extensive application in clinical medicine, no 
substantial breakthrough has been made so far. A possible reason is that the current 
knowledge about cancer and other complex diseases is still not enough for researchers to 
fully take advantage of these technologies. Besides, datasets generated with these 
technologies usually have low quality and small sample size, probably the reason why results 
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of microarray studies usually have not been taken seriously by most medical practitioners. 
Microarray-based diagnosis requires the standardization of technology and the data analysis 
procedures. While microarray technologies will keep developing in near future, suitable and 
practicable data analysis procedure are essential now. Similar to the data analysis procedure 
used in clinical trials, samples selected from various subpopulations should be pooled 
together to draw more solid and general conclusions. This study presented such a procedure 
during the data analysis phase and the MAMA system will help other researchers to develop 
more.   
Although microarray provides gene expression measurements at a genomic level, its 
value should not be exaggerated. The comprehensive description of biological systems 
should cover information at different levels, including sequence, mRNA, protein, metabolite, 
and so on. The integration of data at multiple levels will provide a better understanding about 
investigated subjects. For example, the results of this study demonstrated that expression 
pattern and other clinical indexes jointly accomplished the best prognostic model of breast 
cancer. While systems biology is recently becoming one of the most active topics of 
biomedical research, its success highly relies on the development of data integration 
techniques. This study shared some commonness with systems biology researches in terms of 
data integration. For example, data objects should be formally and consistently annotated. 
Therefore, the vision and process of developing the MAMA project are partly applicable to 
similar projects of systems biology.  
While the current version of MAMA system has met its basic requirements, it is still 
prototypic. Future upgrades under consideration are: 
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• Data collection: More datasets will be loaded into MAMA database as a continuous 
effort. 
• Data presentation: New data presentation functions will be added for users to navigate 
data contents more conveniently. Examples of such functions are rendering data 
distribution in diagrams and sorting or filtering analysis results in tables. 
• Method categories: According to feedbacks from users, new categories of data 
analysis methods will be implemented and corresponding API for method plug-in will 
be provided. 
• Prediction models: The current version of MAMA did not support the functions for 
generating prediction models, an important application of microarray data. Realizing 
this feature involves a major upgrade of MAMA source codes. New data objects need 
to be defined and new data analysis functions, such as testing a model with datasets, 
need to be implemented.  
Biomedical informatics is a new but promising field. Its prospects are highly dependent 
upon the insight and vision of researchers. Presenting some fresh ideas to the research 
community, this study strongly supported the application of microarray on cancer clinics by 
its data analysis results and data mining platform. 
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Appendix A: 
Demo of Data Analysis Steps Using a Pseudo-dataset 
 
This demo uses a simple and artificial microarray dataset of 10 breast cancer patients to 
demonstrate some data analysis steps utilized in this study. Table 1 and 2 separately list the 
clinical data of all patients and the expression measurements of all sequences in the source 
dataset. The original study annotated the sequences using accessions of NCBI RefSeq 
database and has processes microarray images to generate a 2-dimensional matrix of gene 
expression data. The expression profiling procedure used in this study would start with the 
categorization of sample patients into prognosis groups. 
 
Table 1 Clinical Information of Sample Patients 
Sample ID Recurrence Follow-up (year) ER Status 
Tumor 
Size Grade 
Age 
(year) 
p_1 1 2.53 1 2 2 43 
p_2 0 6.44 1 2 1 44 
p_3 1 1.66 0 2 3 41 
p_4 1 1.3 1 2 3 41 
p_5 0 11.98 0 2 3 48 
p_6 1 1.16 1 1 2 49 
p_7 0 10.14 0 2 1 46 
p_8 0 8.8 0 2 3 48 
p_9 0 1.29 1 1 3 48 
p_10 1 6.64 1 1 2 38 
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Table 2 Expression Measurements in Source Dataset 
Sequence p_1 p_2 p_3 p_4 p_5 p_6 p_7 p_8 p_9 p_10 
NM_003000 0.03 -0.09 0.08 0.08 -0.01 0.09 0.1 0 -0.02 -0.08 
NM_003001 1.11 -0.12 1.28 0.2 1.11 -0.04 1.07 -0.13 1.02 -0.14 
NM_003002 -0.26 -0.17 -0.35 -0.26 -0.29 0.03 -0.06 0.12 -0.27 -0.13 
NM_003003 -0.7 -0.04 -0.73 -0.05 -0.71 -0.03 -0.63 -0.01 -0.69 0.03 
NM_003004 0.82 0.25 0.6 -0.08 0.78 0.16 0.63 -0.23 0.65 0.07 
NM_003005 -0.89 0.01 -0.81 0.05 -0.8 0.01 -0.6 -0.02 -0.77 0.13 
NM_003006 -0.78 -0.01 -0.71 0.13 -0.86 -0.09 -0.7 -0.01 -0.76 -0.03 
NM_003007 -1.23 0.25 -1.09 0.23 -1.23 0.05 -1.1 0.04 -1.16 0.45 
NM_003033 -1.29 0.25 -1.11 0.26 -1.34 -0.01 -1.16 0.08 -1.19 0.44 
NM_198139 1.09 -0.15 1.06 -0.18 1.21 0 1.16 -0.07 0.95 -0.34 
 
A.1 Categorization of Sample Patients 
Breast cancer patients are categorized into prognosis groups based on their follow-up data. 
Patients who had observed recurrence within three years after diagnosis are classified into 
poor prognosis group (p_1, p_3, p_4, and p_6). Patients who were followed up for at least 
three year and had no observed recurrence are classified into good prognosis group (p_2, p_5, 
p_7, and p_8). The follow-up of p_9 was too short and the recurrence of p_10 happened too 
late. These two patients cannot be put into either group and will be excluded from all the 
following steps.  
 
A.2 Mapping Sequences to Unigene Clusters 
All sequences are mapped to Unigene clusters. File containing the mapping information 
between RefSeq and Unigene is available at NCBI website. Both of sequence NM_003007 
and NM_198139 are mapped to cluster Hs.1968 (SEMG1), so the expression measurements 
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of these two sequences are averaged for each patient to get rid of redundancy. Sequence 
NM_003303 cannot be mapped to any Unigene cluster, so it is removed from the dataset. 
Table 3 gives the gene expression data of entire dataset after this step. 
 
Table 3 Contents of Dataset after Sample and Sequence Filtering 
Sequence Gene Name p_1 p_2 p_3 p_4 p_5 p_6 p_7 
Hs.1968 SEMG1 -0.07 0.05 -0.02 0.03 -0.01 0.02 0.03
Hs.356270 SDHD -0.26 -0.17 -0.35 -0.26 -0.29 0.03 -0.06
Hs.444472 SDHC 1.11 -0.12 1.28 0.2 1.11 -0.04 1.07
Hs.464184 SEC14L1 -0.7 -0.04 -0.73 -0.05 -0.71 -0.03 -0.63
Hs.465924 SDHB 0.03 -0.09 0.08 0.08 -0.01 0.09 0.1
Hs.506670 SELPLG -0.78 -0.01 -0.71 0.13 -0.86 -0.09 -0.7
Hs.546296 SECTM1 0.82 0.25 0.6 -0.08 0.78 0.16 0.63
Hs.73800 SELP -0.89 0.01 -0.81 0.05 -0.8 0.01 -0.6
 
 
A.3 Pre-processing of Expression Measurements 
Details about pre-processing expression data are given in ‘Specification for Curation of 
Expression Measurements’. In this demo, it is assumed that all expression measurements are 
in good quality and have been log10-transformed. Therefore, all measurements are directly 
normalized. The first normalization step is to make the median of gene expression in each 
patient equal to 0.0 and the standard deviation (SD) equal to 1.0. For example, the median 
and SD of gene expression in patient p_1 are respectively -0.17 and 0.74, so each expression 
measurement of p_1 is subtracted by -0.17 and then divided by 0.74. Afterward, expression 
measurements of each gene are also normalized with the same process. The resultant 
normalized data matrix is given in Table 4.  
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Table 4 Normalized Expression Measurements 
Sequence Gene Name p_1 p_2 p_3 p_4 p_5 p_6 p_7 
Hs.1968 SEMG1 0.14 2.34 0.61 -0.83 0.45 -0.18 -0.14
Hs.356270 SDHD 0.03 -0.97 -0.07 -1.96 -0.03 0.35 0.09
Hs.444472 SDHC 0.23 -1.62 0.44 -0.22 0.23 -1.6 0.22
Hs.464184 SEC14L1 -0.14 1.62 -0.18 0.14 -0.25 0.3 -0.84
Hs.465924 SDHB 0.09 -1.85 0.34 0.13 -0.09 1.84 -0.12
Hs.506670 SELPLG -0.09 1.28 0.09 2.02 -0.28 -0.81 -0.44
Hs.546296 SECTM1 0.11 0.67 -0.07 -1.4 0.07 0.47 -0.11
Hs.73800 SELP -0.99 1.38 -0.74 1 -0.82 0.74 -0.88
 
A.4 Re-sampling of Patients 
Bootstrap strategy repeatedly re-samples patients to generate training and testing 
subgroups. The following steps will be applied to one of such bootstrap re-samplings. The 
results obtained from all re-samplings will be summarized to give unbiased estimation of test 
statistics. It is assumed that patient p_1, p_2, p_3, p_4, p_5, and p_7 are assigned to the 
training subgroup, leaving p_6 and p_8 in the testing subgroup.  
 
A.5 Correlation Analysis 
The Pearson correlation coefficient (r) of each gene to recurrence outcome is calculated 
with data of all training patients. For example, r of sequence Hs.1968 (SEMG1) is calculated 
with {1, 0, 1, 1, 0, 0} and {0.14, 2.34, 0.61, -0.83, 0.45, -0.14}, and the result equals to -0.47. 
Resultant correlation coefficients of all genes are given in Table 5. Genes are also ranked 
according to the magnitude of their r, from the highest to the lowest. Coefficient r can be 
transformed to t statistic using formula: t = r * ((n – 2) / (1 – r2))1/2, where n is sample size.  
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Table 5 Results of statistical tests on gene-recurrence correlation 
Pearson 
Correlation 
Partial 
Correlation 
Rank  
Sum Test Sequence Gene Name 
r rank r rank r rank 
Hs.1968 SEMG1 -0.47 7 -0.51 3 0.65 5.5 
Hs.356270 SDHD -0.24 8 -0.04 8 0.65 5.5 
Hs.444472 SDHC -0.72 3 0.73 2 -0.87 3 
Hs.464184 SEC14L1 -0.51 6 -0.48 5 -0.65 5.5 
Hs.465924 SDHB 0.95 1 0.8 1 -1.96 1 
Hs.506670 SELPLG 0.64 4 0.05 7 -1.09 2 
Hs.546296 SECTM1 -0.59 5 -0.49 4 0.65 5.5 
Hs.73800 SELP 0.92 2 -0.38 6 0.22 8 
 
A.6 Partial Correlation Analysis 
ER status is the controlled variable in this demo. The following description uses sequence 
Hs.1968 as an example to demonstrate the process of controlling ER status from expression 
data. 
1. Training patients are classified based on their ER status. ER-positive group includes 
patient p_1, p_2, and p_4 and ER-negative group includes patient p_3, p_5, and p_7. 
2. Average expression level of Hs.1968 in ER-positive and –negative patients is 
separately calculated. The values are considered as conditional expected expression 
(E) of gene Hs.1968 in all patients. 
• Mean+ {0.14, 2.34, -0.83} = 0.55 
• Mean− {0.61, 0.45, -0.14} = 0.31 
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3. The residuals are calculated by subtracting expression measurements in Table 4 with 
corresponding E values. In the case of Hs.1968, the residuals of all eight patients are:  
• {-0.41, 1.79, 0.30, -1.38, 0.14, -0.73, -0.45, -1.03} 
After all expression measurements are transformed to residuals, the partial correlation 
coefficient (r’) between each gene and the recurrence outcome is calculated with the 
residuals of training patients using the same formula of Pearson correlation. Table 5 gives the 
r’ of each gene and the corresponding rank. The r and r’ values of some genes, such as 
Hs.444472, are dramatically different. 
 
A.7 Wilcoxon Rank Sum Test (RST) 
RST is performed on training data of each gene to calculate a Z statistic. The following 
description uses sequence Hs.1968 as an example to demonstrate the process of RST. 
1. Training patients are put into two groups of opposite recurrence outcome. Group 1 
includes patient p_1, p_3 and p_4, and group 2 includes patient p_2, p_5, and p_7. 
Size of both groups is three.  
2. Expression measurements of gene Hs.1968 in all training patients are transformed to 
ranks. So, given data points {0.14, 2.34, 0.61, -0.83, 0.45, -0.14}, corresponding 
ranks will be {4, 1, 2, 6, 3, 5}. If there are equal data points, their ranks will be 
averaged. 
3. Parameter W1 is calculated as the summation of ranks assigned to group 1:  
• W1 = Σ ranksgroup1 = rankp_1 + rankp_3 + rankp_4 = 4 + 2 + 6 = 12 
4. Parameter U1 is calculated with W1 and the size of group1:  
• U1 = W1 − N1 (N1 + 1) / 2 = 12 – 3 (3 + 1) / 2 = 6 
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5. Mean is calculated as:  
• Mean = (N1 + N2) / 2 = (3 + 3) / 2 = 4.5 
6. Variance is calculated as: 
• Variance = N1 N2 (N1 + N2 + 1) / 12 = 3 * 3 * (3 + 3 + 1) / 12 = 5.25 
7. Z statistic is calculated as: 
• Z = (U – Mean) / Variance1/2 = (6 – 4.5) / 5.251/2 = 0.655 
Table 5 also gives the Z statistic of each gene and the corresponding ranks. The ranks of 
genes having equal Z statistics are averaged.  
 
A.8 Calculation of SEP Score 
In this demo, reporter genes are selected based on RST results. The number of reporters 
(N) is arbitrarily set to two. Therefore, top-ranked sequence Hs.465924 and Hs.506670 are 
selected as reporters and their weights are respectively -1.96 and -1.09. The SEP score of 
each patient is calculated with the following steps, and the intermediate results and final SEP 
scores are given in Table 6. 
1. The expected expression level (E) of each reporter gene is calculated by averaging the 
expression measurement of each reporter in all training patients. In the case of 
Hs.465924, its value of E is calculated as: 
• MeanHs.465924 {0.09, -1.85, 0.34, 0.13, -0.09, -0.12} = -0.25 
2. The difference between the observed and the expected expression levels of each 
reporter gene is calculated and then weighted by the RST Z statistic of the gene.  
3. The resultant values obtained from the last step are summed up to generate a SEP 
score for each patient.  
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The SEP scores of patients can be applied to other statistical analysis to evaluate 
expression profiles or the strategy used to generate them. For example, if cutoff of SEP is set 
as 0, both testing patient p_6 and p_8 will be classified into poor prognosis group. According 
to actual observation of recurrence outcome, p_6 is correctly classified, but p_8 is not, giving 
a classification accuracy of 50%. 
 
Table 6 Step-by-step calculation of SEP scores 
Hs.465924 (E = -0.25, W = -1.96) Hs.506670 (E = 0.43, W = -1.09) 
Patient 
X X–E W(X–E) X X–E W(X–E) 
SEP 
p_1 0.09 0.34 -0.67 -0.09 -0.52 0.57 -0.1
p_2 -1.85 -1.6 3.14 1.28 0.85 -0.93 2.21
p_3 0.34 0.59 -1.16 0.09 -0.34 0.37 -0.79
p_4 0.13 0.38 -0.74 2.02 1.59 -1.73 -2.47
p_5 -0.09 0.16 -0.31 -0.28 -0.71 0.77 0.46
p_6 1.84 2.09 -4.1 -0.81 0.38 -0.41 -4.51
p_7 -0.12 0.13 -0.25 -0.44 -0.01 0.01 -0.24
p_8 -0.21 0.04 -0.08 1.18 0.75 -0.82 -0.9
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Appendix B: 
Sample Class Diagrams of MAGE-OM 
 
MAGE-OM (MicroArray Gene Expression – Object Model) is a complex data model 
developed by MGED (Microarray Gene Expression Data) Society to facilitate the sharing of 
microarray data between data systems. Because MAGE-OM is described with UML (Unified 
Modeling Language), definitions and relationships of entities within this model can be 
graphically represented with class diagrams. Fig. 1 gives the class packages and root classes 
of MAGE-OM. Classes have an object-oriented structure and most of them inherit class 
‘Extendable’. Fig. 2 is a UML class diagram including major classes of ‘BioMaterial’ 
package. The ‘OntologyEntry’ class defines the standard vocabularies that will be used to 
describe characteristics of biological samples.  
 
References: 
1. Source of figures: http://www.ebi.ac.uk/arrayexpress/Schema/MAGE/MAGE.htm 
2. MAGE Web Home: http://www.mged.org/Workgroups/MAGE/mage.html 
3. More MAGE: http://www.mged.org/Workgroups/MAGE/MAGEdescription2.pdf 
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 Figure 1 Class Packages and Root Classes of MAGE-OM 
 
Figure 2 Class Diagram of 'BioMaterial' Package 
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Appendix C: 
Architecture of Tomcat/Servlet Server 
 
Java servlets are small server-side programs that response to connection of clients. They 
extend the functionality of web servers with improved performance and security. The 
execution of servlets needs Java Virtual Machine (JVM) and a service called ‘servlet engine’. 
The servlet engine loads a servlet the first time it is required by client, and keeps it activated 
to handle concurrent requests. The servlet keeps activated until it is explicitly unloaded or the 
servlet engine is stopped. Apache Tomcat is a container that provides a servlet-supporting 
environment. The Tomcat server includes a servlet engine, which incorporates servlets into a 
web server to make their services available to the clients. Fig. 1 demonstrates the general 
architecture of a Tomcat/Servlet server.  
 
References: 
1. Servlet Web Home: http://java.sun.com/products/servlet/ 
2. Servlet API: http://java.sun.com/products/servlet/2.2/javadoc/ 
3. Tomcat Web Home: http://tomcat.apache.org/ 
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Figure 1 Architecture of Tomcat/Servlet Server 
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Appendix D: 
Architecture of MVC Design Pattern 
 
MVC (Model-View-Controller) software architecture is commonly used in applications 
having GUI. It breaks the functions of an application into three parts. The ‘Model’ maintains 
the contents of data objects and is independent of the visual representation of data. The 
‘View’ has two major tasks. It determines how the data should be rendered on screen and 
responds to user actions. The ‘Controller’ accepts the user actions, handles the events, and 
consequently generates results. These three elements interact with each other to keep 
themselves updated. As showed in Fig. 1, a user action is received by View and passed to 
Controller, which will change Model and/or View after the action is handled. Model is 
independent of both View and Controller, and View is independent of Controller. Therefore, 
different types of functions are encapsulated, and the code updates in one element will not 
influence other elements as long as their interfaces keep unchanged. 
  
References: 
1. Source of figure: 
http://java.sun.com/blueprints/guidelines/designing_enterprise_applications_2e/app-
arch/app-arch2.html#1106102 
2. Inderjeet Singh, B.S., Mark Johnson, and the Enterprise Team, Designing Enterprise 
Applications with the J2EETM Platform, 11.1.1 Model-View-Controller Architecture. 
Second ed. 2002. 
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Figure 1 Model-View-Controller Architecture 
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Appendix E: 
Meta-analysis Methods 
 
Meta-analysis collects the results of individual studies to draw integrated conclusion and 
is often referred to as ‘analysis of analyses’. Successful meta-analysis is able to reuse 
research resource to obtain information that cannot be made available by individual studies. 
There are two common types of meta-analysis methods: combined test and measures of 
effect size. 
 
E.1 Combined Test 
Combined test is a procedure that summarizes the results from independent tests of the 
same hypothesis. It can be considered as a hypothesis test performed on the p-values or test 
statistics of individual tests. 
Fisher combined test is one of the best known meta-analysis method. It uses the p-values 
of individual tests to calculate a χ2 statistic:  
χ2 = -2 Σ loge p 
The χ2 statistic obtained from this formula following chi-square distribution with degrees 
of freedom equal to 2N, where N is the number of tests combined. 
Winer combined test uses the t statistics and df (degrees of freedom) of individual tests to 
calculate a Z statistic: 
Z = (Σt) / (Σ (df / (df – 2))) 1/2
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In this formula, df / (df – 2) is the variance of a t distribution. When each df is no less 
than 10, the resultant Z statistic can be transformed to a p-value based standard normal 
distribution.  
Stouffer combined test, on the other hand, uses z statistics of individual tests to calculate 
a summarized Z statistic:  
Z = Σz / N1/2
In this formula, N is the number of tests combined. The resultant Z statistic follows 
standard normal distribution. When all results of individual tests are obtained from large 
samples, Winer and Stouffer combined tests will have nearly the same results.  
The results of different combined tests are mostly consistent with each other although 
each method has its strengths and limitations. Before a combined test, it is often necessary to 
transform various statistics, such as t and z, into a common statistic or one-tailed p-value. 
 
E.2 Measures of Effect Size 
Combined tests provide the statistical significance of the results, but do not any give 
insight into the strength of the relationship, which can be achieved by measures of effect size. 
The phrase ‘effect size’ means ‘the degree to which the null hypothesis is false’ while the 
null hypothesis states that the effect size is zero. 
There are types of effect sizes commonly dealt with by meta-analysis methods: 
1. differences of two groups in their means, as d statistic calculated by Student’s t test. 
• d = |Mean1 – Mean2| / σ 
2. the degree of association between two variables, as Pearson correlation coefficient (r). 
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The average of these effect sizes obtained from individual studies is calculated by meta-
analysis methods for further steps: 
daverage = Σd / N 
and 
raverage = Σr / N 
 
E.3 Transformation of Test Statistics 
For the purpose of meta-analysis, it is often necessary to transform test statistics to each 
other.  
1. Transform to r: 
• t: r = (t2 / (t2 + df))1/2 
• F: r = (F / F + df(error))1/2   
• χ2: r = (χ2 / n)1/2  
• d: r = d / (d2 + 4)1/2 
2. Transform to d: 
• t: d = 2t / df1/2 
• F: d = 2F1/2/df(error) 1/2  
• r: d = 2r / (1 – r2) 1/2 
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Appendix F: 
Complete Lists of Reporter genes 
 
This appendix presents the complete reporter gene lists derived from breast and lung 
cancer microarray datasets using bootstrap procedure. In the tables, ‘ID’ is the Unigene 
accession of a reporter while ‘Name’ is its Unigene symbol. ‘Count’ represents how many 
times a reporter was ranked within top-100 by bootstrapping re-samplings. Finally, ‘Weight’ 
is the Z statistic of a reporter gene obtained from Wilcoxon Rank Sum Test (RST) applied on 
the data of all patients in the dataset.  
 
F.1 Reporter Lists of Breast Cancer 
Table 1-3 separately give the 60-gene reporter list derived from two independent breast 
cancer datasets and their combination. These lists represent gene expression profiles 
corresponding to 3-year recurrence outcome of breast cancer and the list in Table 3 is 
recommended by this study. The counts of reporters are based on 10,000 bootstrapping re-
samplings.  
 
F.2 Reporter Lists of Lung Cancer 
Table 4-6 separately give the 60-gene reporter list derived from two independent breast 
cancer datasets and their combination. These lists represent gene expression profiles 
corresponding to 2-year survival outcome of lung cancer and the list in Table 6 is 
recommended by this study. The counts of reporters are based on 1,000 bootstrapping re-
samplings.  
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Table 1 The Reporter List Derived from Rosetta Breast Dataset 
Sequence Name Count Weight 
Hs.435861 SCUBE2 9991 6.57 
Hs.27860 PTGER3 9463 5.51 
Hs.148767 RQCD1 9432 -5.4 
Hs.352962 HRB 9248 -5.09 
Hs.171834 PCTK1 8768 -5.12 
Hs.25001 YWHAG 8743 -5.05 
Hs.9589 UBQLN1 8723 -5.15 
Hs.433512 ACTR3 8537 -4.74 
Hs.20013 P29 8213 4.66 
Hs.181461 ARIH1 8119 -4.7 
Hs.84113 CDKN3 8114 -4.64 
Hs.1578 BIRC5 8079 -4.55 
Hs.439200 KIAA0090 8012 4.7 
Hs.2006 GSTM3 7915 4.55 
Hs.351680   7855 -4.72 
Hs.30743 PRAME 7646 -4.68 
Hs.429 ATP5G3 7590 -4.52 
Hs.437546 SMARCE1 7577 4.62 
Hs.283532 BM039 7396 -4.35 
Hs.421337 XTP1 7038 -4.25 
Hs.82285 GART 6862 -4.39 
Hs.276466 FLJ21062 6852 4.29 
Hs.178761 PSMD14 6549 -4.2 
Hs.287472 BUB1 6547 -4.2 
Hs.35096 KAISO-L1 6383 4.14 
Hs.424966 PIR 6144 -4.12 
Hs.79353 TFDP1 6035 -4.11 
Hs.155204 ZNF174 5950 4.12 
Hs.25913 PEX12 5771 4.07 
Hs.35120 RFC4 5679 -4 
Hs.184161 EXT1 5652 -4 
Hs.173162 NOC4 5647 -4 
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Hs.2025 TGFB3 5644 4.02 
Hs.23255 NUP155 5636 -4 
Hs.190389 KIAA0266 5492 4 
Hs.128425 NY-REN-24 5463 4 
Hs.153752 CDC25B 5249 -3.92 
Hs.49932 C21orf45 5246 -3.92 
Hs.350966 PTTG1 5204 -3.85 
Hs.443793 MIR 5159 3.92 
Hs.53447 KNSL8 5108 3.92 
Hs.77448 ALDH4A1 5074 3.85 
Hs.78885 BTD 4962 3.92 
Hs.173034 AMPH 4940 3.85 
Hs.433951 GPX4 4831 3.8 
Hs.7888   4811 3.8 
Hs.388921 PSMD2 4717 -3.8 
Hs.348501 PCM1 4652 3.74 
Hs.284153 FANCA 4650 -3.8 
Hs.163091 HIP14L 4647 -3.8 
Hs.407912 COL4A2 4646 -3.74 
Hs.77515 ITPR3 4548 -3.74 
Hs.81934 ACADSB 4538 3.8 
Hs.83383 PRDX4 4515 -3.7 
Hs.109706 HN1 4382 -3.7 
Hs.436187 TRIP13 4343 -3.74 
Hs.308045 BRRN1 4308 -3.7 
Hs.110457 WHSC1 4303 -3.66 
Hs.153357 PLOD3 4281 -3.66 
Hs.410784 LRP8 4211 -3.7 
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Table 2 The Reporter List derived from Stanford Breast Dataset 
Sequence Name Count Weight 
Hs.411509 GSTP1 9866 -5.17 
Hs.1657 ESR1 9297 4.33 
Hs.329989 PLK 9268 -4.25 
Hs.85137 CCNA2 8925 -4.09 
Hs.211589 PPEF1 8822 4.28 
Hs.149156 GLDC 8755 -4.14 
Hs.79748 SLC3A2 8719 -4.11 
Hs.94865 TEAD4 8599 -4.07 
Hs.150684 XPO6 8465 -4.04 
Hs.77329 PTDSS1 8305 -3.92 
Hs.287472 BUB1 8049 -4 
Hs.301011 KIAA0876 8019 3.8 
Hs.79241 BCL2 8003 3.85 
Hs.433984 SLC4A2 7632 -3.74 
Hs.12853   7585 3.7 
Hs.434367 TXNRD1 7402 -3.62 
Hs.82109 SDC1 6652 -3.47 
Hs.416854 RERG 6635 3.42 
Hs.178695 MAPK13 6614 -3.4 
Hs.267659 VAV3 6421 3.42 
Hs.5372 CLDN4 6149 -3.36 
Hs.408219 BCL7B 6099 -3.28 
Hs.435249 KIAA1025 5763 3.24 
Hs.102471 C6orf56 5627 -3.22 
Hs.169946 GATA3 5530 3.21 
Hs.78619 GGH 5439 -3.19 
Hs.3416 ADFP 5113 -3.1 
Hs.30901 SLC39A3 5067 -3.07 
Hs.406491 TLE1 5043 -3.08 
Hs.188011 MS4A7 4994 3.08 
Hs.405774 CTRL 4918 -3.05 
Hs.166071 CDK5 4698 -3 
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Hs.225952 PTPRT 4690 2.98 
Hs.83114 CRYZ 4581 2.97 
Hs.69771 BF 4561 3 
Hs.278526 RNTRE 4555 -2.97 
Hs.406458 GPI 4524 -2.98 
Hs.159637 VARS2 4432 -2.95 
Hs.368149 CCT7 4333 -2.94 
Hs.90911 SLC16A5 4281 -2.94 
Hs.91728 PMSCL1 4109 -2.89 
Hs.155287 KIAA0010 4019 -2.82 
Hs.387906 ABI-2 3993 2.82 
Hs.5719 CNAP1 3984 -2.86 
Hs.150444 KIAA0373 3979 2.83 
Hs.82963 GNRH1 3971 2.85 
Hs.437459 MYO1E 3965 -2.85 
Hs.179718 MYBL2 3913 -2.85 
Hs.83583 ARPC2 3862 -2.83 
Hs.410784 LRP8 3858 -2.85 
Hs.460184 MCM4 3857 -2.8 
Hs.24395 CXCL14 3836 2.82 
Hs.183800 RANGAP1 3829 -2.8 
Hs.12820 USP39 3826 -2.79 
Hs.430725 RHOIP3 3812 -2.79 
Hs.369358 SRPK1 3810 -2.82 
Hs.250712 CACNB3 3770 -2.77 
Hs.362805 MEIS2 3754 -2.79 
Hs.260555 C14orf45 3695 2.77 
Hs.432750 HPN 3685 2.77 
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Table 3 The Reporter List Derived from the Combination of Two Breast Datasets 
Sequence Name Count Weight 
Hs.171834 PCTK1 9862 -4.94 
Hs.435861 SCUBE2 9732 5.18 
Hs.287472 BUB1 9681 -4.56 
Hs.1657 ESR1 9647 5.23 
Hs.35096 KAISO-L1 9559 5.14 
Hs.25001 YWHAG 9426 -4.94 
Hs.436187 TRIP13 9360 -4.48 
Hs.173162 NOC4 8970 -4.42 
Hs.85137 CCNA2 8673 -4.17 
Hs.169946 GATA3 8651 4.93 
Hs.1578 BIRC5 8595 -4.6 
Hs.82906 CDC20 8466 -4.42 
Hs.410784 LRP8 8428 -4.76 
Hs.267659 VAV3 8415 5.01 
Hs.78619 GGH 8407 -4.29 
Hs.308045 BRRN1 8299 -4.5 
Hs.163091 HIP14L 8176 -4.43 
Hs.12272 BECN1 8158 4.92 
Hs.3416 ADFP 8043 -4.45 
Hs.77329 PTDSS1 8035 -4.36 
Hs.83383 PRDX4 7839 -4.36 
Hs.79353 TFDP1 7821 -4.32 
Hs.301011 KIAA0876 7750 4.94 
Hs.153752 CDC25B 7690 -4.47 
Hs.9589 UBQLN1 7634 -3.94 
Hs.27860 PTGER3 7542 4.79 
Hs.2006 GSTM3 7365 4.62 
Hs.49932 C21orf45 7178 -4.69 
Hs.421337 XTP1 7061 -3.9 
Hs.79241 BCL2 7047 4.59 
Hs.12109 CIAO1 6994 -4.07 
Hs.5719 CNAP1 6931 -4.1 
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Hs.434367 TXNRD1 6828 -4.21 
Hs.78771 PGK1 6698 -4.14 
Hs.111554 ARL7 6626 -4.41 
Hs.77515 ITPR3 6519 -4.24 
Hs.81934 ACADSB 6417 4.68 
Hs.374378 CKS1B 6363 -4.07 
Hs.406491 TLE1 6356 -4.3 
Hs.24395 CXCL14 6352 4.37 
Hs.109706 HN1 6339 -4.34 
Hs.435326 BAF53A 6336 -3.91 
Hs.153357 PLOD3 6083 -3.98 
Hs.350966 PTTG1 6024 -3.96 
Hs.433512 ACTR3 5987 -4.13 
Hs.413636 C7orf14 5963 -4.26 
Hs.278526 RNTRE 5925 -4.16 
Hs.348501 PCM1 5901 4.79 
Hs.311054 ITGBL1 5724 4.38 
Hs.184161 EXT1 5655 -4.17 
Hs.171955 TROAP 5653 -4.16 
Hs.188011 MS4A7 5600 4.74 
Hs.20830 KIFC1 5402 -3.95 
Hs.424966 PIR 5357 -3.96 
Hs.35962   5350 -3.99 
Hs.409065 FEN1 5326 -4.02 
Hs.226390 RRM2 5259 -3.99 
Hs.82285 GART 5256 -3.88 
Hs.184601 SLC7A5 5216 -4.14 
Hs.69771 BF 5168 4.08 
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Table 4  The Reporter List Derived from Harvard Lung Dataset 
Sequence Name Count Weight 
Hs.412707 HPRT1 1000 -4.57 
Hs.447492 PGAM1 949 -3.66 
Hs.411312 ITGA2B 889 3.52 
Hs.41270 PLOD2 841 -3.3 
Hs.91747 PFN2 827 -3.24 
Hs.408093 TCF2 825 3.28 
Hs.79037 HSPD1 816 -3.24 
Hs.119000 ACTN1 797 -3.12 
Hs.84136 PITX1 761 -3.07 
Hs.153647 MATN2 745 3.03 
Hs.195825 RBPMS 725 2.95 
Hs.172589 PWP1 693 -2.88 
Hs.155048 LU 673 2.91 
Hs.381072 PPIF 662 -2.88 
Hs.51 PIGA 634 2.77 
Hs.75318 TUBA1 633 -2.79 
Hs.293885 GARS 630 -2.74 
Hs.409965 PNN 620 -2.71 
Hs.436181 HOXB7 595 -2.69 
Hs.89901 PDE4A 593 2.7 
Hs.77917 UCHL3 584 -2.64 
Hs.75823 AF1Q 581 -2.64 
Hs.154672 MTHFD2 578 -2.63 
Hs.2006 GSTM3 573 2.65 
Hs.79347 KIAA0211 569 2.65 
Hs.155206 STK25 531 -2.63 
Hs.512601 HUMCYT2A 529 -2.57 
Hs.446579 HSPCA 528 -2.56 
Hs.58414 FLNC 527 -2.56 
Hs.282260 RPE 526 -2.57 
Hs.77613 ATR 521 -2.53 
Hs.59889 HMGCS2 507 2.48 
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Hs.409065 FEN1 504 -2.41 
Hs.79110 NCL 498 -2.51 
Hs.75160 PFKM 480 -2.46 
Hs.290432 HOXB2 473 -2.43 
Hs.78771 PGK1 460 -2.43 
Hs.512587 MST1 442 2.43 
Hs.150358 DPYSL3 441 -2.34 
Hs.10842 RAN 440 -2.4 
Hs.420563 NDUFS1 437 -2.41 
Hs.73769 FOLR1 429 2.41 
Hs.512711 TPI1 428 -2.32 
Hs.46319 SHBG 428 2.32 
Hs.67928 ELF3 418 2.3 
Hs.155079 PPP2R5A 415 2.28 
Hs.433941 SEPW1 414 2.34 
Hs.245540 ARL4 407 -2.25 
Hs.437475 STAT6 403 2.33 
Hs.360033 KIAA0186 402 -2.28 
Hs.79081 PPP1CC 398 -2.3 
Hs.6906 RALA 386 -2.3 
Hs.640 CALCR 380 -2.2 
Hs.278311 PLXNB1 375 2.22 
Hs.83583 ARPC2 372 -2.29 
Hs.111903 FCGRT 369 2.22 
Hs.226755 YWHAH 361 -2.22 
Hs.1420 FGFR3 360 2.26 
Hs.181973 CYP2A13 359 2.22 
Hs.118127 ACTC 356 -2.16 
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Table 5 The Reporter List Derived from Michigan Lung Dataset 
Sequence Name Count Weight 
Hs.352962 HRB 946 -3.85 
Hs.75968 TMSB4X 930 3.74 
Hs.75514 NP 917 -3.66 
Hs.99029 CEBPB 912 -3.62 
Hs.511822 CRK 908 -3.7 
Hs.119192 H2AFZ 900 -3.47 
Hs.576 FUCA1 881 3.42 
Hs.73800 SELP 853 3.42 
Hs.231975 CREM 850 -3.47 
Hs.517814 CCR2 829 3.27 
Hs.77961 HLA-B 822 3.21 
Hs.156324 PRKACB 803 3.24 
Hs.304682 CST3 796 3.21 
Hs.408615 P2RX5 783 3.15 
Hs.362807 IL7R 721 3.08 
Hs.2375 EMR1 711 2.98 
Hs.17287 KCNJ15 708 3.03 
Hs.75671 STX1A 690 -3.03 
Hs.381072 PPIF 662 -2.89 
Hs.433416 NME2 653 -2.92 
Hs.169824 KLRB1 649 2.82 
Hs.83795 IRF2 642 2.89 
Hs.433888 RAB11B 634 2.89 
Hs.1765 LCK 612 2.77 
Hs.173381 DPYSL2 580 2.76 
Hs.79993 PEX7 575 -2.74 
Hs.436949 CD6 557 2.65 
Hs.162757 LRP1 531 2.69 
Hs.414480 DBP 530 2.61 
Hs.386748 MS4A2 527 2.63 
Hs.512640 PRKCSH 526 2.64 
Hs.394609 SORT1 506 2.69 
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Hs.75932 NAPA 496 2.61 
Hs.119651 GPC3 494 2.5 
Hs.285091 C18orf1 482 2.57 
Hs.142912 FZD2 475 2.56 
Hs.278426 PDAP1 473 -2.54 
Hs.435342 SLU7 468 2.54 
Hs.1578 BIRC5 466 -2.54 
Hs.150580 SUI1 455 -2.54 
Hs.169476 GAPD 446 -2.54 
Hs.434367 TXNRD1 443 -2.51 
Hs.95327 CD3D 434 2.43 
Hs.73793 VEGF 428 -2.47 
Hs.524835 UBC 415 -2.43 
Hs.12013 ABCE1 411 -2.39 
Hs.73172 GFI1 406 2.4 
Hs.159494 BTK 405 2.37 
Hs.409934 HLA-DQB1 397 2.37 
Hs.172609 NUCB1 393 2.36 
Hs.439911 TERT 392 -2.37 
Hs.57718 CHRNA2 382 2.28 
Hs.246381 CD68 378 2.28 
Hs.150930 XRCC4 377 -2.36 
Hs.433319 CTF1 374 2.32 
Hs.417361 UGP2 369 -2.4 
Hs.91390 PARG 369 -2.32 
Hs.169849 MYBPC1 357 2.29 
Hs.68877 CYBA 353 2.24 
Hs.388617 RORA 353 2.24 
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Table 6 The Reporter List Derived from Combination of Two Lung Datasets 
Sequence Name Count Weight 
Hs.381072 PPIF 965 -4.33 
Hs.412707 HPRT1 911 -3.97 
Hs.75514 NP 904 -4.08 
Hs.409065 FEN1 882 -3.84 
Hs.433416 NME2 873 -3.87 
Hs.79037 HSPD1 873 -3.85 
Hs.119192 H2AFZ 868 -3.81 
Hs.41270 PLOD2 846 -3.82 
Hs.433888 RAB11B 840 3.91 
Hs.10842 RAN 822 -3.76 
Hs.576 FUCA1 817 3.7 
Hs.55279 SERPINB5 804 -3.77 
Hs.155048 LU 764 3.72 
Hs.75318 TUBA1 750 -3.69 
Hs.304682 CST3 735 3.56 
Hs.195825 RBPMS 712 3.58 
Hs.78771 PGK1 711 -3.63 
Hs.447492 PGAM1 696 -3.56 
Hs.352962 HRB 693 -3.59 
Hs.172589 PWP1 668 -3.46 
Hs.94367 TITF1 654 3.5 
Hs.433941 SEPW1 639 3.4 
Hs.463110 ANXA8 631 -3.46 
Hs.75671 STX1A 625 -3.43 
Hs.6906 RALA 623 -3.47 
Hs.58414 FLNC 619 -3.48 
Hs.435342 SLU7 616 3.44 
Hs.1578 BIRC5 583 -3.38 
Hs.154672 MTHFD2 583 -3.34 
Hs.153884 APACD 581 -3.39 
Hs.414480 DBP 579 3.33 
Hs.3281 NPTX2 572 -3.42 
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Hs.2006 GSTM3 562 3.4 
Hs.437475 STAT6 562 3.4 
Hs.78563 UBE2G1 552 -3.33 
Hs.149957 RPS6KA1 552 3.31 
Hs.436657 CLU 526 3.26 
Hs.79347 KIAA0211 518 3.31 
Hs.1420 FGFR3 516 3.28 
Hs.32393 DARS 516 -3.29 
Hs.394609 SORT1 501 3.24 
Hs.154846 PIK4CB 494 3.25 
Hs.111903 FCGRT 487 3.21 
Hs.404814 VDAC1 486 -3.28 
Hs.348500 VIPR1 486 3.35 
Hs.446429 PTGDS 483 3.26 
Hs.405958 CDC6 473 -3.35 
Hs.82432 KIAA0089 456 3.18 
Hs.119000 ACTN1 455 -3.18 
Hs.356342 RPL27A 443 -3.22 
Hs.352119 GGT1 441 3.18 
Hs.77917 UCHL3 436 -3.17 
Hs.83795 IRF2 433 3.11 
Hs.1594 CENPA 429 -3.19 
Hs.75932 NAPA 428 3.1 
Hs.191990 PRKCBP1 422 -3.1 
Hs.282260 RPE 419 -3.09 
Hs.79993 PEX7 416 -3.14 
Hs.169824 KLRB1 410 3.25 
Hs.81892 KIAA0101 407 -3.09 
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Appendix G: 
Requirements of MAMA Project 
 
G.1 General Description 
Microarray technology is a powerful tool for the research of complex diseases like 
cancers. Many microarray datasets have been generated from cancer tissues in order to 
identify gene expression profiles corresponding to various features of tumors. However, due 
to the high expense of microarray experiment, the sample sizes of individual microarray 
studies (usually around 100) are rather small comparing to the number of genes (up to 30 
thousands) under investigation. The generality of profiles identified from single datasets are 
then questionable. One solution to this issue is to increase the sample size and power of 
statistical analyses by integrating information from multiple datasets.  Results from previous 
studies already showed that despite of various inter-study variations, independent microarray 
datasets did share significant consistence if proper assumptions and data processing were 
made.  
It is not technically straightforward to achieve analysis involving multiple microarray 
datasets. Datasets from independent resources are processed and formatted differently. Each 
study has its own experiment design, so the cancer tissues may be sampled from disparate 
populations. Even when two studies use identical samples, inter-dataset variations still could 
be significant because microarray experiment is a complicate process during which factors 
including experimenter, protocol, instrument, and array quality may introduce systematic 
bias into the final measurements. Furthermore, statistical methods used for microarray 
analysis are becoming more and more complex and sophisticated, and increasing sample size 
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will aggravate the computational burden of these methods. For biologists and statisticians 
who want to focus their work on the high-level data analysis, dealing with these issues is 
distracting and time-consuming.  
The general purpose of MAMA project is to provide researchers a data mining platform 
that will support the precise gene expression profiling of cancer tissues using microarray data 
from independent resources. Users of MAMA will be able to access a centralized repository 
of microarray datasets about cancer and investigate them simultaneously, so they can identify 
gene expression profiles of certain features of cancer patients, such tumor stage or patient 
survival. The data repository will be a relational database located on a server machine. All 
datasets will be processed and formatted with same criteria before they are loaded into the 
database. Besides gene expression measurements, the database will also store related 
information about microarray experiments, such as author contact, experiment design and 
clinical scenario of patients. This database is accessible to users through a server program, 
which can handle concurrent requests from multiple clients. The client program developed by 
MAMA project will be data analysis application, which implements statistical methods 
suitable for microarray analysis. Other components of MAMA system include user interface, 
web server, data processing package, and so on.  
 
G.2 Definitions 
Workspace --- It is the root of data object in MAMA client program within which end 
users perform operations such as manipulating, retrieving, and analyze data. Each client 
program opens and operates on one and only one workspace at a time. Workspaces can be 
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stored on local disk as XML documents. Workspace maintains the information about data, 
results, and procedures in a hierarchical tree structure.  
Virtual experiment --- Virtual experiment is a key feature of MAMA system. Each virtual 
experiment is built with genes and samples originated from one or more original studies. 
Building virtual experiments will allow researchers to analyze data with purposes different 
from those of the original studies. For example, with a microarray dataset originally used to 
profile normal and cancer lung tissues, users can select only the data from the cancer tissues 
to build a virtual experiment and use this experiment to profile subtypes of lung cancer. In 
MAMA system, virtual experiments are the units to which analysis methods are applied. 
Meta-analysis --- Meta-analysis is the technique used to draw summary conclusions from 
the results of multiple independent studies. Therefore, the inputs of meta-analysis are the 
results of individual studies rather than the source data of those studies. Implementing meta-
analysis algorithms is a major, but not the only, purpose of developing MAMA system. For 
example, meta-analysis can be used to evaluate the consistence of several expression profiles 
or to combine test statistics obtained from individual tests.  
Expression profile --- Expression profiles are identified from one or more microarray 
datasets using certain statistical methods and can be used to classify sample tissues. An 
expression profile includes a group of reporter genes and their relative weights.  
Metadata of microarray experiment --- In MAMA system, metadata refer to all 
information related to microarray experiments except the gene expression measurements, 
including attributes of experiments, samples, and genes. Users are commended to investigate 
the metadata of a dataset before loading the complete dataset into the client program because 
of the large size of the expression measurements matrix.  
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MIAME, MAGE, and MGED ontology --- The MGED (Microarray Gene Expression 
Data) society (www.mged.org) has developed three standards for description of microarray 
data: MIAME, MAGE, and MGED ontology. MIAME (Minimum Information About a 
Microarray Experiment) describes the information needed to unambiguously interpret results 
of a microarray experiment and potentially reproduce it. Providers of microarray data can 
satisfy MAMA requirements by following up a checklist. The database of this system will be 
designed as MIAME-compatible. MAGE (MicroArray and Gene Expression) is a standard 
defining the entities related to microarray experiments and their relationship. MAGE is 
composed of an object model represented with UML (MAGE-OM) and a markup language 
developed as an XML-DTD (MAGE-ML). MAGE-OM captures the information specified by 
MIAME. The MGED ontology provides a standard specification of microarray-related 
vocabularies and their relationship. MAMA database adopts MAGE-OM for database 
schema and MGED ontology for description of samples and other data objects. 
 
G.3 Functional Requirements 
Database: 
1. A relational database schema 
2. MAGE-OM and MIAME compliant 
3. Use controlled vocabularies, such as MGED ontology, to describe samples, 
experiment design, and other data objects. 
4. Support storage of microarray datasets generated on both of oligonucleotide and 
cDNA platform. 
5. Have genes annotated by accessions of common sequence databases. 
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6. Separately store frequently requested data, such as metadata about microarray 
experiments, for quick access. 
7. Accept data submission through the web. 
 
Server Program: 
1. Access to the database. 
2. Process microarray datasets by following a standard guideline before loading them 
into the database. 
3. Execute build-in database queries for experiments, samples, sequences and 
expression measurements. 
4. Implement a pre-defined communication protocol between the server and the client 
programs. 
5. Handle concurrent requests from multiple clients. 
 
Client Program: 
1. Load/retrieve data to/from the database by communicating with the server program. 
2. Import microarray datasets from the database or text files 
3. Maintain data objects in a tree-like structure. 
4. Save data on local disk as XML documents and map between java objects and XML 
elements. 
5. Manipulate data objects with operations such as filtering samples and normalizing 
expression measurements. 
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6. Have a graphic user interface and render data objects with GUI components such as 
lists and tables. 
7. Implement common statistical processes of microarray analysis, such as calculation 
of descriptive statistics and gene-feature correlation. 
8. Provide APIs for plug-in of user-specific methods. 
9. Support meta-analysis of microarray data. 
 
User Interface: 
1. Render data objects and their relationship in a way consistent to the data model. 
2. Allow for browsing of data objects in a folder-like structure. 
3. Provide Wizards for multi-step operations. 
4. Group related operations into menus. 
 
G. 4 Non-functional Requirements 
Performance --- The performance of MAMA system is mostly dependent upon the 
network connection and complexity of operations. While immediate response is unachievable, 
users should be informed that the operations is on its way. On the other hand, a quick 
response is required for operations such as showing the description of an experiment. Due to 
the large size of microarray datasets, the downloading of complete datasets is usually time-
consuming. Therefore, users will be recommended to execute such operations only when 
they are necessary.  The performance of plug-in methods is the responsibility of 
corresponding developers.  
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Security --- Security is a major concern of MAMA system since the database and the 
client-side program is open to the public. However, the database needs to be protected from 
the unexpected data. Therefore, only authorized users or administrators are allowed to load or 
update database data. 
Availability --- The client-side package will be downloaded for free and run on any 
computer installing Java Virtual Machine. Database and server-side program will be 
available as long as the server machine is running. Updating and maintenance will be 
scheduled occasionally. There is no backup of server and database services. 
Usability --- User guides should be provided for users to learn the concepts and methods 
of MAMA system. Operations need user guide include, but not limited to: dataset importing, 
method plug-in, defining database query or analysis, and so on. The user interface should 
look familiar to experienced users of GUI software. Guided by instructions, these users 
should be able to execute most operations within an hour.  The analysis methods 
implemented in the standard release should partly satisfy basic data analysis needs of users.  
Modifiability and extensibility --- The client program of MAMA system should be highly 
modifiable and extensible. Major software packages, such as user interface and data analysis 
packages, should be encapsulated, so the updating of one package will not affect the others. 
As an open-source application, all source codes of MAMA system will be publicly available. 
Furthermore, a plug-in mechanism should be provided for other developers to add their own 
methods. The data model and database schema of MAMA are less flexible. They should be 
cautiously designed at the beginning. 
Portability --- The client program should be runnable on any computer having Java 
Virtual Machine installed. Stored data will be exported in a standard format, such as tab-
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delimited text or XML. Besides Oracle, it is not required that MAMA database can be 
installed to other database administration system, such as MySQL.  
 
Maintainability --- Due to the limited human resource, the system will have a simple 
architecture to keep the burden of its maintenance minimal. Source codes will be updated and 
tested periodically. The major maintenance issue is the updating and inspection of microarray 
datasets. 
Reusability --- No a concern for MAMA project.   
 
G. 5 System Requirements for Development 
Software: 
1. Administration of relational database (Oracle) 
2. High-level programming language (Java, with Java Virtual Machine) 
3. Web server  and Servlet engine (Apache Tomcat) 
4. Source code and project management (Eclipse) 
5. XML parsing (Castor) 
6. UML diagram (SmartDraw) 
7. Ontology (MGED Ontology, NCI Thesaurus, … ) 
 
Hardware: 
1. Enough disk space on server machine to store at least 100 microarray datasets in 
regular size.  
2. I/O bandwidth of server machine to handle 10 or more concurrent requests. 
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3. Stable network connection between server and client. 
4. High speed network connection of client machine (1 mbps or faster). 
5. Enough internal memory (512 MB or more) of client machine to handle operations 
that need to load the complete expression data matrix into the memory.  
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Appendix H: 
User Cases of the MAMA Client Program 
 
The following is a list of major use cases of the MAMA client program: 
• Manage Workspace: use cases operating on workspaces, the root of tree-like structure 
of MAMA client data model. 
o Create Workspace: create a new workspace and related files on local disk and 
open it as the current workspace 
o Open Workspace: open an existing workspace as the current workspace, 
update the data object tree on user interface 
o Delete Workspace: delete an existing workspace and related files from local 
disk. 
o Save Workspace: save the currently opened workspace and its contents to 
local disk. 
o Sort Objects: sort the data objects by specified order on user interface. 
o Delete Object from Workspace: delete a specified data object from the 
currently opened workspace. 
• Query Database: use cases querying the database to retrieve data. 
o Query Experiments: query for microarray experiments. 
o Query Samples: query for biological samples by their features. 
o Query Sequences: query for nucleotide sequences by their names or 
accessions. 
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o Query Database Metadata: take a snapshot about the current status of MAMA 
database, retrieving information such as the number of currently stored 
datasets.  
o Export Query Results: export query results to external files in standard format. 
• Manipulate Experiment: use cases creating or customizing the microarray 
experiments. 
o Submit Experiment to Database: submit a new microarray dataset to the 
database by running a wizard or importing XML documents. 
o Create Virtual Experiment: create a experiment in the current workspace by 
querying database or direct submitting. 
o User-specific Data Processing: customize the contents of a virtual experiment 
by filtering samples or sequences, discretizing sample features, or normalizing 
expression measurements. 
• Data Analysis: use cases related to the analysis of microarray data. 
o Create Analysis: create and run a microarray analysis by specifying statistical 
method to use and the inputs of the analysis. 
o Create Meta-analysis: create and run a meta-analysis based on the outputs of 
individual analyses, and specify the meta-analysis methods. 
o Plug in Method: Plug in a user-specific statistical method. 
o Export Results: export the results of an analysis to external files in standard 
format. 
• Render Data: use cases specifying the functions of user interface. 
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o Initiate Operations with Menus: browse menus and select menu item to 
initiate an operation. 
o Run Wizard: run a GUI wizard for multi-step operations. 
o Summarize Database Status: summarize the major contents of database, such 
as existing array designs or experiments. 
o Browse Structured Data Objects: browse the data objects in a folder-like 
structure.  
o List Details of Data Objects: render the details of a data objects, such as the 
samples, sequences, or expression measurements of an experiment. 
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 Figure 1 Use Cases Packages 
 
Figure 2 Use Cases about Workspace 
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 Figure 3 Use Cases about Database Query 
 
Figure 4 Use Cases about Microarray Experiment 
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 Figure 5 Use Cases about Data Analysis 
 
Figure 6 Use Cases about User Interface 
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The following tables give the detailed description about the use cases of Workspace 
package: 
 
Use Case Name Create Workspace 
Author Zhe Zhang 
Date 2004/11/16 
Objective Create a new, empty workspace and open it. If there already is a workspace opened, 
close it 
Actor User, System 
Level Primary 
Trigger User decides to create a new workspace 
Included Use Case <<save workspace>> 
Extended Use Case  
Frequency Intermediate 
Pre-condition • Client program is running 
Post-condition • A new, empty workspace is created and opened in the client program  
Actor Action System Action 
1. User clicks ‘Workspace’ menu, then 
clicks ‘New’ menu item 
 
 2. System shows a dialog box asking for 
the name of the new workspace 
3. User specifies the directory of the 
workspace and names it, then clicks 
‘Create’ 
 
 4. System creates the new workspace 
object and opens it in the client program 
5. User Clicks ‘OK’  
Main Flow 
 6. System terminates process 
Steps Blanching Action 
4. There already is a currently opening 
workspace in the client program 
1. System prompts for what to do: 
• Save 
• Not save 
• Cancel 
2. User selects one 
3. System responds to user’s selection 
• Save it, open the new one 
• Not Save it, open the new one 
• Abort creating, keep the old one 
INCLUDE <<save workspace>> 
Sub flows 
3. User clicks ‘Cancel’ System aborts process 
Conditions Actions Exceptions 
4. Redundant workspace name System prompts for what to do: 
• Overwrite (will replace the old one) 
• Change name (will repeat step 3) 
• Cancel (will abort process) 
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Use Case Name Open Workspace 
Author Zhe Zhang 
Date 2004/11/16 
Objective Open a stored workspace from disk and make it the active workspace in the client 
program. Close the currently opening workspace. 
Actor User, System 
Level Primary 
Trigger User decides to open a stored workspace. 
Included Use Case  
Extended Use Case  
Frequency Intermediate 
Pre-condition • Client program is running 
• There is at least one workspace stored in the disk 
Post-condition • A stored workspace is resumed in the client program  
Actor Action System Action 
1. User clicks ‘Workspace’ menu, then 
clicks ‘Open’ menu item 
 
 2. System shows a dialog box for user to 
select a workspace XML file from the 
disk 
3. User browses the directories on the 
disk and clicks the file to be opened, 
then clicks ‘open’ 
 
Main Flow 
 4. System validates the XML file with 
DTD, parses it to workspace object, and 
opens it in the client program 
Steps Blanching Action 
4. There already is a opening workspace 
in the client program 
1. System prompts for what to do: 
• Save 
• Not save 
• Cancel 
2. User selects one 
3. System responds to user’s selection 
• Save it, open the stored one 
• Not Save it, open the stored one 
• Abort opening, keep the old one 
INCLUDE <<save workspace>> 
Sub flows 
3. User clicks ‘Cancel’ System aborts process 
Conditions Actions Exceptions 
4. XML file is invalid System shows error message and aborts 
process 
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Use Case Name Close Workspace 
Author Zhe Zhang 
Date 2004/11/16 
Objective Close the workspace currently opened in the client program. 
Actor User, System 
Level Primary 
Trigger User decides to close the opened workspace. 
Included Use Case  
Extended Use Case  
Frequency intermediate 
Pre-condition • Client program is running 
• There is an opened workspace in the client program 
Post-condition • There is no opened workspace in the client program  
Actor Action System Action 
1. User clicks ‘Workspace’ menu, then 
clicks ‘Close’ menu item 
 
 2. System asks user whether to save the 
workspace 
3. User makes the selection about 
saving 
 
Main Flow 
 4. System removes the workspace from 
the client program 
Steps Blanching Action 
3a. User selects to save the workspace 
to disk 
System transforms the workspace to 
XML file and saves it to the disk 
3b. User selects not to save the 
workspace to disk 
System closes workspace without 
saving it 
Sub flows 
3c. User clicks ‘Cancel’ System aborts closing 
Conditions Actions Exceptions 
There is no currently opened workspace None 
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Use Case Name Save Workspace 
Author Zhe Zhang 
Date 2004/11/16 
Objective Save the opened workspace to disk as an XML file 
Actor User, System 
Level Included 
Trigger User needs to backup the opened workspace, or other procedures, such as close 
workspace, initiate it 
Included Use Case None 
Extended Use Case None 
Frequency high 
Pre-condition • Client program is running 
• There is an opened workspace in the client program 
Post-condition • A up-to-date version of the workspace is saved to disk 
Actor Action System Action 
1. User sends ‘Save workspace’ 
command 
 
Main Flow 
 2. System transforms the workspace 
object to an XML file and saves it to 
disk 
Steps Blanching Action 
2a. The XML file of this workspace 
already exists in the disk 
Overwrite the old one 
2b. There is no XML file of this 
workspace exists 
Just write the XML file to the disk 
Sub flows 
  
Conditions Actions Exceptions 
Transform to XML error System aborts saving 
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Use Case Name Delete an Object from Workspace 
Author Zhe Zhang 
Date 2004/11/16 
Objective Remove a query, experiment, analysis, or profile object from workspace.  
Actor User, System 
Level Included 
Trigger An object in the workspace is not needed any more.  
Included Use Case  
Extended Use Case <<Browse Workspace>> 
Frequency High 
Pre-condition • Client program is running 
• There is a opened workspace in the client program 
• There at least exists one sub-class object of the opened workspace 
Post-condition • An object is removed from the workspace 
Actor Action System Action 
1. User clicks to highlight an object, 
then right-clicks 
 
 2. System shows right-click menu 
3. User clicks ‘delete’  
 4. System asks for confirmation of 
deletion 
5. User clicks ‘delete’  
Main Flow 
 6. System removes the object 
Steps Blanching Action 
5a. User clicks ‘delete’ System removes the object 
Sub flows 
5b. User clicks ‘cancel’ System aborts deletion 
Conditions Actions Exceptions 
Objects is used by other objects System shows error message and aborts 
deletion 
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Use Case Name Sort Objects 
Author Zhe Zhang 
Date 2004/11/17 
Objective Sort a field in the table of objects currently showed in the central panel.  
Actor User, System 
Level Primary 
Trigger User decides to sort the object according to one of its attributes.  
Included Use Case  
Extended Use Case  
Frequency High  
Pre-condition • Client program is running 
• There is an opened workspace 
• There is list of objects showed in the central panel as a table 
Post-condition • Search result is showed in the central panel 
Actor Action System Action 
1. User right-clicks a field name in the 
table 
 
 2. System shows a right-click menu 
3. User clicks ‘sort’ in the menu  
Main Flow 
 4. System sorts the rows in the table and 
refreshes table to show updated order of 
objects  
Steps Blanching Action 
3a. Sort ascending  System sorts objects in ascending 
Sub flows 
3b. Sort descending System sorts objects in descending 
Exceptions Conditions Actions 
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Appendix I: 
Client-server Communication Protocol of the MAMA System 
 
Code  Definition 
1000 Continue --- waiting for user to send more requests. 
  
2000 User request has been successfully handled; the type of request is unspecified. 
    2010 ‘None’ request is handled, an ‘echo’ response is sent back to the client. 
  2100 ‘Select’ request has been handled successfully without specified knowledge about returned data.  
    2110 No entry is returned by database as the result of query specified in the ‘select’ request. 
    2120 A single entry is returned by database as the result of query specified in the ‘select’ request. 
    2130 Multiple and same type of entries are returned by database as the result of query specified in the ‘select’ request. 
    2140 Multiple and different type of entries are returned by database as the result of query specified in the ‘select’ request. 
  2200 ‘Insert’ request has been handled successfully, with unspecified consequence. 
    2210 Successfully ‘insert’ a single entry into a single database table. 
    2220 Successfully ‘insert’ multiple entries into a single database table. 
    2230 Successfully ‘insert’ one or multiple entries into multiple database tables. 
  2300 ‘Delete’ request has been handled successfully, with unspecified consequence. 
  2400 ‘Update’ request has been handled successfully, with unspecified consequence. 
  2500 ‘Save’ request has been handled successfully, with unspecified consequence. 
    2510 Successfully save data in the request into a single file. 
    2520 Successfully save data in the request into multiple files. 
    2530 Successfully save data in the request into one or multiple files within a newly created directory. 
  2600 ‘Load’ request has been handled successfully without specified knowledge about loaded data. 
    2610 No data are loaded and returned. 
    2620 Data in a single file is loaded and returned. 
    2630 Data from multiple file is loaded and returned. 
    2640 Data are loaded from a specified directory with one or multiple files.  
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4000 There exists error in the request, type of error and request is unspecified.  
    4010 Null request error: the received request is null. 
    4020 Null action error: the ‘action’ field of the request is null. 
    4030 Unknown action error: the ‘action’ field specified in the request cannot be recognized.  
    4040 Obsolete version error: received request has newer version than the one implemented on the server. 
  4100 ‘Select’ request includes client error due to unspecified reason. 
    4110 Null query error: query is not specified in the request.  
    4120 Unknown data type error: the query specified in the request cannot be interpreted by the server program.  
    4130 SQL error: error happens when database executes SQL script . 
  4200 ‘Insert’ request includes client error due to unspecified reason. 
    4210 Null request error: no data are given in the request to ‘insert’. 
    4220 Unknown data type error: server doesn’t know how to handle the type of data to be inserted.  
    4230 SQL error: error happens when database executes SQL script.  
      4231 Batch execution error: error happens when database executes a batch of SQL scripts. 
    4240 Duplicate entry error: value of ‘non-duplicate’ field of inserted entry already exists in the database.   
      424X X: an Integer indicates the field going wrong, sequentially number fields from 1. 
    4250 Missing data error: value of ‘non-null’ field is not given in the inserted entry. 
      425X X: an Integer indicates the field going wrong, sequentially number fields from 1. 
    4260 Unexpected data content error: the data to be submitted include unexpected contents. 
      426X X: an Integer indicates the field going wrong, sequentially number fields from 1. 
  4500 ‘Insert’ request includes client error due to unspecified reason. 
      4510 File not found error: cannot find XML mapping file in specified location. 
      4520 I/O error: I/O error happened during file read or write. 
      4530 Mapping error: error in the mapping between XML and data objects. 
      4540 Marshal error: error when parsing data object to XML document. 
      4550 Validation error: XML file failed validation. 
  
5000 Error on the server side or in the response. 
    5010 Null response error: the expected response is null object. 
    5020 Null action error: the ‘action’ field of the response is null. 
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    5030 Unknown action error: the ‘action’ field specified in the response cannot be recognized.  
    5040 Obsolete version error: received response has newer version than the one implemented on the client. 
    5050 Missed response error: expected response of a specified request not received from server. 
      5050.X X: identifier of the specified request. 
  5100 Database connection error: unspecified error happens during establishing or maintaining a connection to database 
    5110 Driver not found error: Fail to load database driver. 
    5120 Database access error  
  5200 Program error: Bug detected in server program. 
  
  200 Requests handled and response returned. 
  
  400 Error in the received ‘REQUESTER’ with unknown reason. 
    410 Unexpected data type error: the object received from client is null or not a ‘REQUESTER’. 
    420 No request error: no request is given. 
    430 User name specified in the request does not exist.  
    440 Password specified in the request is wrong.   
    450 Obsolete version error: received ‘REQUESTER’ has newer version than the one implemented on the server. 
    460 Client-side communication error 
      461 Communication timeout: client did not send requests to server within specified time scale. 
  
  500 Error happened when on the server is handling the ‘REQUESTER’ or in the ‘RESPONSER’. 
    510 Unexpected data type error: the object received from server is null or not a ‘RESPONSER’. 
    520 No response error: no response is given in the ‘RESPONSER’. 
    550 Obsolete version error: received ‘RESPONSER’ has newer version than the one implemented on the client. 
    560 Server-side communication error 
      561 Communication timeout: server did not send responses within specified time. Server may still finish the operation. 
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Appendix J: 
Database Schema of MAMA project 
 
The complete MAMA database includes tables derived from MAGE object model and 
denormalization tables. The overall schema is too complex to be showed in one diagram and 
most MAGE tables are not involved in the current version of MAMA system. This appendix 
only demonstrates tables having data loaded into them. The general schema is broken down 
to smaller diagrams for the convenience of illustration. These schema diagrams are given in 
the ‘Database Schema’ folder within the data disc attached to this article. MAGE-derived 
tables have names started with ‘TT_’ are and denormalization tables have names started with 
‘T_’. In the current version of MAMA system, some database tables are only used for 
permanent storage of source data and not accessible to the queries. These tables are drawn in 
black color. Tables whose data will be queried by the current version of MAMA client 
program are drawn in blue color. 
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Appendix K: 
Specification for Pre-processing of Expression Data 
 
The general purpose of this specification is to define a data processing guideline, which 
will be applied to expression data matrix of all microarray datasets before loading them into 
the MAMA database. It is expected that by following this guideline, all gene expression 
datasets permanently stored in this system will have same format, as well as similar median 
(or mean), scale, and distribution. These processed datasets could be considered as the basis 
of many user-specific operations, such as retrieving data and building virtual experiments.  
MIAME specified three level of data processing: image, image quantitative output, and 
expression data matrix. However, images and the immediate quantitative output of images 
are often missing in the published experimental results. Instead, authors tend to provide their 
data after performing some data curating steps. For example, some authors just make ratio 
data available for their 2-color cDNA arrays. Furthermore, different authors treat their raw 
data differently according to the purpose of their studies. While there still have no widely-
adopted standards about the processing of microarray data yet, we try to define a ‘common 
sense’ guideline for the curating of all microarray datasets. This guideline will utilize 
relatively common and straightforward processing strategies so it could be generally 
accepted. For example, it will prefer linear normalization rather than the non-linear ones. In 
later development stages, we may provide user-specific processing options by implementing 
more sophisticated steps, but all datasets permanently stored in the database will always be 
treated following this guideline. This guideline will be implemented as a data curating 
program. A data curator runs this program by choosing parameters according to related 
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metadata and description, and make sure that the guideline is fulfilled before loading data to 
database. We will keep tuned to the progression of MGED data transformation and 
normalization working group. Once standards are recommended by this group, we will adopt 
them soon.  
The data curating steps proposed in this guideline can be classified into four categories, 
which are: 
• Filtering, e.g. removal of low quality or non-positive data points; 
• Transformation, e.g. ratio and/or log transformation; 
• Within array normalization, e.g. density-dependent normalization; and 
• Between array normalization, e.g. scale normalization 
In practice, it is not always doable, or necessary, to apply all these steps on a specific 
dataset. For example, if authors have carried out ratio transformation and only publish the 
resulting ratio data, density-dependent normalization will be unfeasible and ratio 
transformation can be skipped during the curating. Some authors may publish their data in 
multiple levels, which is a more plausible activity according to MIAME requirements. In 
such instances, the ‘rawest’ level of data will be taken, as many common processing steps as 
possible can be applied to each dataset.  
Currently, we only consider one-color oligonucleotide/cDNA data and two-color cDNA 
data in this guideline. Different processing steps will be applied to these two different types 
of data. In later stages, more types of expression data will be added. 
 
K.1 Guidelines for Pre-processing 2-color cDNA Datasets 
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The processing of 2-color data starts from the intensity measurements obtained from two 
channels if they are available. ‘Rawer’ data such as readings on each pixel will not be 
processed because they are highly dependent on the scanning equipment and image analysis 
software used by authors. It is assumed that the original authors had performed necessary 
background correction and spatial adjustment before they published their 2-color or ratio data. 
Up to seven steps could be applied to a 2-color cDNA dataset. Some of them are not always 
necessary, such as log-transformation, if they have been done the original authors. The 
normalization of the expression measurements is limited to each single array. Users perform 
cross-array normalization within the client program. 
Fig.1 illustrates the following steps using an activity diagram. 
1. Filtering of low quality measurements. This step will only be performed when the 
original authors provided a single-value index, such as a flag, to indicate the quality 
of measurements.  
2. Filtering of non-positive values. All non-positive values should be removed before 
log-transformation no matter the original authors provided the measurements as 
intensity or ratio data. Low variance and other types of filtering will not be performed. 
Instead, user-specific filtering was enabled in the client program. The descriptive 
statistics of each gene are calculated in advanced and saved in a separate database 
table for the convenience of advance filtering. This step will be performed on all 
datasets. 
3. Ratio transformation. If intensity measurements of the two colors are provided 
separately, their ratio is calculated. The gene expression intensity in the 
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samples will be divided by the gene expression intensity in the reference, no 
matter which color the samples are labeled with.  
4. Log transformation. All ratio data will be log2-transformed. If the original 
authors only provided log-transformed ratio data with base=n, all data points 
will be adjusted by multiplying a constant log2n. This step will be performed 
on all datasets. 
5. Intensity-dependent linear normalization. When intensity data is available, this 
step is carried out to correct the dye imbalance caused by different spot 
intensity. Linear normalization is preferred other than non-linear ones because 
of its simplicity and generality. After this step, data are transformed to 
corresponding residual values of a linear model. 
6. Global median normalization of samples. All measurements of each sample 
are subtracted with their median value, so they will be centered at zero. This 
step will be performed on all datasets. 
7. Scale normalization of samples. All expression measurements of each sample 
are divided by a scaling factor, which indicates the variance of data in each 
array.  For simplicity, the standard deviation of measurements is used as the 
scaling factor. 
 
K.2 Guidelines for Pre-processing 1-color cDNA Datasets 
1. Filtering low quality data points. Quality filtering will only be performed when 
authors provide a single-value index, such as a flag, to indicate the quality of data 
points.  
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2. Global median normalization. All data points within an array are subtracted with their 
median value, so they will be centered at zero. This step will be performed on all 
datasets. 
3. Log transformation. All expression data will be log2-transformed. If data provider 
already log-transformed data with base=n, their log ratio data will be adjusted by 
multiplying a constant log2n. If provider have not log-transformed the source data, the 
transformation will follow: 1) If value X is greater than 1.0, transform it to log2X; 
else if X is between 1 and -1, transform it to 0; else if X is less than -1, transform it to 
-log2|X|. This step will be performed on all datasets.  
4. Scale normalization. Each data point is divided by a scaling factor, which indicates 
the variance of data in each array.  For simplicity, the standard deviation is used as 
the scaling factor. 
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Figure 1 Pre-processing of 2-Channel cDNA Microarray Datasets 
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Appendix L: 
Mapping between XML Elements and Java Data Objects 
 
The Java/XML data binding is accomplished in the MAMA client program using the 
XML package developed by Castor project. The Castor XML achieved mapping between 
XML elements and Java data objects by reading a file including mapping information. The 
file is called ‘mapping.MAMA’ in MAMA system and can be downloaded together with the 
client program. In the mapping file, Java classes and their attributes are related to XML 
elements. 
The following is a segment of the mapping file that maps Java ‘QueryResult’ class and its 
attributes to XML elements. The complete mapping file is given in the ‘XML Mapping’ 
folder within the data disc attached to this article. 
<!-- CLASS: QueryResult --> 
<class name="edu.upenn.bmif.mama.model.QueryResult" auto-
complete="false">     
<field name="runTime"> 
<bind-xml node="attribute"/> 
</field>  
<field name="query" 
type="edu.upenn.bmif.mama.model.Query" 
get-method="getQuery" set-method="setQuery" > 
<bind-xml name="query" node="element" /> 
</field>  
<field name="resultUnits" 
type="edu.upenn.bmif.mama.model.QueryResultUnit" 
collection="collection" 
get-method="getResultUnits" set-method="addResultUnit" > 
<bind-xml name="result-unit" node="element" /> 
</field>  
</class> 
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Appendix M:  
Glossary 
 
Correlation and Partial Correlation 
Statistical correlation is a measure about the relationship between two variables. Strength 
of correlation can be numerically represented by a number of correlation coefficients, among 
which the best known one is Pearson’s product-moment correlation coefficient (r). The value 
of r ranges from -1.0 to 1.0. Two variables having perfect negative or positive correlation 
will correspondingly have an r of -1.0 or 1.0 while a value of 0.0 represents a totally 
unrelated relationship. 
When a third variable intervenes the correlation between two variable, it can be 
controlled out by partial correlation analysis. Partial correlation is commonly used for 
controlling only one variable because the process itself will introduce extra bias into results. 
However, it can be iteratively used to control more variables too if sample is large enough. 
According to the type of intervening effect, partial correlation coefficient may be equal to or 
larger/smaller than corresponding correlation coefficient. 
 
Database Denormalization 
Database denormalization is a technique used to speed up database access by introducing 
certain level of redundant data storage. A normalized database schema often stores logically 
related data in separated tables. Queries that draw data by joining several table could be slow. 
Denormalization improves the performance of database by tradeoff some costs. Besides data 
redundancy, it requires extra efforts of database designer to maintain data integrity. 
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Denormalization design are more error-prone in practice. However, it fits to databases whose 
stored data are rarely updated or deleted, such as data warehouses. 
 
Java 
Java is an object-oriented programming language developed by Sun Microsystems. Sun’s 
standard edition of Java is freely available, and developers are using it for various types of 
software from web applications to desktop programs. With a purely object-oriented 
architecture, Java codes are highly reusable and extensible. The running of Java programs is 
independent of operation systems, but only relies on installation of Java Virtual Machine 
(JVM). The official Java website is java.sun.com. 
 
Meta-Analysis 
Meta-analysis is a type of statistical methods that combines the results from multiple 
independent studies dealing with the same research question. Therefore, it is often referred to 
as ‘analysis of analyses’. By integrating findings of individual studies about the same 
hypothesis, meta-analysis methods conclude a summary overall result of hypothesis testing. 
Properly designed meta-analysis will take full advantage of the research efforts having been 
made by discovering information that cannot be obtained from individual studies. Despite of 
its advantages, meta-analysis also receives criticisms. For example, one of its weakness is 
that it has no control on the quality of individual studies, and badly design studies may cause 
biased results even if the meta-analysis method is faultless. Steps of a typical meta-analysis 
include: problem formulation, data collection and evaluation, analysis and interpretation, etc.  
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Microarray 
Microarray is a high-throughput technology that allows researchers to measure the 
expression level of genes at a genomic level. Physically, it is collection of tiny DNA spots 
attached to a solid surface such as glass and silicon chip to form a 2-dimensional array of 
probes. In a microarray experiment, these spots are hybridized to the DNA in a given cell 
extraction and the expression level of genes in the extraction is measured by the amount of 
hybridized DNA. Two types of nucleotide sequences are commonly used as probes: cDNA 
and oligonucleotide.  
 
MVC (Model-View-Controller) Architecture 
MVC is a software design pattern often used for graphic user interface of applications. Its 
basic idea is to divide and encapsulate codes of an application into three major components: 
model (data model), view (user interface), and controller (business logic), so the modification 
of one component will have minimal influence on the others. These packages interact with 
each other by passing inputs/outputs without worrying about the implementation details in 
other packages. MVC is often used in web applications within which code modularization is 
preferred. Although MVC has various flavors, the typical control flow works as the 
following: 
1. ‘View’ renders ‘model’ on user interface; 
2. User interacts with ‘view’ to initiate an action; 
3. The action is passed to ‘controller’; 
4. The action is handled by ‘controller’, which may access ‘model’ to get data input; 
5. ‘Controller’ informs ‘view’ and/or ‘model’ for proper updates at the end of the action; 
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6. User interface waits for next action. 
 
Open Source Software 
Officially, open source and free software are two similar but different concepts, 
separately defined by Open Source Initiative (www.opensource.org) and Free Software 
Foundation (www.fsf.org). Developers of open source software make their source codes 
freely available for other developers to modify or extend under an open source license. 
Although the definition open source software involves complicate legal issues, it generally 
means free-of-charge software to ordinary users.  
 
Parametric vs. Non-Parametric Statistical Tests 
Choice of parametric or non-parametric methods is a common decision for statistical tests. 
Parametric methods have relatively stricter assumptions on analyzed data, including: 
1. normal distribution 
2. homogeneous variances between data groups 
3. continuous measures with equal intervals 
Non-parametric methods do not require above assumptions, so they are computationally 
easier and quicker but statistically less powerful. Most parametric methods have their 
equivalent non-parametric ones. For example, the most common parametric and non-
parametric methods for two group comparison are respectively Student’s t test and Wilcoxon 
rank sum test.  
 
Servlet and Tomcat 
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Java servlet is a type of web application implementing the Java Servlets API. A servlet 
accepts HTTP requests from its clients and correspondingly responds with dynamically 
generated web pages. Dynamic building of web pages is necessary when contents of pages 
are based on user inputs, retrieved from database, or frequently updated (e.g. weather report). 
Servlets interact with web server via servlet container, which maps a URL to each particular 
servlet. Tomcat is such a servlet container developed by Apache Software Foundation. It 
implements the standard servlet specification from Sun Microsystems. Tomcat also includes 
its own HTTP server internally, so it also works as an independent web server.  
 
Statistical Power 
In statistical hypothesis testing, ‘power’ of a test means the probability of rejecting the 
null hypothesis H0 when the alternative hypothesis Ha is true. Larger sample size usually 
leads to higher power. Quality of experimental data and used analysis methods also have 
their influence. Methods that need stricter assumptions usually have higher statistical power. 
 
TNM Classification 
TNM is the most widely used staging system of malignant tumors. It is developed and 
maintained by International Union Against Cancer and has become a standard in clinical 
practice. The three letters stand for Tumor, Node, and Metastasis. This system classifies 
cancer patients into categories according to size of tumor, number of infected lymph nodes, 
and presence of distant metastasis, so proper treatment decisions can be made based on their 
classification. Definition of categories varies among cancer types.  
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UML (Unified Modeling Language) 
UML defines the standards of data modeling and documentation language for design of 
object-oriented software. It is used to formally specify, visualize, and document the structure 
and functions of software under development. Standardized diagrams play a key role in UML 
design. Commonly used UML diagram include use case diagram (general functions), class 
diagram (system structure), activity diagram (general system workflows), sequence 
diagram(interaction between classes and detailed workflows), and so on.  
 
XML (eXtensible Markup Language) 
A markup language labels and format the contents of plain text to make them machine-
readable. XML is a general-purposed markup language recommended by W3C consortium. 
Its primary purpose is to facilitate automatic data sharing across different software systems. 
The basic units of XML documents are called elements, which have a hierarchical structure. 
XML elements can be defined with XML schema or DTD (Data Type Definition). Format of 
XML documents must follow a few rules, so computer programs can recognize their 
elements and parse their contents. Many programming languages including Java provide 
standard libraries for parsing and writing XML documents. XML documents are nothing but 
labeled plain text files, which makes them independent of platforms and unaffected by 
changes in software. How to deal with these documents are program-specific. Despite of 
many advantages of XML format, its verbose structure is not very friendly for human reading 
and may substantially reduce program performance. 
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